NZ715818B2 - Antimicrobial Compounds And Methods Of Making And Using The Same - Google Patents
Antimicrobial Compounds And Methods Of Making And Using The Same Download PDFInfo
- Publication number
- NZ715818B2 NZ715818B2 NZ715818A NZ71581812A NZ715818B2 NZ 715818 B2 NZ715818 B2 NZ 715818B2 NZ 715818 A NZ715818 A NZ 715818A NZ 71581812 A NZ71581812 A NZ 71581812A NZ 715818 B2 NZ715818 B2 NZ 715818B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- compound
- tautomer
- alkyl
- membered saturated
- unsaturated
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 712
- 238000000034 method Methods 0.000 title description 95
- 230000000845 anti-microbial effect Effects 0.000 title description 16
- 150000003839 salts Chemical class 0.000 claims description 289
- 150000002148 esters Chemical class 0.000 claims description 275
- 125000000217 alkyl group Chemical group 0.000 claims description 236
- 229920006395 saturated elastomer Polymers 0.000 claims description 220
- 229910052757 nitrogen Inorganic materials 0.000 claims description 178
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 130
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 126
- 229910052739 hydrogen Inorganic materials 0.000 claims description 118
- 229910052760 oxygen Inorganic materials 0.000 claims description 118
- 239000001257 hydrogen Substances 0.000 claims description 114
- 125000005842 heteroatom Chemical group 0.000 claims description 113
- 239000001301 oxygen Chemical group 0.000 claims description 112
- 229910052717 sulfur Chemical group 0.000 claims description 112
- 239000011593 sulfur Chemical group 0.000 claims description 111
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 110
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 109
- 229910052799 carbon Inorganic materials 0.000 claims description 96
- 125000001424 substituent group Chemical group 0.000 claims description 96
- 208000015181 infectious disease Diseases 0.000 claims description 80
- 125000003118 aryl group Chemical group 0.000 claims description 77
- 125000004432 carbon atom Chemical group C* 0.000 claims description 72
- 125000000623 heterocyclic group Chemical group 0.000 claims description 65
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 63
- 239000003814 drug Substances 0.000 claims description 52
- 229910052736 halogen Inorganic materials 0.000 claims description 51
- 244000005700 microbiome Species 0.000 claims description 51
- 241001465754 Metazoa Species 0.000 claims description 48
- 125000004429 atom Chemical group 0.000 claims description 48
- 125000002837 carbocyclic group Chemical group 0.000 claims description 48
- 241000282414 Homo sapiens Species 0.000 claims description 47
- 125000003342 alkenyl group Chemical group 0.000 claims description 44
- 125000000304 alkynyl group Chemical group 0.000 claims description 42
- 150000002367 halogens Chemical class 0.000 claims description 40
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 37
- 230000000813 microbial effect Effects 0.000 claims description 30
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 26
- 150000001721 carbon Chemical group 0.000 claims description 22
- 125000001188 haloalkyl group Chemical group 0.000 claims description 21
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 20
- 229960003085 meticillin Drugs 0.000 claims description 20
- 108090000204 Dipeptidase 1 Proteins 0.000 claims description 18
- 102000006635 beta-lactamase Human genes 0.000 claims description 18
- 206010035664 Pneumonia Diseases 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 17
- 241000588724 Escherichia coli Species 0.000 claims description 16
- 238000001228 spectrum Methods 0.000 claims description 15
- 241000191967 Staphylococcus aureus Species 0.000 claims description 13
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 13
- 230000001580 bacterial effect Effects 0.000 claims description 13
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 13
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 13
- 241000606768 Haemophilus influenzae Species 0.000 claims description 12
- 229930182555 Penicillin Natural products 0.000 claims description 12
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 12
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 12
- 229940049954 penicillin Drugs 0.000 claims description 12
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims description 12
- 208000008745 Healthcare-Associated Pneumonia Diseases 0.000 claims description 11
- 108010059993 Vancomycin Proteins 0.000 claims description 11
- 229940047650 haemophilus influenzae Drugs 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- 229960003165 vancomycin Drugs 0.000 claims description 11
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 11
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 10
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 10
- 108010068385 carbapenemase Proteins 0.000 claims description 10
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 10
- 241000606124 Bacteroides fragilis Species 0.000 claims description 9
- 241000194033 Enterococcus Species 0.000 claims description 9
- 241000588749 Klebsiella oxytoca Species 0.000 claims description 9
- 241000191992 Peptostreptococcus Species 0.000 claims description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- 206010040872 skin infection Diseases 0.000 claims description 9
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 9
- 241001135211 Porphyromonas asaccharolytica Species 0.000 claims description 8
- 241001135215 Prevotella bivia Species 0.000 claims description 8
- 241000588770 Proteus mirabilis Species 0.000 claims description 8
- 241000193985 Streptococcus agalactiae Species 0.000 claims description 8
- 208000009470 Ventilator-Associated Pneumonia Diseases 0.000 claims description 8
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- 241001135228 Bacteroides ovatus Species 0.000 claims description 7
- 241000606123 Bacteroides thetaiotaomicron Species 0.000 claims description 7
- 241000606219 Bacteroides uniformis Species 0.000 claims description 7
- 241000193468 Clostridium perfringens Species 0.000 claims description 7
- 241001657508 Eggerthella lenta Species 0.000 claims description 7
- 241000588655 Moraxella catarrhalis Species 0.000 claims description 7
- 241000606210 Parabacteroides distasonis Species 0.000 claims description 7
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 7
- 241000186561 [Clostridium] clostridioforme Species 0.000 claims description 7
- 230000001154 acute effect Effects 0.000 claims description 7
- 241000588626 Acinetobacter baumannii Species 0.000 claims description 6
- 241000588919 Citrobacter freundii Species 0.000 claims description 6
- 241000588697 Enterobacter cloacae Species 0.000 claims description 6
- 241000194032 Enterococcus faecalis Species 0.000 claims description 6
- 241000605909 Fusobacterium Species 0.000 claims description 6
- 241000606766 Haemophilus parainfluenzae Species 0.000 claims description 6
- 241000588915 Klebsiella aerogenes Species 0.000 claims description 6
- 241000588772 Morganella morganii Species 0.000 claims description 6
- 241000588767 Proteus vulgaris Species 0.000 claims description 6
- 241000588777 Providencia rettgeri Species 0.000 claims description 6
- 241000588778 Providencia stuartii Species 0.000 claims description 6
- 241000607715 Serratia marcescens Species 0.000 claims description 6
- 229940092559 enterobacter aerogenes Drugs 0.000 claims description 6
- 229940076266 morganella morganii Drugs 0.000 claims description 6
- 206010034674 peritonitis Diseases 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000003386 piperidinyl group Chemical group 0.000 claims description 6
- 229940007042 proteus vulgaris Drugs 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 208000019206 urinary tract infection Diseases 0.000 claims description 6
- 241000606215 Bacteroides vulgatus Species 0.000 claims description 5
- 208000036209 Intraabdominal Infections Diseases 0.000 claims description 5
- 241000589248 Legionella Species 0.000 claims description 5
- 208000007764 Legionnaires' Disease Diseases 0.000 claims description 5
- 206010058674 Pelvic Infection Diseases 0.000 claims description 5
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 5
- 125000003725 azepanyl group Chemical group 0.000 claims description 5
- 125000002393 azetidinyl group Chemical group 0.000 claims description 5
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
- 125000003566 oxetanyl group Chemical group 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 5
- 241000589291 Acinetobacter Species 0.000 claims description 4
- 208000031729 Bacteremia Diseases 0.000 claims description 4
- 241000204031 Mycoplasma Species 0.000 claims description 4
- 241000122973 Stenotrophomonas maltophilia Species 0.000 claims description 4
- 241000194008 Streptococcus anginosus Species 0.000 claims description 4
- 241001291896 Streptococcus constellatus Species 0.000 claims description 4
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical class C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 claims description 4
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 4
- 229940032049 enterococcus faecalis Drugs 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 claims description 4
- 229960003907 linezolid Drugs 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 4
- 241000588923 Citrobacter Species 0.000 claims description 3
- 241000588917 Citrobacter koseri Species 0.000 claims description 3
- 206010031252 Osteomyelitis Diseases 0.000 claims description 3
- 206010040047 Sepsis Diseases 0.000 claims description 3
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 claims description 3
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 claims description 3
- 125000005942 tetrahydropyridyl group Chemical group 0.000 claims description 3
- 206010060968 Arthritis infective Diseases 0.000 claims description 2
- 201000009906 Meningitis Diseases 0.000 claims description 2
- 208000037942 Methicillin-resistant Staphylococcus aureus infection Diseases 0.000 claims description 2
- 206010035148 Plague Diseases 0.000 claims description 2
- 206010035737 Pneumonia viral Diseases 0.000 claims description 2
- 206010058028 Shunt infection Diseases 0.000 claims description 2
- 206010041925 Staphylococcal infections Diseases 0.000 claims description 2
- 208000034784 Tularaemia Diseases 0.000 claims description 2
- 208000022338 anthrax infection Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 206010014665 endocarditis Diseases 0.000 claims description 2
- 208000013223 septicemia Diseases 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 208000009421 viral pneumonia Diseases 0.000 claims description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 claims 3
- -1 pyrrolopyrimidinone derivative compounds Chemical class 0.000 abstract description 53
- 239000004599 antimicrobial Substances 0.000 abstract description 19
- 239000000651 prodrug Substances 0.000 description 269
- 229940002612 prodrug Drugs 0.000 description 269
- 239000000203 mixture Substances 0.000 description 115
- 229920000728 polyester Polymers 0.000 description 96
- 239000000243 solution Substances 0.000 description 55
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
- 239000000543 intermediate Substances 0.000 description 43
- 230000015572 biosynthetic process Effects 0.000 description 42
- 239000012634 fragment Substances 0.000 description 40
- 238000003786 synthesis reaction Methods 0.000 description 39
- 238000009472 formulation Methods 0.000 description 36
- 229940079593 drug Drugs 0.000 description 29
- 150000002431 hydrogen Chemical class 0.000 description 29
- 238000002360 preparation method Methods 0.000 description 29
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 28
- 229910052731 fluorine Inorganic materials 0.000 description 28
- 229910052794 bromium Inorganic materials 0.000 description 26
- 229910052740 iodine Inorganic materials 0.000 description 26
- 229910052801 chlorine Inorganic materials 0.000 description 25
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 229910052727 yttrium Inorganic materials 0.000 description 20
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 19
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 239000012267 brine Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 15
- 230000014616 translation Effects 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 210000004708 ribosome subunit Anatomy 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 235000019439 ethyl acetate Nutrition 0.000 description 13
- 238000001243 protein synthesis Methods 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 230000027455 binding Effects 0.000 description 12
- 239000012043 crude product Substances 0.000 description 12
- 238000003818 flash chromatography Methods 0.000 description 12
- 125000005843 halogen group Chemical group 0.000 description 12
- 238000001990 intravenous administration Methods 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 10
- 239000003242 anti bacterial agent Substances 0.000 description 10
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 10
- 125000001841 imino group Chemical group [H]N=* 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 229910052786 argon Inorganic materials 0.000 description 9
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000013078 crystal Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 238000003419 tautomerization reaction Methods 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 8
- 206010062255 Soft tissue infection Diseases 0.000 description 7
- 108020004566 Transfer RNA Proteins 0.000 description 7
- 239000002253 acid Chemical group 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical group C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 239000000370 acceptor Substances 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 5
- 150000001345 alkine derivatives Chemical group 0.000 description 5
- 125000004414 alkyl thio group Chemical group 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 210000000689 upper leg Anatomy 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 230000001028 anti-proliverative effect Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 125000001743 benzylic group Chemical group 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 239000006161 blood agar Substances 0.000 description 4
- 238000006664 bond formation reaction Methods 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000002875 fluorescence polarization Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 210000003705 ribosome Anatomy 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- RBEVBNYRFFHCSN-UHFFFAOYSA-N 1,5-dibromo-3-chloro-2-fluorobenzene Chemical compound FC1=C(Cl)C=C(Br)C=C1Br RBEVBNYRFFHCSN-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- IDWUQUCUBHNHMG-UHFFFAOYSA-N C#CC1=CC=C(C(F)(F)F)C(CCCCCNC(OCC2=CC=CC=C2)=O)=N1 Chemical compound C#CC1=CC=C(C(F)(F)F)C(CCCCCNC(OCC2=CC=CC=C2)=O)=N1 IDWUQUCUBHNHMG-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical class O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 3
- 150000001204 N-oxides Chemical class 0.000 description 3
- BHUQQERMIIASMQ-UHFFFAOYSA-N O=C(NCCCCC(C=CC(C#CCl)=C1)=C1F)OCC1=CC=CC=C1 Chemical compound O=C(NCCCCC(C=CC(C#CCl)=C1)=C1F)OCC1=CC=CC=C1 BHUQQERMIIASMQ-UHFFFAOYSA-N 0.000 description 3
- ZCLYOYHYBUZPHO-UHFFFAOYSA-N O=C(NCCCCCC1=NC(Cl)=CC=C1C(F)(F)F)OCC1=CC=CC=C1 Chemical compound O=C(NCCCCCC1=NC(Cl)=CC=C1C(F)(F)F)OCC1=CC=CC=C1 ZCLYOYHYBUZPHO-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 238000007295 Wittig olefination reaction Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000003172 aldehyde group Chemical group 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 229960004977 anhydrous lactose Drugs 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000000843 anti-fungal effect Effects 0.000 description 3
- 230000002924 anti-infective effect Effects 0.000 description 3
- 230000002141 anti-parasite Effects 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- RJALRHNIDGJNNJ-UHFFFAOYSA-N benzyl n-[5-[4-(trifluoromethyl)pyridin-2-yl]pentan-2-yl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NC(C)CCCC1=CC(C(F)(F)F)=CC=N1 RJALRHNIDGJNNJ-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- NLUNLVTVUDIHFE-UHFFFAOYSA-N cyclooctylcyclooctane Chemical compound C1CCCCCCC1C1CCCCCCC1 NLUNLVTVUDIHFE-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 238000009510 drug design Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 238000013537 high throughput screening Methods 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 210000001069 large ribosome subunit Anatomy 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000010287 polarization Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000002600 positron emission tomography Methods 0.000 description 3
- 150000003138 primary alcohols Chemical class 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000006268 reductive amination reaction Methods 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 2
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- AMKGKYQBASDDJB-UHFFFAOYSA-N 9$l^{2}-borabicyclo[3.3.1]nonane Chemical compound C1CCC2CCCC1[B]2 AMKGKYQBASDDJB-UHFFFAOYSA-N 0.000 description 2
- FEJUGLKDZJDVFY-UHFFFAOYSA-N 9-borabicyclo[3.3.1]nonane Substances C1CCC2CCCC1B2 FEJUGLKDZJDVFY-UHFFFAOYSA-N 0.000 description 2
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- UDOPZRVSCVUDAE-UHFFFAOYSA-N C[Si](C)(C)C#CC1=C(CCCCNC(OCC2=CC=CC=C2)=O)C=CC(Cl)=C1F Chemical compound C[Si](C)(C)C#CC1=C(CCCCNC(OCC2=CC=CC=C2)=O)C=CC(Cl)=C1F UDOPZRVSCVUDAE-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 241001360526 Escherichia coli ATCC 25922 Species 0.000 description 2
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 2
- 208000002633 Febrile Neutropenia Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108010007979 Glycocholic Acid Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229930194542 Keto Natural products 0.000 description 2
- 201000008225 Klebsiella pneumonia Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 2
- FMBKPSPRQQJQEA-UHFFFAOYSA-N O=C(NCCCCC(C=CC(Cl)=C1Br)=C1F)OCC1=CC=CC=C1 Chemical compound O=C(NCCCCC(C=CC(Cl)=C1Br)=C1F)OCC1=CC=CC=C1 FMBKPSPRQQJQEA-UHFFFAOYSA-N 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 229920002352 Peptidyl-tRNA Polymers 0.000 description 2
- 206010035717 Pneumonia klebsiella Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 102000004389 Ribonucleoproteins Human genes 0.000 description 2
- 108010081734 Ribonucleoproteins Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229940125877 compound 31 Drugs 0.000 description 2
- 229940125807 compound 37 Drugs 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 230000005595 deprotonation Effects 0.000 description 2
- 238000010537 deprotonation reaction Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 150000002081 enamines Chemical group 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 229940014425 exodus Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 125000001151 peptidyl group Chemical group 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 230000002974 pharmacogenomic effect Effects 0.000 description 2
- PMOIAJVKYNVHQE-UHFFFAOYSA-N phosphanium;bromide Chemical compound [PH4+].[Br-] PMOIAJVKYNVHQE-UHFFFAOYSA-N 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000003761 preservation solution Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000005588 protonation Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008261 resistance mechanism Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000001812 small ribosome subunit Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 239000008347 soybean phospholipid Substances 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- LJVAJPDWBABPEJ-PNUFFHFMSA-N telithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3C=C(N=C3)C=3C=NC=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O LJVAJPDWBABPEJ-PNUFFHFMSA-N 0.000 description 2
- MLDSDVASYUUDLT-UHFFFAOYSA-N tert-butyl n-(3-oxopropyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCC=O MLDSDVASYUUDLT-UHFFFAOYSA-N 0.000 description 2
- KTFLPCUEEXVHSD-UHFFFAOYSA-N tert-butyl n-[1-(4-bromophenyl)ethyl]-n-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCN(C(=O)OC(C)(C)C)C(C)C1=CC=C(Br)C=C1 KTFLPCUEEXVHSD-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- XJRIDJAGAYGJCK-UHFFFAOYSA-N (1-acetyl-5-bromoindol-3-yl) acetate Chemical compound C1=C(Br)C=C2C(OC(=O)C)=CN(C(C)=O)C2=C1 XJRIDJAGAYGJCK-UHFFFAOYSA-N 0.000 description 1
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 1
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 1
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000005955 1H-indazolyl group Chemical group 0.000 description 1
- NOGFHTGYPKWWRX-UHFFFAOYSA-N 2,2,6,6-tetramethyloxan-4-one Chemical compound CC1(C)CC(=O)CC(C)(C)O1 NOGFHTGYPKWWRX-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical group O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
- FBPINGSGHKXIQA-UHFFFAOYSA-N 2-amino-3-(2-carboxyethylsulfanyl)propanoic acid Chemical compound OC(=O)C(N)CSCCC(O)=O FBPINGSGHKXIQA-UHFFFAOYSA-N 0.000 description 1
- CIHKVMHPDDJIIP-UHFFFAOYSA-N 2-methylperoxybenzoic acid Chemical compound COOC1=CC=CC=C1C(O)=O CIHKVMHPDDJIIP-UHFFFAOYSA-N 0.000 description 1
- WADSJYLPJPTMLN-UHFFFAOYSA-N 3-(cycloundecen-1-yl)-1,2-diazacycloundec-2-ene Chemical group C1CCCCCCCCC=C1C1=NNCCCCCCCC1 WADSJYLPJPTMLN-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- PAIJFGAVPJOVTI-UHFFFAOYSA-N 4-amino-1-iodopyrimidin-2-one Chemical group NC=1C=CN(I)C(=O)N=1 PAIJFGAVPJOVTI-UHFFFAOYSA-N 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- TZKBVRDEOITLRB-UHFFFAOYSA-N 4-methyl-n-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1h-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2C=C3C=NNC3=NC=2)=C1 TZKBVRDEOITLRB-UHFFFAOYSA-N 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 1
- 206010056519 Abdominal infection Diseases 0.000 description 1
- 206010000228 Abortion infected Diseases 0.000 description 1
- YCIPQJTZJGUXND-UHFFFAOYSA-N Aglaia odorata Alkaloid Natural products C1=CC(OC)=CC=C1C1(C(C=2C(=O)N3CCCC3=NC=22)C=3C=CC=CC=3)C2(O)C2=C(OC)C=C(OC)C=C2O1 YCIPQJTZJGUXND-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- JHRJQNGCAJNFOI-UHFFFAOYSA-N CC(C1=CC=C(C(N=CC2=O)(N=C2N)I)C=C1)N(CCCNC(OC(C)(C)C)=O)C(OC(C)(C)C)=O Chemical compound CC(C1=CC=C(C(N=CC2=O)(N=C2N)I)C=C1)N(CCCNC(OC(C)(C)C)=O)C(OC(C)(C)C)=O JHRJQNGCAJNFOI-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 238000006969 Curtius rearrangement reaction Methods 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010060803 Diabetic foot infection Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000409898 Empodisma minus Species 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- UGINYGKAOMIEIJ-UHFFFAOYSA-N FN(C(C(Br)=CC=C1)=C1Br)Cl Chemical compound FN(C(C(Br)=CC=C1)=C1Br)Cl UGINYGKAOMIEIJ-UHFFFAOYSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical group C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108090000279 Peptidyltransferases Proteins 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229940123573 Protein synthesis inhibitor Drugs 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 208000002359 Septic Abortion Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000031650 Surgical Wound Infection Diseases 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108700042768 University of Wisconsin-lactobionate solution Proteins 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- CKUAXEQHGKSLHN-UHFFFAOYSA-N [C].[N] Chemical group [C].[N] CKUAXEQHGKSLHN-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000005466 alkylenyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 238000002802 antimicrobial activity assay Methods 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 150000001499 aryl bromides Chemical class 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 238000006254 arylation reaction Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 125000004931 azocinyl group Chemical group N1=C(C=CC=CC=C1)* 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004935 benzoxazolinyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 125000005512 benztetrazolyl group Chemical group 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000004623 carbolinyl group Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- BJDCWCLMFKKGEE-CMDXXVQNSA-N chembl252518 Chemical compound C([C@@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-CMDXXVQNSA-N 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000010878 colorectal surgery Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- XSYZCZPCBXYQTE-UHFFFAOYSA-N cyclodecylcyclodecane Chemical compound C1CCCCCCCCC1C1CCCCCCCCC1 XSYZCZPCBXYQTE-UHFFFAOYSA-N 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- USVZFSNDGFNNJT-UHFFFAOYSA-N cyclopenta-1,4-dien-1-yl(diphenyl)phosphane (2,3-dichlorocyclopenta-1,4-dien-1-yl)-diphenylphosphane iron(2+) Chemical compound [Fe++].c1cc[c-](c1)P(c1ccccc1)c1ccccc1.Clc1c(cc[c-]1Cl)P(c1ccccc1)c1ccccc1 USVZFSNDGFNNJT-UHFFFAOYSA-N 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 125000005433 dihydrobenzodioxinyl group Chemical group O1C(COC2=C1C=CC=C2)* 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000023042 endomyometritis Diseases 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000012854 evaluation process Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 229940081104 fibrinogen / thrombin Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003574 free electron Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 210000003976 gap junction Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 239000008236 heating water Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000012203 high throughput assay Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 150000004680 hydrogen peroxides Chemical class 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical group 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004926 indolenyl group Chemical group 0.000 description 1
- LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000004936 isatinoyl group Chemical group N1(C(=O)C(=O)C2=CC=CC=C12)C(=O)* 0.000 description 1
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 125000005438 isoindazolyl group Chemical group 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229940083668 ketek Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 150000002762 monocarboxylic acid derivatives Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006218 nasal suppository Substances 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 125000004930 octahydroisoquinolinyl group Chemical group C1(NCCC2CCCC=C12)* 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 239000000162 organ preservation solution Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 125000004095 oxindolyl group Chemical group N1(C(CC2=CC=CC=C12)=O)* 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- FSEKYSAWZRQAPN-UHFFFAOYSA-N pent-1-en-1-amine Chemical compound CCCC=CN FSEKYSAWZRQAPN-UHFFFAOYSA-N 0.000 description 1
- LHTVMBMETNGEAN-UHFFFAOYSA-N pent-1-en-1-ol Chemical compound CCCC=CO LHTVMBMETNGEAN-UHFFFAOYSA-N 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000004932 phenoxathinyl group Chemical group 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000004928 piperidonyl group Chemical group 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 125000004591 piperonyl group Chemical group C(C1=CC=2OCOC2C=C1)* 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 239000000007 protein synthesis inhibitor Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010916 retrosynthetic analysis Methods 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229960003250 telithromycin Drugs 0.000 description 1
- XDJCYKMWJCYQJM-UHFFFAOYSA-N tert-butyl n-(3-hydroxypropyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCO XDJCYKMWJCYQJM-UHFFFAOYSA-N 0.000 description 1
- MICJTMZJQYSHFF-UHFFFAOYSA-N tert-butyl n-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propyl]-n-[1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethyl]carbamate Chemical compound C1=CC(C(N(CCCNC(=O)OC(C)(C)C)C(=O)OC(C)(C)C)C)=CC=C1B1OC(C)(C)C(C)(C)O1 MICJTMZJQYSHFF-UHFFFAOYSA-N 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 239000003106 tissue adhesive Substances 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000005820 transferase reaction Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000006168 tricyclic group Chemical group 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
- 239000006150 trypticase soy agar Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Provided are pyrrolopyrimidinone derivative compounds of the general formula (IA), where the variables are as defined in the specification. The compounds may be useful as antimicrobial agents.
Description
ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME RELATED APPLICATIONS This application is a divisional application of New Zealand application no. 617116, which claims priority to U.S. provisional application no. 61/476,138, filed April 15, 2011, U.S. provisional application no. 61/535,118, filed September 15, 2011, and U.S. provisional application no. 61/610,363, filed March 13, 2012. The contents of the aforementioned applications are hereby incorporated by reference in their entirety.
FIELD OF THE INVENTION The present invention relates generally to the field of antimicrobial compounds and to methods of making and using them. These compounds are useful for treating, preventing, and reducing the risk of microbial infections in humans and animals.
BACKGROUND Since the discovery of penicillin in the 1920s and streptomycin in the 1940s, many new compounds have been discovered or specifically designed for use as antibiotic agents. It was once thought that infectious diseases could be completely controlled or eradicated with the use of such therapeutic agents. However, such views have been challenged because strains of cells or microorganisms resistant to currently effective therapeutic agents continue to evolve. Almost every antibiotic agent developed for clinical use has ultimately encountered problems with the emergence of resistant bacteria. For example, resistant strains of Gram–positive bacteria such as methicillin–resistant staphylococci, penicillin–resistant streptococci, and vancomycin–resistant enterococci have developed. Resistant bacteria can cause serious and even fatal results for infected patients. See, e.g., Lowry, F.D.
"Antimicrobial Resistance: The Example of Staphylococcus aureus," J. Clin. Invest., vol. 111, no. 9, pp. 1265–1273 (2003); and Gold, H.S. and Moellering, R.C., Jr., "Antimicrobial– Drug Resistance," N. Engl. J. Med., vol. 335, pp. 1445–53 (1996).
The discovery and development of new antibacterial agents have been for decades a major focus in many pharmaceutical companies. Nonetheless, in more recent years there has been an exodus of pharmaceutical companies from this area of research and drug development. As a consequence of this exodus, there have been very few new antibiotics entering the market. This lack of new antibiotics is particularly disturbing, especially at a time when bacterial resistance to current therapies is increasing both in the hospital and community settings.
In the search for new antibiotic agents, researchers have tried combining or linking various portions of antibiotic molecules to create multifunctional or hybrid compounds Other researchers have tried making derivatives of known classes of antibiotics, e.g., telithromycin, which is sold under the trade name Ketek®, is a derivative of erythromycin. However, these approaches have met with limited success.
An approach to developing new antimicrobial compounds is to design modulators, for example, inhibitors, of bacterial ribosome function. By modulating or inhibiting bacterial ribosome function such antimicrobial compounds could interfere with essential processes such as RNA translation and protein synthesis, thereby providing an antimicrobial effect. In fact, some antibiotic compounds such as erythromycin, clindamycin, and linezolid are known to bind to the ribosome.
The present invention utilizes a structure based drug design approach for discovering and developing new antimicrobial agents. This approach starts with the high resolution X– ray crystal of the ribosome to design new classes of antimicrobial compounds having specific chemical structures, ribosome binding characteristics, and antimicrobial activity. This structure based drug discovery approach is described in the following publication: Franceschi, F. and Duffy, E.M., "Structure–based drug design meets the ribosome", Biochemical Pharmacology, vol. 71, pp. 1016–1025 (2006).
Based on this structure based drug design approach, the present invention describes new chemical classes of antimicrobial compounds useful for treating bacterial infections in humans and animals. Without being limited by theories, these compounds are believed to inhibit bacterial ribosome function by binding to the ribosome. By taking advantage of these ribosome binding sites, the antimicrobial compounds of the present invention can provide better activity, especially against resistant strains of bacteria, than current antibiotic compounds.
The present invention therefore fills an important ongoing need for providing new antimicrobial agents, particularly for antimicrobial agents, having activity against resistant pathogenic bacterial organisms.
SUMMARY OF THE INVENTION The present invention relates generally to the field of antimicrobial compounds and to methods of making and using them. These compounds and tautomers thereof are useful for treating, preventing, and reducing the risk of microbial infections in humans and animals.
The present invention also provides pharmaceutically acceptable salts, esters, and prodrugs of these compounds and tautomers.
In one aspect, the present invention relates to a compound having the formula: (IA), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, wherein 1 2 3 4 5 X is CR or N; X is CR or N; X is CR or N; X is CR or N; X is CR or N; with 1 2 3 4 5 the proviso that X , X , X , X , and X are not all N; 1 2 3 4 5 6 7 8 9 10 Y is CR or N; Y is CR or N; Y is CR or N; Y is CR or N; Y is CR or N; 6 7 8 9 10 with the proviso that Y , Y , Y , Y , and Y are not all N; wherein 6 7 8 9 10 1 2 4 5 6 7 8 10 R , R , R , R , R , R , R and R are each independently selected from (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) –CF , (g) –CF H, (h) –CFH , (i) –OCF , (j) –OCF H, (k) –OCFH , (l) 2 2 3 2 2 11 11 11 11 11 11 –OCH , (m) –CN, (n) –N , (o) –NO , (p) –NR R , (q) –NR C(O)R , (r) –C(O)NR R , (s) 11 11 11 11 11 11 –OR , (t) –COH, (u) –CO(C –C alkyl), (v) –COR , (w) –NR (CNR )NR R , (x) – 11 11 11 11 11 11 S(O) R , (y) –NR S(O) R , (z) –SR , (aa) –SCF , (bb) –C(CF )H-NH-CHR R , (cc) – p p 3 3 11 11 11 COOR , (dd) –(OCH CH ) R , (ee) –(OCH CH ) OR , (ff) –C –C alkyl, (gg) –C –C 2 2 t 2 2 t 1 8 2 8 alkenyl, (hh) –C –C alkynyl, (ii) –(C –C alkyl)–(3–14 membered saturated, unsaturated, or 2 8 1 8 aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (jj) –(C –C alkyl)–(3–14 membered saturated, unsaturated, or aromatic carbocycle), (kk) –haloalkyl, (ll) –3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (mm) –3–14 membered saturated, unsaturated, or aromatic carbocycle, and (nn) –CHR -NH-(3-14 membered saturated, unsaturated, or aromatic heterocycle containing one of more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur); wherein each (ff) through (nn) is optionally substituted with one or more R ; 6 7 8 alternatively, wherein two substituents selected from R , R , and R are taken together with the carbon atom to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; wherein each (a) through (b) is optionally substituted with one or more R ; each R is independently selected from (a) hydrogen, (b) halogen, (c) –OH, (d) –SH, (e) –(C –C alkyl)OH, (f) –OCF , (g) –OCF H, (h) –OCFH , (i) –OCH , (j) –OR , (k) – 1 8 3 2 2 3 12 12 12 COR , (l) –CN, (m) –NO , (n) –CONH , (o) –CONR R , (p) –COCH , (q) –S(O) CH , (r) 2 2 3 p 3 12 12 12 12 –S(O) NR R , (s) –SR , (t) –C(O)OH, (u) –C(O)OR , (v) –N , (w) –NH , (x) – p 3 2 12 12 NR C(O)R , (y) –NH(C –C alkyl), (z) –N(C –C alkyl) , (aa) –C –C alkyl, (bb) –C –C 1 8 1 8 2 1 8 2 8 alkenyl, (cc) –C –C alkynyl, (dd) –haloalkyl, (ee) –(C –C alkyl)–(3–14 membered 2 8 1 8 saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (ff) –(C –C alkyl)–(3–14 membered saturated, unsaturated, or aromatic carbocycle), (gg) –3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (hh) –3–14 membered saturated, 12 12 unsaturated, or aromatic carbocycle, and (ii) –(C=NH)NR R ; wherein each (y) through (hh) is optionally substituted with one or more R ; alternatively two R substituents are taken together to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, wherein each (a) through (b) is optionally substituted with one or more R ; R is selected from: , , , , , , , and ; 3a 3b 3c 3d 3e 3f 3g 3h 3i 3j 3k 3l wherein R , R , R , R , R , R , R , R , R , R , R , and R are each independently selected from (a) hydrogen, (b) halogen, (c) –CN, (d) –N , (e) –NO , (f) – 11 11 11 11 OCF , (g) –OCF H, (h) –OCFH , (i) –OCH , (j) –OR , (k) –C(O)R , (l) –C(O)NR R , (m) 3 2 2 3 11 11 11 11 11 11 –NH , (n) –NR R , (o) –NR C(O)R , (p) –S(O) R , (q) –C(O)OH, (r) –C(O)OR , (s) – C –C alkyl, (t) –C –C alkenyl, (u) –C –C alkynyl, (v) haloalkyl, (w) –3–14 membered 1 8 2 8 2 8 saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (x) –3–14 membered saturated, unsaturated, or aromatic carbocycle; wherein each (s) through (x) is optionally substituted with one or more R ; 3a 3b 3c 3d alternatively, one or more pairs of substituents selected from R and R , R and R , 3e 3f 3g 3h 3i 3j 3k 3l R and R , R and R , R and R , and R and R are taken together with the carbon atom to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic, (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (c) an exo carbon-carbon double bond, (d) carbonyl group, or (e) thiocarbonyl group; wherein each (a) through (b) is optionally substituted with one or more R ; 3a 3b 3c 3d 3e 3f 3g alternatively, wherein two substituents selected from R , R , R , R , R , R , R , 3h 3i 3j 3k 3l R , R , R , R , and R on different carbon atoms are taken together with the intervening atoms to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; wherein each (a) through (b) is optionally substituted with one or more R ; 3a 3b 3c 3d 3e 3f 3g alternatively, wherein two substituents selected from R , R , R , R , R , R , R , 3h 3i 3j 3k 3l R , R , R , R , and R on two adjacent carbon atoms are taken together with the bond between said adjacent carbon atoms form a substituted or unsubstituted carbon-carbon double 3a 3b 3c 3d 3e 3f 3g 3h 3i 3j bond, or wherein four substituents selected from R , R , R , R , R , R , R , R , R , R , 3k 3l R , and R on two adjacent carbon atoms are taken together with the bond between said adjacent carbon atoms form a carbon-carbon triple bond; 11 11 11 U is selected from –O–, –S(O) –, –NR –, –(C=O)–, –NR (C=O)–, –(C=O)NR –, – 11 11 11 11 11 11 S(O) NR –, –NR S(O) – , –NR S(O) NR –, and –NR C(O)NR -; p p p 11 11 11 11 11 11 11 11 11 T is selected from –NR R , –NR (C=O)OR , –NR (C=NR )NR R , and OR ; 11 3a 3b 3c 3d 3e 3f alternatively, one R and one substituent selected from R , R , R , R , R , R , 3g 3h 3i 3j 3k 3l R , R , R , R , R , and R are taken together with the intervening atoms to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; wherein each (a) through (b) is optionally substituted with one or more R ; R is selected from: , , , , , , , , , , , , , , and ; 9k 9l 9m 9n 9o 9p 9q 9r 9s 9t wherein R , R , R , R , R , R , R , R , R , and R are each independently selected from (a) hydrogen, (b) halogen, (c) –CN, (d) –N , (e) –NO , (f) –OCF , (g) –OCH , 3 2 3 3 11 11 11 11 11 (h) –OCF H, (i) –OCFH , (j) –OR , (k) –NH , (l) –NR R , (m) –C(O)R , (n) –C(O)OR , 2 2 2 11 11 11 11 11 (o) –C(O)NR R , (p) –NR C(O)R , (q) –S(O) R , (r) –C –C alkyl, (s) –C –C alkenyl, p 1 8 2 8 (t) –C –C alkynyl, (u) haloalkyl, (v) –3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (w) –3–14 membered saturated, unsaturated, or aromatic carbocycle; wherein each (r) through (w) is optionally substituted with one or more R ; 9k 9l 9m 9n alternatively, one or more pairs of substituents selected from R and R , R and R , 9o 9p 9q 9r 9s 9t R and R , R and R , and R and R are taken together with the carbon atom to which they are attached to form (a) 3–7 membered saturated or unsaturated carbocyclic, (b) 3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (c) an exo carbon-carbon double bond, (d) carbonyl group, or (e) thiocarbonyl group; wherein each (a) through (c) is optionally substituted with one or more R ; 9k 9l 9m 9n 9o 9p 9q 9r 9s alternatively, two substituents selected from R , R , R , R , R , R , R , R , R , and R on different carbon atoms are taken together with the intervening atoms to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; wherein each (a) through (b) is optionally substituted with one or more R ; 9k 9l 9m 9n 9o 9p 9q 9r 9s alternatively, two substituents selected from R , R , R , R , R , R , R , R , R , and R on two adjacent carbon atoms are taken together with the bond between said adjacent carbon atoms form a substituted or unsubstituted carbon-carbon double bond, or four 9k 9l 9m 9n 9o 9p 9q 9r 9s 9t substituents selected from R , R , R , R , R , R , R , R , R , and R on two adjacent carbon atoms are taken together with the bond between said adjacent carbon atoms form a carbon-carbon triple bond; 11 11 11 Z is selected from –O–, –S(O) –, –NR –, –(C=O)–, –NR (C=O)–, –(C=O)NR –, – 11 11 11 11 11 11 S(O) NR –, –NR S(O) –, –NR S(O) NR –, and –NR C(O)NR –; p p p 11 11 11 11 11 11 11 11 11 W is selected from –NR R , –NR (CO)OR , –NR (C=NR )NR R , and –OR ; 11 9k 9l 9m 9n 9o 9p alternatively, one R and one substituent selected from R , R , R , R , R , R , 9q 9r 9s 9t R , R , R , and R are taken together with the intervening atoms to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; wherein each (a) through (b) is optionally substituted with one or more R ; R is independently selected from (a) hydrogen, (b) halogen, (c) –OH, (d) –SH, (e) – (C –C alkyl)OH, (f) –OCF , (g) –OCH , (h) –OCF H, (i) –OCFH , (j) –O(C –C alkyl), (k) – 1 8 3 3 2 2 1 8 CN, (l) –NO , (m) –CONH , (n) C(O)NH(C -C alkyl), (o) C(O)N(C -C alkyl) , (p) –COH, 2 2 1 8 1 8 2 (q) –COCH , (r) –S(O) CH , (s) –S(O) N(C –C alkyl) , (t) –S(C –C alkyl), (u) –C(O)OH, 3 p 3 p 1 8 2 1 8 (v) –C(O)O(C –C alkyl), (w) –N , (x) –NHC(O)(C –C alkyl), (y) –N(C –C alkyl)C(O)(C – 1 8 3 1 8 1 8 1 C alkyl), (z) –NH , (aa) –NH(C –C alkyl), (bb) –N(C –C alkyl) , (cc) –C –C alkyl, (dd) – 8 2 1 8 1 8 2 1 8 C –C alkenyl, (ee) –C –C alkynyl, (ff) –haloalkyl, (gg) –(C –C alkyl)–(3–14 membered 2 8 2 8 1 8 saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (hh) –(C –C alkyl)–(3–14 membered saturated, unsaturated, or aromatic carbocycle), (ii) –3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (jj) –3–14 membered saturated, unsaturated, or aromatic carbocycle, (kk) –(C=NH)NH , (ll) –C(=NH)NH , (mm) –C(O)R , (nn) =O, and (oo) =NR ; wherein each (aa) through (jj) is optionally substituted with one or more R ; R is independently selected from (a) hydrogen, (b) halogen, (c) –C –C alkyl, (d) –C –C 1 8 2 8 alkenyl, (e) –C –C alkynyl, (f) –haloalkyl, (g) –OH, (h) –OC -C alkyl, (i) –OC –C alkenyl, 2 8 1 8 2 8 (j) –OC –C alkynyl, (k) –OCF , (l) –OCH , (m) –OCF H, (n) –OCFH , (o) –NH , (p) –CN, 2 8 3 3 2 2 2 (q) –N , (r) –S(O) C -C alkyl, (s) –3–14 membered saturated, unsaturated, or aromatic 3 p 1 8 heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (t) –3–14 membered saturated, unsaturated, or aromatic carbocycle; p is 0, 1, or 2; and t is 0, 1, or 2.
In one aspect, the present invention relates to a compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, having the formula: (I), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, wherein 1 2 3 4 5 X is CR or N; X is CR or N; X is CR or N; X is CR or N; X is CR or N; with 1 2 3 4 5 the proviso that X , X , X , X , and X are not all N; 1 2 3 4 5 6 7 8 9 10 Y is CR or N; Y is CR or N; Y is CR or N; Y is CR or N; Y is CR or N; 6 7 8 9 10 with the proviso that Y , Y , Y , Y , and Y are not all N; wherein 6 7 8 9 10 1 2 4 5 6 7 8 10 R , R , R , R , R , R , R and R are each independently selected from (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) –CF , (g) –CF H, (h) –CFH , (i) –OCF , (j) –OCF H, (k) – 2 2 3 2 11 11 11 11 OCFH , (l) –OCH , (m) –CN, (n) –N , (o) –NO , (p) –NR R , (q) –NR (CO)R , (r) – 2 3 3 11 11 11 11 (CO)NR R , (s) –OR , (t) –COH, (u) –CO(C –C alkyl), (v) –COR , (w) – 11 11 11 11 11 11 11 11 NR (CNR )NR R , (x) –S(O) R , (y) –NR S(O) R , (z) –SR , (aa) –SCF , (bb) – p p 3 11 11 11 11 11 C(CF )H-NH-CHR R , (cc) –COOR , (dd) –(OCH CH ) R , (ee) –(OCH CH ) OR , (ff) 3 2 2 t 2 2 t –C –C alkyl, (gg) –C –C alkenyl, (hh) –C –C alkynyl, (ii) –(C –C alkyl)–(3–14 1 8 2 8 2 8 1 8 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (jj) –(C –C alkyl)–(3–14 membered saturated, unsaturated, or aromatic carbocycle), (kk) –haloalkyl, (ll) –3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (mm) –3–14 membered saturated, unsaturated, or aromatic carbocycle, and (nn) –CHR -NH-(3-14 membered saturated, unsaturated, or aromatic heterocycle containing one of more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur); wherein each (ff) through (nn) is optionally substituted with one or more R ; each R is independently selected from (a) hydrogen, (b) halogen, (c) –CF , (d) – CF H, (e) –CFH , (f) –OH, (g) –SH, (h) –(C –C alkyl)OH, (i) –OCF , (j) –OCF H, (k) – 2 2 1 8 3 2 12 12 OCFH , (l) –OCH , (m) –OR , (n) –COR , (o) –CN, (p) –NO , (q) –CONH , (r) – 2 3 2 2 12 12 12 12 12 CONR R , (s) –C(O)CH , (t) –S(O) CH , (u) –S(O) NR R , (v) –SR , (w) –C(O)OH, (x) 3 p 3 p 12 12 12 –C(O)OR , (y) –N , (z) –NH , (aa) –NR C(O)R , (bb) –NH(C –C alkyl), (cc) –N(C –C 3 2 1 8 1 8 alkyl) , (dd) –C –C alkyl, (ee) –C –C alkenyl, (ff) –C –C alkynyl, (gg) –haloalkyl, (hh) – 2 1 8 2 8 2 8 (C –C alkyl)–(3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (ii) –(C –C alkyl)–(3–14 membered saturated, unsaturated, or aromatic carbocycle), (jj) –3– 14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (kk) –3–14 12 12 membered saturated, unsaturated, or aromatic carbocycle, and (ll) –(C=NH)NR R ; wherein each (bb) through (kk) is optionally substituted with one or more R ; alternatively two R subsituents are taken together to form (a) 3–7 membered saturated or unsaturated carbocyclic or (b) 3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, wherein each (a) through (b) is optionally substituted with one or more R ; R is selected from: , , , , , and ; 3a 3b 3c 3d 3e 3f 3g 3h 3i 3j wherein R , R , R , R , R , R , R , R , R , and R are each independently selected from (a) hydrogen, (b) halogen, (c) –CH , (d) –CF , (e) –CF H, (f) –CFH , (g) – 3 3 2 2 OCF , (h) –OCF H, (i) –OCFH , (j) –OCH , (k) –OR , (l) –C –C alkyl, (m) haloalkyl, (n) – 3 2 2 3 1 8 3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (o) –3– 14 membered saturated, unsaturated, or aromatic carbocycle; wherein each (l) through (o) is optionally substituted with one or more R ; 3a 3b 3c 3d alternatively, one or more pairs of substituents selected from R and R , R and R , 3e 3f 3g 3h 3i 3j R and R , R and R , and R and R are taken together with the carbon atom to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic, (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (c) an exo carbon-carbon double bond, (d) carbonyl group, or (e) thiocarbonyl group; wherein each (a) through (b) is optionally substituted with one or more R ; 3a 3b 3c 3d 3e 3f 3g alternatively, wherein two substituents selected from R , R , R , R , R , R , R , 3h 3i 3j R , R , and R on different carbon atoms are taken together with the intervening atoms to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; wherein each (a) through (b) is optionally substituted with one or more R ; 3a 3b 3c 3d 3e 3f 3g alternatively, wherein two substituents selected from R , R , R , R , R , R , R , 3h 3i 3j R , R , and R on two adjacent carbon atoms are taken together with the bond between said adjacent carbon atoms form a substituted or unsubstituted carbon-carbon double bond, or 3a 3b 3c 3d 3e 3f 3g 3h 3i 3j wherein four substituents selected from R , R , R , R , R , R , R , R , R , and R on two adjacent carbon atoms are taken together with the bond between said adjacent carbon atoms form a carbon-carbon triple bond; 11 11 11 U is selected from –O–, –S(O) –, –NR –, –(C=O)–, –NR (C=O)–, –(C=O)NR –, – 11 11 11 11 S(O) NR –, –NR S(O) – and –NR S(O) NR –; p p p 11 11 11 11 11 11 11 11 11 T is selected from –NR R , –NR (C=O)OR , –NR (C=NR )NR R , and OR ; 11 3a 3b 3c 3d 3e 3f alternatively, one R and one substituent selected from R , R , R , R , R , R , 3g 3h 3i 3j R , R , R , and R are taken together with the intervening atoms to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; wherein each (a) through (b) is optionally substituted with one or more R ; R is selected from: , , , , , , , , , , , , , , and ; 9k 9l 9m 9n 9o 9p 9q 9r 9s 9t wherein R , R , R , R , R , R , R , R , R , and R are each independently selected from (a) hydrogen, (b) halogen, (c) –CH , (d) –CF , (e) –CF H, (f) –CFH , (g) – 3 3 2 2 OCF , (h) –OCH , (i) –OCF H, (j) –OCFH , (k) –OR , (l) –C –C alkyl, (m) haloalkyl, (n) – 3 3 2 2 1 8 3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (o) –3– 14 membered saturated, unsaturated, or aromatic carbocycle; wherein each (l) through (o) is optionally substituted with one or more R ; 9k 9l 9m 9n alternatively, one or more pairs of substituents selected from R and R , R and R , 9o 9p 9q 9r 9s 9t R and R , R and R , and R and R are taken together with the carbon atom to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic, (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (c) an exo carbon-carbon double bond, (d) carbonyl group, and (e) thiocarbonyl group; wherein each (a) through (c) is optionally substituted with one or more R ; 9k 9l 9m 9n 9o 9p 9q 9r 9s alternatively, two substituents selected from R , R , R , R , R , R , R , R , R , and R on different carbon atoms are taken together with the intervening atoms to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; wherein each (a) through (b) is optionally substituted with one or more R ; 9k 9l 9m 9n 9o 9p 9q 9r 9s alternatively, two substituents selected from R , R , R , R , R , R , R , R , R , and R on two adjacent carbon atoms are taken together with the bond between said adjacent carbon atoms form a substituted or unsubstituted carbon-carbon double bond, or four 9k 9l 9m 9n 9o 9p 9q 9r 9s 9t substituents selected from R , R , R , R , R , R , R , R , R , and R on two adjacent carbon atoms are taken together with the bond between said adjacent carbon atoms form a carbon-carbon triple bond; 11 11 11 Z is selected from –O–, –S(O) –, –NR –, –(C=O)–, –NR (C=O)–, –(C=O)NR –, – 11 11 11 11 S(O) NR –, –NR S(O) – and –NR S(O) NR –; p p p 11 11 11 11 11 11 11 11 11 W is selected from –NR R , –NR (CO)OR , –NR (C=NR )NR R , and –OR ; 11 9k 9l 9m 9n 9o 9p alternatively, one R and one substituent selected from R , R , R , R , R , R , 9q 9r 9s 9t R , R , R , and R are taken together with the intervening atoms to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; wherein each (a) through (b) is optionally substituted with one or more R ; R is independently selected from (a) hydrogen, (b) halogen, (c) –CF , (d) –CF H, (e) –CFH , (f) –OH, (g) –SH, (h) –(C –C alkyl)OH, (i) –OCF , (j) –OCH , (k) –OCF H, (l) – 2 1 8 3 3 2 OCFH , (m) –O(C –C alkyl), (n) –CN, (o) –NO , (p) –CONH , (q) –C(O)H, (r) –C(O)CH , 2 1 8 2 2 3 (s) –S(O) CH , (t) –S(O) N(C –C alkyl) , (u) –S(C –C alkyl), (v) –C(O)OH, (w) – p 3 p 1 8 2 1 8 C(O)O(C –C alkyl), (x) –N , (y) –NHC(O)(C –C alkyl), (z) –N(C –C alkyl)C(O)(C –C 1 8 3 1 8 1 8 1 8 alkyl), (aa) –NH , (bb) –NH(C –C alkyl), (cc) –N(C –C alkyl) , (dd) –C –C alkyl, (ee) – 2 1 8 1 8 2 1 8 C –C alkenyl, (ff) –C –C alkynyl, (gg) –haloalkyl, (hh) –(C –C alkyl)–(3–14 membered 2 8 2 8 1 8 saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (ii) –(C –C alkyl)–(3–14 membered saturated, unsaturated, or aromatic carbocycle), (jj) –3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (kk) –3–14 membered saturated, unsaturated, or aromatic carbocycle, (ll) –(C=NH)NH , (mm) –C(O)NH(C -C alkyl), (nn) – 2 1 8 C(O)N(C -C alkyl) , and (oo) –C(=NH)NH ; 1 8 2 2 p is 0, 1, or 2; and t is 0, 1, or 2.
In addition, the invention provides methods of synthesizing the foregoing compounds and tautomers thereof, and pharmaceutically acceptable salts, esters and prodrugs of said compounds and tautomers. Following synthesis, an effective amount of one or more of the compounds or tautomers thereof, or pharmaceutically acceptable salts, esters or prodrugs of said compounds or tautomers can be formulated with a pharmaceutically acceptable carrier for administration to a human or animal for use as antimicrobial agents, particularly as antibacterial agents. In certain embodiments, the compounds of the present invention are useful for treating, preventing, or reducing the risk of microbial infections or for the manufacture of a medicament for treating, preventing, or reducing the risk of microbial infections. Accordingly, the compounds or tautomers thereof, or pharmaceutically acceptable salts, esters, or prodrugs of said compounds or tautomers or their formulations can be administered, for example, via oral, parenteral, intravenous, otic, ophthalmic, nasal, or topical routes, to provide an effective amount of the compound or tautomer thereof, or pharmaceutically acceptable salt, ester or prodrug of said compound or tautomer to the human or animal.
The foregoing and other aspects and embodiments of the invention can be more fully understood by reference to the following detailed description and claims.
Definitions of specific embodiments of the invention as claimed herein follow.
According to a first embodiment of the invention, there is provided a compound having the formula: (II) or a tautomer thereof, or a pharmaceutically acceptable salt, or ester of said compound or tautomer, wherein 1 2 4 5 X is CR or N; X is CR or N; X is CR or N; X is CR or N; 1 2 4 5 1 2 4 5 R , R , R , and R are each independently selected from (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) –CF , (g) –CF H, (h) –CFH , (i) –OCF , (j) –OCF H, (k) –OCFH , (l) –OCH , (m) 2 2 3 2 2 3 11 11 11 11 11 11 11 –CN, (n) –N , (o) –NO , (p) –NR R , (q) –NR C(O)R , (r) –C(O)NR R , (s) –OR , (t) – 11 11 11 11 11 11 COH, (u) –CO(C –C alkyl), (v) –COR , (w) –NR (CNR )NR R , (x) –S(O) R , (y) – 1 8 p 11 11 11 11 11 11 NR S(O) R , (z) –SR , (aa) –SCF , (bb) –C(CF )H-NH-CHR R , (cc) –COOR , (dd) – p 3 3 11 11 (OCH CH ) R , (ee) –(OCH CH ) OR , (ff) –C –C alkyl, (gg) –C –C alkenyl, (hh) –C –C 2 2 t 2 2 t 1 8 2 8 2 8 alkynyl, (ii) –(C –C alkyl)–(3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (jj) –(C –C alkyl)–(3–14 membered saturated, unsaturated, or aromatic carbocycle), (kk) –haloalkyl, (ll) –3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (mm) –3–14 membered saturated, unsaturated, or aromatic carbocycle, and (nn) –CHR -NH-(3-14 membered saturated, unsaturated, or aromatic heterocycle containing one of more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur); wherein each (ff) through (nn) is optionally substituted with one or more R ; wherein: is selected from the group consisting of: each R is independently selected from (a) hydrogen, (b) halogen, (c) –OH, (d) –SH, (e) 12 12 –(C –C alkyl)OH, (f) –OCF , (g) –OCF H, (h) –OCFH , (i) –OCH , (j) –OR , (k) –COR , (l) 1 8 3 2 2 3 12 12 –CN, (m) –NO , (n) –CONH , (o) –CONR R , (p) –COCH , (q) –S(O) CH , (r) 2 2 3 p 3 12 12 12 12 –S(O) NR R , (s) –SR , (t) –C(O)OH, (u) –C(O)OR , (v) –N , (w) –NH , (x) – p 3 2 12 12 NR C(O)R , (y) –NH(C –C alkyl), (z) –N(C –C alkyl) , (aa) –C –C alkyl, (bb) –C –C 1 8 1 8 2 1 8 2 8 alkenyl, (cc) –C –C alkynyl, (dd) –haloalkyl, (ee) –(C –C alkyl)–(3–14 membered saturated, 2 8 1 8 unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (ff) –(C –C alkyl)–(3–14 membered saturated, unsaturated, or aromatic carbocycle), (gg) –3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (hh) –3–14 membered saturated, unsaturated, or aromatic carbocycle, and (ii) 12 12 –(C=NH)NR R ; wherein each (y) through (hh) is optionally substituted with one or more R ; alternatively two R substituents are taken together to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, wherein each (a) through (b) is optionally substituted with one or more R ; R is selected from: , , , , , , , and ; 3a 3b 3c 3d 3e 3f 3g 3h 3i 3j 3k 3l wherein R , R , R , R , R , R , R , R , R , R , R , and R are each independently selected from (a) hydrogen, (b) halogen, (c) –CN, (d) –N , (e) –NO , (f) –OCF , (g) –OCF H, 3 2 3 2 11 11 11 11 11 11 (h) –OCFH , (i) –OCH , (j) –OR , (k) –C(O)R , (l) –C(O)NR R , (m) –NH , (n) –NR R , 2 3 2 11 11 11 11 (o) –NR C(O)R , (p) –S(O) R , (q) –C(O)OH, (r) –C(O)OR , (s) –C –C alkyl, (t) –C –C p 1 8 2 8 alkenyl, (u) –C –C alkynyl, (v) haloalkyl, (w) –3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (x) –3–14 membered saturated, unsaturated, or aromatic carbocycle; wherein each (s) through (x) is optionally substituted with one or more R ; 3a 3b 3c 3d alternatively, one or more pairs of substituents selected from R and R , R and R , 3e 3f 3g 3h 3i 3j 3k 3l R and R , R and R , R and R , and R and R are taken together with the carbon atom to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic, (b) – 3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (c) an exo carbon-carbon double bond, (d) carbonyl group, or (e) thiocarbonyl group; wherein each (a) through (b) is optionally substituted with one or more R ; 3a 3b 3c 3d 3e 3f 3g alternatively, wherein two substituents selected from R , R , R , R , R , R , R , 3h 3i 3j 3k 3l R , R , R , R , and R on different carbon atoms are taken together with the intervening atoms to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; wherein each (a) through (b) is optionally substituted with one or more R ; 3a 3b 3c 3d 3e 3f 3g alternatively, wherein two substituents selected from R , R , R , R , R , R , R , 3h 3i 3j 3k 3l R , R , R , R , and R on two adjacent carbon atoms are taken together with the bond between said adjacent carbon atoms form a substituted or unsubstituted carbon-carbon double 3a 3b 3c 3d 3e 3f 3g 3h 3i 3j bond, or wherein four substituents selected from R , R , R , R , R , R , R , R , R , R , 3k 3l R , and R on two adjacent carbon atoms are taken together with the bond between said adjacent carbon atoms form a carbon-carbon triple bond; 11 11 11 U is selected from –O–, –S(O) –, –NR –, –(C=O)–, –NR (C=O)–, –(C=O)NR –, 11 11 11 11 11 11 –S(O) NR –, –NR S(O) – , –NR S(O) NR –, and –NR C(O)NR -; p p p 11 11 11 11 11 11 11 11 11 T is selected from –NR R , –NR (C=O)OR , –NR (C=NR )NR R , and OR ; 11 3a 3b 3c 3d 3e 3f 3g alternatively, one R and one substituent selected from R , R , R , R , R , R , R , 3h 3i 3j 3k 3l R , R , R , R , and R are taken together with the intervening atoms to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; wherein each (a) through (b) is optionally substituted with one or more R ; R is selected from: , , , , , , , , , , , and 9k 9l 9m 9n 9o 9p 9q 9r 9s 9t wherein R , R , R , R , R , R , R , R , R , and R are each independently selected from (a) hydrogen, (b) halogen, (c) –CN, (d) –N , (e) –NO , (f) –OCF , (g) –OCH , (h) 3 2 3 3 11 11 11 11 11 –OCF H, (i) –OCFH , (j) –OR , (k) –NH , (l) –NR R , (m) –C(O)R , (n) –C(O)OR , (o) 2 2 2 11 11 11 11 11 –C(O)NR R , (p) –NR C(O)R , (q) –S(O) R , (r) –C –C alkyl, (s) –C –C alkenyl, (t) – p 1 8 2 8 C –C alkynyl, (u) haloalkyl, (v) –3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (w) –3–14 membered saturated, unsaturated, or aromatic carbocycle; wherein each (r) through (w) is optionally substituted with one or more R ; 9k 9l 9m 9n alternatively, one or more pairs of substituents selected from R and R , R and R , 9o 9p 9q 9r 9s 9t R and R , R and R , and R and R are taken together with the carbon atom to which they are attached to form (a) 3–7 membered saturated or unsaturated carbocyclic, (b) 3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (c) an exo carbon-carbon double bond, (d) carbonyl group, or (e) thiocarbonyl group; wherein each (a) through (c) is optionally substituted with one or more R ; 9k 9l 9m 9n 9o 9p 9q 9r 9s alternatively, two substituents selected from R , R , R , R , R , R , R , R , R , and R on different carbon atoms are taken together with the intervening atoms to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; wherein each (a) through (b) is optionally substituted with one or more R ; 9k 9l 9m 9n 9o 9p 9q 9r 9s alternatively, two substituents selected from R , R , R , R , R , R , R , R , R , and R on two adjacent carbon atoms are taken together with the bond between said adjacent carbon atoms form a substituted or unsubstituted carbon-carbon double bond, or four 9k 9l 9m 9n 9o 9p 9q 9r 9s 9t substituents selected from R , R , R , R , R , R , R , R , R , and R on two adjacent carbon atoms are taken together with the bond between said adjacent carbon atoms form a carbon-carbon triple bond; 11 11 11 Z is selected from –O–, –S(O) –, –NR –, –(C=O)–, –NR (C=O)–, –(C=O)NR –, 11 11 11 11 11 11 –S(O) NR –, –NR S(O) –, –NR S(O) NR –, and –NR C(O)NR –; p p p 11 11 11 11 11 11 11 11 11 W is selected from –NR R , –NR (CO)OR , –NR (C=NR )NR R , and –OR ; 11 9k 9l 9m 9n 9o 9p 9q alternatively, one R and one substituent selected from R , R , R , R , R , R , R , 9r 9s 9t R , R , and R are taken together with the intervening atoms to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; wherein each (a) through (b) is optionally substituted with one or more R ; R is independently selected from (a) hydrogen, (b) halogen, (c) –OH, (d) –SH, (e) – (C –C alkyl)OH, (f) –OCF , (g) –OCH , (h) –OCF H, (i) –OCFH , (j) –O(C –C alkyl), (k) – 1 8 3 3 2 2 1 8 CN, (l) –NO , (m) –CONH , (n) C(O)NH(C -C alkyl), (o) C(O)N(C -C alkyl) , (p) –COH, (q) 2 2 1 8 1 8 2 –COCH , (r) –S(O) CH , (s) –S(O) N(C –C alkyl) , (t) –S(C –C alkyl), (u) –C(O)OH, (v) 3 p 3 p 1 8 2 1 8 –C(O)O(C –C alkyl), (w) –N , (x) –NHC(O)(C –C alkyl), (y) –N(C –C alkyl)C(O)(C –C 1 8 3 1 8 1 8 1 8 alkyl), (z) –NH , (aa) –NH(C –C alkyl), (bb) –N(C –C alkyl) , (cc) –C –C alkyl, (dd) –C – 2 1 8 1 8 2 1 8 2 C alkenyl, (ee) –C –C alkynyl, (ff) –haloalkyl, (gg) –(C –C alkyl)–(3–14 membered 8 2 8 1 8 saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (hh) –(C –C alkyl)–(3–14 membered saturated, unsaturated, or aromatic carbocycle), (ii) –3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (jj) –3–14 membered saturated, unsaturated, or aromatic carbocycle, (kk) 13 13 –(C=NH)NH , (ll) –C(=NH)NH , (mm) –C(O)R , (nn) =O, and (oo) =NR ; wherein each (aa) through (jj) is optionally substituted with one or more R ; R is independently selected from (a) hydrogen, (b) halogen, (c) –C –C alkyl, (d) –C –C 1 8 2 8 alkenyl, (e) –C –C alkynyl, (f) –haloalkyl, (g) –OH, (h) –OC -C alkyl, (i) –OC –C alkenyl, 2 8 1 8 2 8 (j) –OC –C alkynyl, (k) –OCF , (l) –OCH , (m) –OCF H, (n) –OCFH , (o) –NH , (p) –CN, (q) 2 8 3 3 2 2 2 –N , (r) –S(O) C -C alkyl, (s) –3–14 membered saturated, unsaturated, or aromatic heterocycle 3 p 1 8 containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (t) –3–14 membered saturated, unsaturated, or aromatic carbocycle; p is 0, 1, or 2; and t is 0, 1, or 2; and wherein the nitrogen and sulfur heteroatoms in any heterocycle in the compound are unoxidized or oxidized (N→O and S(O) , wherein p = 1 or 2).
According to a second embodiment of the invention, there is provided a pharmaceutical composition comprising a compound according to the first embodiment or a tautomer thereof, or a pharmaceutically acceptable salt, or ester of said compound or tautomer, and a pharmaceutically acceptable carrier.
According to a third embodiment of the invention, there is provided use of a compound according to the first embodiment, or a tautomer thereof, or a pharmaceutically acceptable salt, or ester of said compound or tautomer, in the manufacture of a medicament for treating, preventing, or reducing a microbial infection in a human or animal.
According to a fourth embodiment of the invention, there is provided a medical device containing a compound according to the first embodiment, or a tautomer thereof, or a pharmaceutically acceptable salt, or ester of said compound or tautomer.
DETAILED DESCRIPTION OF THE INVENTION The present invention provides a family of compounds or tautomers thereof that can be used as antimicrobial agents, more particularly as antibacterial agents.
The present invention also includes pharmaceutically acceptable salts, esters, and prodrugs of said compounds and tautomers.
The compounds or tautomers thereof, or pharmaceutically acceptable salts, esters, or prodrugs of said compounds or tautomers described herein can have asymmetric centers.
Compounds or tautomers thereof or pharmaceutically acceptable salts, esters, or prodrugs of said compounds or tautomers of the present invention containing an asymmetrically substituted atom can be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds or tautomers thereof, or pharmaceutically acceptable salts, esters, or prodrugs of said compounds or tautomers described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds or tautomers thereof, or pharmaceutically acceptable salts, esters, or prodrugs of said compounds or tautomers of the present invention are described and can be isolated as a mixture of isomers or as separate isomeric forms. All chiral, diastereomeric, racemic, and geometric isomeric forms of a structure are intended, unless specific stereochemistry or isomeric form is specifically indicated. All processes used to prepare compounds or tautomers thereof, or pharmaceutically acceptable salts, esters, or prodrugs of said compounds or tautomers of the present invention and intermediates made therein are considered to be part of the present invention. All tautomers of shown or described compounds are also considered to be part of the present invention. Furthermore, the invention also includes metabolites of the compounds described herein.
The invention also comprehends isotopically-labeled compounds or tautomers thereof, or pharmaceutically acceptable salts, esters, or prodrugs of said compounds or tautomers, which are identical to those recited in formulae of the invention and following, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number most commonly found in nature.
Examples of isotopes that can be incorporated into compounds or tautomers thereof, or pharmaceutically acceptable salts, esters, or prodrugs of said compounds or tautomers of the 3 11 14 invention include isotopes of hydrogen, carbon, nitrogen, fluorine, such as H, C, C and F.
Compounds or tautomers thereof, or pharmaceutically acceptable salts, esters, or prodrugs of said compounds or tautomers of the present invention that contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of the present invention. Isotopically-labeled compounds or tautomers thereof, or pharmaceutically acceptable salts, esters, or prodrugs of said compounds or tautomers of the present invention, 3 14 for example those into which radioactive isotopes such as H, C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., H, and carbon-14, i.e., C, isotopes are particularly preferred for their ease of preparation and detectability. 11 8 C and F isotopes are particularly useful in PET (positron emission tomography). PET is useful in brain imaging. Further, substitution with heavier isotopes such as deuterium, i.e., H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances, isotopically labeled compounds or tautomers thereof, or pharmaceutically acceptable salts, esters, or prodrugs of said compounds or tautomers having a formula of the invention can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples below, by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent. In one embodiment, the compounds or tautomers thereof, or pharmaceutically acceptable salts, esters, or prodrugs of said compounds or tautomers of the invention are not isotopically labelled.
When any variable (e.g., R ) occurs more than one time in any constituent or formulae of the invention, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with one or 12 12 more R moieties, then R at each occurrence is selected independently from the definition of R . Also, combinations of substituents and/or variables are permissible, but only if such combinations result in stable compounds within a designated atom’s normal valency.
A chemical structure showing a dotted line representation for a chemical bond indicates that the bond is optionally present. For example, a dotted line drawn next to a solid single bond indicates that the bond can be either a single bond or a double bond.
When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent can be bonded to any atom on the ring. When a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound of a given formula, then such substituent can be bonded via any atom in such substituent.
Combinations of substituents and/or variables are permissible, but only if such combinations result in stable compounds.
In cases wherein there are nitrogen atoms in the compounds or tautomers thereof, or pharmaceutically acceptable salts, esters, or prodrugs of said compounds or tautomers of the present invention, these, where appropriate, can be converted to N–oxides by treatment with an oxidizing agent (e.g., MCPBA and/or hydrogen peroxides). Thus, shown and claimed nitrogen atoms are considered to cover both the shown nitrogen and its N–oxide (N O) derivative, as appropriate. In some embodiments, the present invention relates to N-oxides of the compounds or tautomers thereof, or pharmaceutically acceptable salts, esters, or prodrugs of said compounds or tautomers disclosed herein.
One approach to developing improved anti–proliferative and anti–infective agents is to provide modulators (for example, inhibitors) of ribosome function.
Ribosomes are ribonucleoproteins, which are present in both prokaryotes and eukaryotes. Ribosomes are the cellular organelles responsible for protein synthesis. During gene expression, ribosomes translate the genetic information encoded in a messenger RNA into protein (Garrett et al. (2000) "The Ribosome: Structure, Function, Antibiotics and Cellular Interactions," American Society for Microbiology, Washington, D.C.).
Ribosomes comprise two nonequivalent ribonucleoprotein subunits. The larger subunit (also known as the "large ribosomal subunit") is about twice the size of the smaller subunit (also known as the "small ribosomal subunit"). The small ribosomal subunit binds messenger RNA (mRNA) and mediates the interactions between mRNA and transfer RNA (tRNA) anticodons on which the fidelity of translation depends. The large ribosomal subunit catalyzes peptide bond formation, i.e. the peptidyl–transferase reaction of protein synthesis, and includes, at least, three different tRNA binding sites known as the aminoacyl, peptidyl, and exit sites. The aminoacyl site or A–site accommodates the incoming aminoacyl–tRNA that is to contribute its amino acid to the growing peptide chain. Also, the A space of the A– site is important. The peptidyl site or P–site accommodates the peptidyl–tRNA complex, i.e., the tRNA with its amino acid that is part of the growing peptide chain. The exit or E–site accommodates the deacylated tRNA after it has donated its amino acid to the growing polypeptide chain. 1. Definitions "Isomerism" means compounds that have identical molecular formulae but that differ in the nature or the sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed "stereoisomers". Stereoisomers that are not mirror images of one another are termed "diastereoisomers", and stereoisomers that are non-superimposable mirror images are termed "enantiomers", or sometimes optical isomers. A carbon atom bonded to four nonidentical substituents is termed a "chiral center".
"Chiral isomer" means a compound with at least one chiral center. A compound with one chiral center has two enantiomeric forms of opposite chirality and may exist either as an individual enantiomer or as a mixture of enantiomers. A mixture containing equal amounts of individual enantiomeric forms of opposite chirality is termed a "racemic mixture". A compound that has more than one chiral center has 2 enantiomeric pairs, where n is the number of chiral centers. Compounds with more than one chiral center may exist as either an individual diastereomer or as a mixture of diastereomers, termed a "diastereomeric mixture".
When one chiral center is present, a stereoisomer may be characterized by the absolute configuration (R or S) of that chiral center. Absolute configuration refers to the arrangement in space of the substituents attached to the chiral center. The substituents attached to the chiral center under consideration are ranked in accordance with the Sequence Rule of Cahn, Ingold and Prelog. (Cahn et al, Angew. Chem. Inter. Edit. 1966, 5, 385; errata 511; Cahn et al., Angew. Chem. 1966, 78, 413; Cahn and Ingold, J. Chem. Soc. 1951 (London), 612; Cahn et al., Experientia 1956, 12, 81; Cahn, J., Chem. Educ. 1964, 41, 116).
"Geometric Isomers" means the diastereomers that owe their existence to hindered rotation about double bonds. These configurations are differentiated in their names by the prefixes cis and trans, or Z and E, which indicate that the groups are on the same or opposite side of the double bond in the molecule according to the Cahn-Ingold-Prelog rules.
Further, the compounds discussed in this application include all atropic isomers thereof. "Atropic isomers" are a type of stereoisomer in which the atoms of two isomers are arranged differently in space. Atropic isomers owe their existence to a restricted rotation caused by hindrance of rotation of large groups about a central bond. Such atropic isomers typically exist as a mixture, however as a result of recent advances in chromatography techniques, it has been possible to separate mixtures of two atropic isomers in select cases.
"Tautomers" refers to compounds whose structures differ markedly in arrangement of atoms, but which exist in easy and rapid equilibrium. It is to be understood that compounds of present invention may be depicted as different tautomers. It should also be understood that when compounds have tautomeric forms, all tautomeric forms are intended to be within the scope of the invention, and the naming of the compounds does not exclude any tautomer form.
Some compounds of the present invention can exist in a tautomeric form which is also intended to be encompassed within the scope of the present invention.
The compounds, pharmaceutically acceptable salts, esters and prodrugs of the present invention can exist in several tautomeric forms, including the enol and imine form, and the keto and enamine form and geometric isomers and mixtures thereof. All such tautomeric forms are included within the scope of the present invention. Tautomers exist as mixtures of a tautomeric set in solution. In solid form, usually one tautomer predominates. Even though one tautomer may be described, the present invention includes all tautomers of the present compounds.
A tautomer is one of two or more structural isomers that exist in equilibrium and are readily converted from one isomeric form to another. This reaction results in the formal migration of a hydrogen atom accompanied by a switch of adjacent conjugated double bonds.
In solutions where tautomerization is possible, a chemical equilibrium of the tautomers can be reached. The exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH. The concept of tautomers that are interconvertable by tautomerizations is called tautomerism.
Of the various types of tautomerism that are possible, two are commonly observed. In keto-enol tautomerism a simultaneous shift of electrons and a hydrogen atom occurs. Ring- chain tautomerism, is exhibited by glucose. It arises as a result of the aldehyde group (-CHO) in a sugar chain molecule reacting with one of the hydroxy groups (-OH) in the same molecule to give it a cyclic (ring-shaped) form.
Tautomerizations are catalyzed by: Base: 1. deprotonation; 2. formation of a delocalized anion (e.g. an enolate); 3. protonation at a different position of the anion; Acid: 1. protonation; 2. formation of a delocalized cation; 3. deprotonation at a different position adjacent to the cation.
Common tautomeric pairs are: ketone - enol, amide - nitrile, lactam - lactim, amide - imidic acid tautomerism in heterocyclic rings (e.g. in the nucleobases guanine, thymine, and cytosine), amine - enamine and enamine - enamine. An example below is included for illustrative purposes, and the present invention is not limited to this example: The terms "crystal polymorphs" or "polymorphs" or "crystal forms" means crystal structures in which a compound (or salt or solvate thereof) can crystallize in different crystal packing arrangements, all of which have the same elemental composition. Different crystal forms usually have different X-ray diffraction patterns, infrared spectral, melting points, density hardness, crystal shape, optical and electrical properties, stability and solubility.
Recrystallization solvent, rate of crystallization, storage temperature, and other factors may cause one crystal form to dominate. Crystal polymorphs of the compounds can be prepared by crystallization under different conditions.
The term "substituted," as used herein, means that any one or more hydrogens on the designated atom, usually a carbon, oxygen, or nitrogen atom, is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substituent is keto (i.e., =O), then 2 hydrogens on the atom are replaced. Ring double bonds, as used herein, are double bonds that are formed between two adjacent ring atoms (e.g., C=C, C=N, N=N, etc.).
As used herein, the term "anomeric carbon" means the acetal carbon of a glycoside.
As used herein, the term "glycoside" is a cyclic acetal.
As used herein, "alkyl" is intended to include both branched and straight–chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. For example C is intended to include C , C , C , and C C alkyl is intended to include C , 1-4 1 2 3 4 1–6 1 C , C , C , C , and C alkyl groups and C is intended to include C , C , C , C , C , C , C , 2 3 4 5 6 1-8 1 2 3 4 5 6 7 and C . Some examples of alkyl include, but are not limited to, methyl, ethyl, n–propyl, i– propyl, n–butyl, s–butyl, t–butyl, n–pentyl, s–pentyl, n–hexyl, n–heptyl, and n–octyl.
As used herein, "alkenyl" is intended to include hydrocarbon chains of either straight or branched configuration and one or more unsaturated carbon–carbon bonds that can occur in any stable point along the chain, such as ethenyl and propenyl. For example C alkenyl is intended to include C , C , C , C , and C alkenyl groups and C alkenyl is intended to 2 3 4 5 6 include C , C , C , C , C , C , and C . 2 3 4 5 6 7 8 As used herein, "alkynyl" is intended to include hydrocarbon chains of either straight or branched configuration and one or more triple carbon–carbon bonds that can occur in any stable point along the chain, such as ethynyl and propynyl. For example, C alkynyl is intended to include C , C , C , C , and C alkynyl groups and C alkynyl is intended to 2 3 4 5 6 include C , C , C , C , C , C , and C . 2 3 4 5 6 7 8 Furthermore, "alkyl", "alkenyl", and "alkynyl" are intended to include moieties which are diradicals, i.e., having two points of attachment. A nonlimiting example of such an alkyl moiety that is a diradical is –CH CH –, i.e., a C alkyl group that is covalently bonded via each terminal carbon atom to the remainder of the molecule. The alkyl diradicals are also known as "alkylenyl" radicals. The alkenyl diradicals are also known as "alkenylenyl" radicals. The alkynyl diradicals are also known as "alkynylenyl" radicals..
As used herein, "cycloalkyl" is intended to include saturated ring groups, such as cyclopropyl, cyclobutyl, or cyclopentyl. C cycloalkyl is intended to include C , C , C , 3–8 3 4 5 C , C , and C cycloalkyl groups. 6 7 8 As used herein "counterion" is used to mean a positively or negatively charged species present in conjunction with an ion of opposite charge. A nonlimiting example of a counterion is an ion or ions present to counterbalance the charge or charges on an organic compound. Nonlimiting examples of counterions include chloride, bromide, hydroxide, acetate, sulfate, and ammonium.
As used herein, "halo" or "halogen" refers to fluoro, chloro, bromo, and iodo substituents.
As used herein, "haloalkyl" is intended to include both branched and straight–chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or more halogen (for example –C F wherein v = 1 to 3 and w = 1 to (2v+1)). Examples of haloalkyl include, but are not limited to, trifluoromethyl, trichloromethyl, pentafluoroethyl, and pentachloroethyl.
As used herein, "alkoxy" refers to an alkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge. C alkoxy, is intended to include C , C , C , C , C , and C alkoxy groups. C alkoxy, is intended to include C , C , 1 2 3 4 5 6 1–8 1 2 C , C , C , C , C , and C alkoxy groups. Examples of alkoxy include, but are not limited to, 3 4 5 6 7 8 methoxy, ethoxy, n–propoxy, i–propoxy, n–butoxy, s–butoxy, t–butoxy, n–pentoxy, s– pentoxy, n–heptoxy, and n–octoxy.
As used herein, "alkylthio" refers to an alkyl group as defined above with the indicated number of carbon atoms attached through a sulfur bridge. C alkylthio, is intended to include C , C , C , C , C , and C alkylthio groups. C alkylthio, is intended to 1 2 3 4 5 6 1–8 include C , C , C , C , C , C , C , and C alkylthio groups. 1 2 3 4 5 6 7 8 As used herein, "carbocycle" or "carbocyclic ring" is intended to mean, unless otherwise specified, any stable 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12–membered monocyclic, bicyclic or tricyclic ring, any of which can be saturated, unsaturated (including partially and fully unsaturated), or aromatic and said ring consists of carbon atoms in its core ring structure.
Examples of such carbocycles or carbocyclic rings include, but are not limited to, cyclopropyl, cyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, adamantyl, cyclooctyl, cyclooctenyl, cyclooctadienyl, [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane, [2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, and tetrahydronaphthyl. As shown above, bridged rings are also included in the definition of carbocycle (e.g., [2.2.2]bicyclooctane). A bridged ring occurs when one or more carbon atoms link two non–adjacent carbon atoms.
Preferred bridges are one or two carbon atoms. It is noted that a bridge always converts a monocyclic ring into a tricyclic ring. When a ring is bridged, the substituents recited for the ring can also be present on the bridge. Fused (e.g., naphthyl and tetrahydronaphthyl) and spiro rings are also included.
As used herein, the term "heterocycle" or "heterocyclic" ring means, unless otherwise stated, a stable 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12–membered monocyclic, bicyclic or tricyclic ring which is saturated, unsaturated (including partially and fully unsaturated), or aromatic, and said ring consists of carbon atoms and one or more heteroatoms in its core ring structure, e.g., 1 or 1–2 or 1–3 or 1–4 or 1–5 or 1–6 heteroatoms, independently selected from nitrogen, oxygen, and sulfur, and including any bicyclic or tricyclic group in which any of the above– defined heterocyclic rings is fused or attached to a second ring (e.g., a benzene ring). The nitrogen and sulfur heteroatoms can optionally be oxidized (i.e., N→O and S(O) , wherein p = 1 or 2). When a nitrogen atom is included in the ring it is either N or NH, depending on whether or not it is attached to a double bond in the ring (i.e., a hydrogen is present if needed to maintain the tri–valency of the nitrogen atom). The nitrogen atom can be substituted or unsubstituted (i.e., N or NR wherein R is H or another substituent, as defined). The heterocycle or heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure. The heterocycle or heterocyclic rings described herein can be substituted on carbon or on a nitrogen atom if the resulting compound is stable.
A nitrogen in the heterocycle or heterocyclic ring can optionally be quaternized. Bridged rings are also included in the definition of heterocycle or heterocyclic ring. A bridged ring occurs when one or more atoms (i.e., C, O, N, or S) link two non–adjacent carbon or nitrogen atoms. Preferred bridges include, but are not limited to, one carbon atom, two carbon atoms, one nitrogen atom, two nitrogen atoms, and a carbon–nitrogen group. When a ring is bridged, the substituents recited for the ring can also be present on the bridge. Spiro and fused rings are also included.
As used herein, the term "aromatic heterocycle", "aromatic heterocylic" or "heteroaryl" ring is intended to mean a stable 5, 6, 7, 8, 9, 10, 11, or 12–membered monocyclic or bicyclic aromatic ring which consists of carbon atoms and one or more heteroatoms, e.g., 1 or 1–2 or 1–3 or 1–4 or 1–5 or 1–6 heteroatoms, independently selected from nitrogen, oxygen, and sulfur. In the case of bicyclic aromatic heterocyclic or heterocycle or heteroaryl rings, only one of the two rings needs to be aromatic (e.g., 2,3– dihydroindole), though both can be (e.g., quinoline). The second ring can also be fused or bridged as defined above for heterocycles. The nitrogen atom can be substituted or unsubstituted (i.e., N or NR wherein R is H or another substituent, as defined). The nitrogen and sulfur heteroatoms can optionally be oxidized (i.e., N→O and S(O) , wherein p = 1 or 2).
In certain compounds, the total number of S and O atoms in the aromatic heterocycle is not more than 1.
Examples of aromatic heterocycles, aromatic heterocyclics or heteroaryls include, but are not limited to, acridinyl, azabicyclooctanonyl, azepanyl, azetidinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzoxazolinyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, benzodioxoly, benzooxadiazoly, carbazolyl, 4aH–carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, cycloheptyl, decahydroquinolinyl, dihydrobenzodioxinyl, 2H,6H–1,5,2–dithiazinyl, dihydrofuro[2,3–b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolidinylimine, imidazolinyl, imidazolyl, imidazolonyl, 1H–indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, 3H–indolyl, isatinoyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, methylenedioxyphenyl, methylbenztriazolyl, methylfuranyl, methylimidazolyl, methylthiazolyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3– oxadiazolyl, 1,2,4–oxadiazolyl, 1,2,5–oxadiazolyl, 1,3,4–oxadiazolyl, oxazolidinyl, oxazolidinonyl, oxazolyl, oxindolyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperazinonyl, piperidinyl, piperidenyl, piperidonyl, 4–piperidonyl, piperonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridinyl, pyridinonyl, pyridyl, pyrimidinyl, pyrroldionyl, pyrrolidinyl, pyrrolidinonyl, pyrrolinyl, 2H–pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H– quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrazolyl, 6H–1,2,5–thiadiazinyl, 1,2,3–thiadiazolyl, 1,2,4–thiadiazolyl, 1,2,5–thiadiazolyl, 1,3,4–thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, thiomorpholinyldioxidyl, triazinyl, triazolopyrimidinyl, 1,2,3–triazolyl, 1,2,4–triazolyl, 1,2,5–triazolyl, 1,3,4–triazolyl, and xanthenyl.
As used herein, the phrase "pharmaceutically acceptable" refers to those compounds or tautomers thereof, or salts, esters, or prodrugs thereof, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds or tautomers thereof, wherein the parent compound or a tautomer thereof, is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
The pharmaceutically acceptable salts include the conventional non–toxic salts or the quaternary ammonium salts of the parent compound or a tautomer thereof formed, for example, from non–toxic inorganic or organic acids. For example, such conventional non– toxic salts include, but are not limited to, those derived from inorganic and organic acids selected from 2–acetoxybenzoic, 2–hydroxyethane sulfonic, acetic, ascorbic, benzene sulfonic, benzoic, bicarbonic, carbonic, citric, edetic, ethane disulfonic, ethane sulfonic, fumaric, glucoheptonic, gluconic, glutamic, glycolic, glycollyarsanilic, hexylresorcinic, hydrabamic, hydrobromic, hydrochloric, hydroiodide, hydroxymaleic, hydroxynaphthoic, isethionic, lactic, lactobionic, lauryl sulfonic, maleic, malic, mandelic, methane sulfonic, napsylic, nitric, oxalic, pamoic, pantothenic, phenylacetic, phosphoric, polygalacturonic, propionic, salicylic, stearic, subacetic, succinic, sulfamic, sulfanilic, sulfuric, tannic, tartaric, and toluene sulfonic.
The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound or a tautomer thereof that contains a basic or acidic moiety by conventional chemical methods. Generally, such pharmaceutically acceptable salts can be prepared by reacting the free acid or base forms of these compounds or tautomers thereof with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non–aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing Company, Easton, PA, USA, p. 1445 (1990).
Since prodrugs are known to enhance numerous desirable qualities of pharmaceuticals (e.g., solubility, bioavailability, manufacturing, etc.) the compounds or tautomers thereof of the present invention can be delivered in prodrug form. Thus, the present invention is intended to cover prodrugs of the presently claimed compounds or tautomers thereof, methods of delivering the same and compositions containing the same. "Prodrugs" are intended to include any covalently bonded carriers that release an active parent drug of the present invention in vivo when such prodrug is administered to a mammalian subject. Prodrugs of the present invention are prepared by modifying functional groups present in the compound or a tautomer thereof in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound or a tautomer thereof. Prodrugs include compounds or tautomers thereof of the present invention wherein a hydroxy, amino, or sulfhydryl group is bonded to any group that, when the prodrug of the present invention is administered to a mammalian subject, it cleaves to form a free hydroxyl, free amino, or free sulfhydryl group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate, and benzoate derivatives of alcohol and amine functional groups in the compounds of the present invention.
As used herein, "stable compound" and "stable structure" are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
As used herein, the term "patient", as used herein, means the human or animal (in the case of an animal, more typically a mammal) subject that would be subjected to a surgical or invasive medical procedure. Such patient or subject could be considered to be in need of the methods of treating, reducing the risk of or preventing the infection due to a surgical procedure or an invasive medical procedure. Such patient or subject can also be considered to be in need of peri–operative prophylaxis.
As used herein, the term "treating" means to provide a therapeutic intervention to cure or ameliorate an infection.
As used herein, the term "preventing", as used herein means, to completely or almost completely stop an infection from occurring, for example when the patient or subject is predisposed to an infection or at risk of contracting an infection. Preventing can also include inhibiting, i.e. arresting the development, of an infection.
As used herein, the term "reducing the risk of", as used herein, means to lower the likelihood or probability of an infection occurring, for example when the patient or subject is predisposed to an infection or at risk of contracting an infection.
As used herein, "unsaturated" refers to compounds having at least one degree of unsaturation (e.g., at least one multiple bond) and includes partially and fully unsaturated compounds.
As used herein, the term "effective amount" refers to an amount of a compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, (including combinations of compounds and/or tautomers thereof, and/or pharmaceutically acceptable salts, esters, or prodrugs of said compound or tautomer), of the present invention that is effective when administered alone or in combination as an antimicrobial agent. For example, an effective amount refers to an amount of the compound or tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug said compound or tautomer that is present in a composition, a formulation or on a medical device given to a recipient patient or subject sufficient to elicit biological activity, for example, anti–infective activity, such as e.g., anti–microbial activity, anti–bacterial activity, anti–fungal activity, anti–viral activity, or anti–parasitic activity.
The term "prophylactically effective amount" means an amount of a compound or a tautomer of said compound or tautomer, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer (including combinations of compounds and/or tautomers thereof, and/or pharmaceutically acceptable salts, esters, or prodrugs thereof), of the present invention that is effective prophylactically when administered alone or in combination as an antimicrobial agent. For example, a prophylactically effective amount refers to an amount of the compound or tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer that is present in a composition, a formulation, or on a medical device given to a recipient patient or subject sufficient to prevent or reduce the risk of an infection due to a surgical procedure or an invasive medical procedure.
It is to be further understood that the representations for "Hydrogen Bond Acceptor – Hydrogen Bond Acceptor – Hydrogen Bond Donor" and "Hydrogen Bond Acceptor – Hydrogen Bond Acceptor – Hydrogen Bond Acceptor" are meant to indicate the relative orientation of the hydrogen bond acceptors and donor and not meant to limit that such groups are directly connected together as it is contemplated that additional atoms or groups of atoms can be included between such groups.
In the specification, the singular forms also include the plural, unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In the case of conflict, the present specification will control. As used herein, "mammal" refers to human and non–human patients.
As used herein, the term "therapeutically effective amount" refers to an amount of a compound or a tautomer thereof or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, (also including combinations of compounds and/or tautomers thereof, and/or pharmaceutically acceptable salts, esters, or prodrugs or said compounds or tautomers), of the present invention that is effective when administered alone or in combination as an antimicrobial agent. For example, a therapeutically effective amount refers to an amount of the compound or tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer that is present in a composition, a formulation, or on a medical device given to a recipient patient or subject in an amount sufficient to elicit biological activity, for example, anti–microbial activity, anti–fungal activity, anti–viral activity, anti–parasitic activity, anti–diarrheal activity, and/or anti– proliferative activity. In one aspect, the combination of compounds and/or tautomers thereof, and/or pharmaceutically acceptable salts, esters, or prodrugs or said compounds or tautomers is a synergistic combination. Synergy, as described, for example, by Chou and Talalay, Adv.
Enzyme Regul. vol. 22, pp. 27–55 (1984), occurs when the effect of the compounds or tautomers thereof or pharmaceutically acceptable salts, esters, or prodrugs of said compounds or tautomers when administered in combination is greater than the additive effect of the compounds or tautomers thereof, or pharmaceutically acceptable salts, esters, or prodrugs of said compounds or tautomers when administered alone as a single agent. In general, a synergistic effect is most clearly demonstrated at sub–optimal concentrations of the compounds or tautomers thereof, or pharmaceutically acceptable salts, esters, or prodrugs of said compounds or tautomers. Synergy can be in terms of lower cytotoxicity, increased anti– proliferative and/or anti–infective effect, or some other beneficial effect of the combination compared with the individual components.
As used herein, the term "RNA microhelix binding site" refers to the ribofunctional locus of the large ribosomal subunit occupied by the RNA microhelix of Formula III. The RNA microhelix binding site defines at least a portion of or overlaps with the E–site.
As used herein, the term "A–site" refers to the ribofunctional locus occupied by an aminoacyl–tRNA molecule immediately prior to its participation in the peptide–bond forming reaction.
As used herein, the term "E–site" refers to the ribofunctional locus occupied by a deacylated tRNA molecule following its participation in the peptide–bond forming reaction.
As used herein, the term "P–site" refers to the ribofunctional locus occupied by a peptidyl–tRNA at the time it participates in the peptide–bond forming reaction.
As used herein, the term "A–space" refers to the portion of the A–site within the peptidyl transferase center in which the amino acid portion of the aminoacylated t–RNA binds, or alternatively the portion of the A–site in which the oxazolidinone ring of linezolid binds.
As used herein and in reference to a ribosome or ribosomal subunit, the terms "a portion of" or "a portion of the three–dimensional structure of" are understood to mean a portion of the three–dimensional structure of a ribosome or ribosomal subunit, including charge distribution and hydrophilicity/hydrophobicity characteristics, formed by at least three, more preferably at least three to ten, and most preferably at least ten amino acid residues and/or nucleotide residues of the ribosome or ribosomal subunit. The residues forming such a portion can be, for example, (i) contiguous residues based upon, for example, a primary sequence of a ribosomal RNA or ribosomal protein, (ii) residues which form a contiguous portion of the three–dimensional structure of the ribosome or ribosomal subunit, or (c) a combination thereof. As used herein and in reference to the RNA microhelix, the terms "a portion of" or "a portion of the three–dimensional structure of" are understood to mean a portion of the three–dimensional structure of RNA microhelix, including charge distribution and hydrophilicity/hydrophobicity characteristics, formed by at least three, more preferably at least three to ten atoms of one or more core residues of Formula III. The atoms forming such a portion can be, for example, (i) solvent inaccessible atoms buried within the core of the RNA microhelix, (ii) solvent accessible atoms of the RNA microhelix, or (iii) a combination thereof.
As used herein, the term ESBL is extended spectrum beta-lactamase. The term KPC is Klebsiella pneumonia carbapenemase.
As used herein, the term acute bacterial skin and skin structure infection (ABSSSI) encompasses complicated skin and skin structure infections (cSSSI) and complication skin and soft tissue infections (cSSTI), which have been used interchangeably. The terms uncomplicated skin and skin structure infections (uCSSSI) and uncomplicated skin and soft tissue infections (uCSSTI) have been used interchangeably.
As used herein, the term "spp." is the abbreviation for species.
As used herein, the term "formulae of the invention" includes one or more of the formulae: IA, I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, Va, VIa, VIIa, VIIIa, IXa, Xa, XIa, XIIa, XIIIa, XIVa, XVa, XVIa, XVIIa, XVIIIa, XXa, XXa1, XXb, XXb1, A1, A2, A3, A4, A5, A6, A7, B1, B2, B3, B4, B5, B6, B7, C1, C2, C3, C4, C5, C6, C7, D1, D2, D3, D4, D5, D6, D7, E1, E2, E3, E4, E5, E6, E7, A1a, A2a, A3a, A4a, A5a, A6a, A7a, A8a, A9a, B1a, B2a, B3a, B4a, B5a, B6a, B7a, B8a, B9a, C1a, C2a, C3a, C4a, C5a, C6a, C7a, C8a, C9a, D1a, D2a, D3a, D4a, D5a, D6a, D7a, D8a, D9a, E1a, E2a, E3a, E4a, E5a, E6a, E7a, E8a, F1, F2, G1, G2, G3, G4, H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, I1, I2, I3, I4, I5, I6, I7, I8, I9, I10, I11, and I12.
As used herein, the term "compound of the invention" includes one or more compounds of the formulae of the invention or a compound explicitly disclosed herein.
All percentages and ratios used herein, unless otherwise indicated, are by weight.
Throughout the description, where compositions are described as having, including, or comprising specific components, or where processes are described as having, including, or comprising specific process steps, it is contemplated that compositions of the present invention also consist essentially of, or consist of, the recited components, and that the processes of the present invention also consist essentially of, or consist of, the recited processing steps. Further, it should be understood that the order of steps or order for performing certain actions are immaterial so long as the invention remains operable.
Moreover, two or more steps or actions can be conducted simultaneously. 2. Compounds of the Invention In some embodiments, the present invention relates to a compound having the formula: (IA), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, wherein 1 2 3 4 5 X is CR or N; X is CR or N; X is CR or N; X is CR or N; X is CR or N; with 1 2 3 4 5 the proviso that X , X , X , X , and X are not all N; 1 2 3 4 5 6 7 8 9 10 Y is CR or N; Y is CR or N; Y is CR or N; Y is CR or N; Y is CR or N; 6 7 8 9 10 with the proviso that Y , Y , Y , Y , and Y are not all N; wherein 6 7 8 9 10 1 2 4 5 6 7 8 10 R , R , R , R , R , R , R and R are each independently selected from (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) –CF , (g) –CF H, (h) –CFH , (i) –OCF , (j) –OCF H, (k) –OCFH , (l) 2 2 3 2 2 11 11 11 11 11 11 –OCH , (m) –CN, (n) –N , (o) –NO , (p) –NR R , (q) –NR C(O)R , (r) –C(O)NR R , (s) 11 11 11 11 11 11 –OR , (t) –COH, (u) –CO(C –C alkyl), (v) –COR , (w) –NR (CNR )NR R , (x) – 11 11 11 11 11 11 S(O) R , (y) –NR S(O) R , (z) –SR , (aa) –SCF , (bb) –C(CF )H-NH-CHR R , (cc) – p p 3 3 11 11 11 COOR , (dd) –(OCH CH ) R , (ee) –(OCH CH ) OR , (ff) –C –C alkyl, (gg) –C –C 2 2 t 2 2 t 1 8 2 8 alkenyl, (hh) –C –C alkynyl, (ii) –(C –C alkyl)–(3–14 membered saturated, unsaturated, or 2 8 1 8 aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (jj) –(C –C alkyl)–(3–14 membered saturated, unsaturated, or aromatic carbocycle), (kk) –haloalkyl, (ll) –3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (mm) –3–14 membered saturated, unsaturated, or aromatic carbocycle, and (nn) –CHR -NH-(3-14 membered saturated, unsaturated, or aromatic heterocycle containing one of more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur); wherein each (ff) through (nn) is optionally substituted with one or more R ; 6 7 8 alternatively, wherein two substituents selected from R , R , and R are taken together with the carbon atom to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; wherein each (a) through (b) is optionally substituted with one or more R ; each R is independently selected from (a) hydrogen, (b) halogen, (c) –OH, (d) –SH, (e) –(C –C alkyl)OH, (f) –OCF , (g) –OCF H, (h) –OCFH , (i) –OCH , (j) –OR , (k) – 1 8 3 2 2 3 12 12 12 COR , (l) –CN, (m) –NO , (n) –CONH , (o) –CONR R , (p) –COCH , (q) –S(O) CH , (r) 2 2 3 p 3 12 12 12 12 –S(O) NR R , (s) –SR , (t) –C(O)OH, (u) –C(O)OR , (v) –N , (w) –NH , (x) – p 3 2 12 12 NR C(O)R , (y) –NH(C –C alkyl), (z) –N(C –C alkyl) , (aa) –C –C alkyl, (bb) –C –C 1 8 1 8 2 1 8 2 8 alkenyl, (cc) –C –C alkynyl, (dd) –haloalkyl, (ee) –(C –C alkyl)–(3–14 membered 2 8 1 8 saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (ff) –(C –C alkyl)–(3–14 membered saturated, unsaturated, or aromatic carbocycle), (gg) –3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (hh) –3–14 membered saturated, 12 12 unsaturated, or aromatic carbocycle, and (ii) –(C=NH)NR R ; wherein each (y) through (hh) is optionally substituted with one or more R ; alternatively two R substituents are taken together to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, wherein each (a) through (b) is optionally substituted with one or more R ; R is selected from: , , , , , , , and ; 3a 3b 3c 3d 3e 3f 3g 3h 3i 3j 3k 3l wherein R , R , R , R , R , R , R , R , R , R , R , and R are each independently selected from (a) hydrogen, (b) halogen, (c) –CN, (d) –N , (e) –NO , (f) – 11 11 11 11 OCF , (g) –OCF H, (h) –OCFH , (i) –OCH , (j) –OR , (k) –C(O)R , (l) –C(O)NR R , (m) 3 2 2 3 11 11 11 11 11 11 –NH , (n) –NR R , (o) –NR C(O)R , (p) –S(O) R , (q) –C(O)OH, (r) –C(O)OR , (s) – C –C alkyl, (t) –C –C alkenyl, (u) –C –C alkynyl, (v) haloalkyl, (w) –3–14 membered 1 8 2 8 2 8 saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (x) –3–14 membered saturated, unsaturated, or aromatic carbocycle; wherein each (s) through (x) is optionally substituted with one or more R ; 3a 3b 3c 3d alternatively, one or more pairs of substituents selected from R and R , R and R , 3e 3f 3g 3h 3i 3j 3k 3l R and R , R and R , R and R , and R and R are taken together with the carbon atom to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic, (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (c) an exo carbon-carbon double bond, (d) carbonyl group, or (e) thiocarbonyl group; wherein each (a) through (b) is optionally substituted with one or more R ; 3a 3b 3c 3d 3e 3f 3g alternatively, wherein two substituents selected from R , R , R , R , R , R , R , 3h 3i 3j 3k 3l R , R , R , R , and R on different carbon atoms are taken together with the intervening atoms to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; wherein each (a) through (b) is optionally substituted with one or more R ; 3a 3b 3c 3d 3e 3f 3g alternatively, wherein two substituents selected from R , R , R , R , R , R , R , 3h 3i 3j 3k 3l R , R , R , R , and R on two adjacent carbon atoms are taken together with the bond between said adjacent carbon atoms form a substituted or unsubstituted carbon-carbon double 3a 3b 3c 3d 3e 3f 3g 3h 3i 3j bond, or wherein four substituents selected from R , R , R , R , R , R , R , R , R , R , 3k 3l R , and R on two adjacent carbon atoms are taken together with the bond between said adjacent carbon atoms form a carbon-carbon triple bond; 11 11 11 U is selected from –O–, –S(O) –, –NR –, –(C=O)–, –NR (C=O)–, –(C=O)NR –, – 11 11 11 11 11 11 S(O) NR –, –NR S(O) – , –NR S(O) NR –, and –NR C(O)NR -; p p p 11 11 11 11 11 11 11 11 11 T is selected from –NR R , –NR (C=O)OR , –NR (C=NR )NR R , and OR ; 11 3a 3b 3c 3d 3e 3f alternatively, one R and one substituent selected from R , R , R , R , R , R , 3g 3h 3i 3j 3k 3l R , R , R , R , R , and R are taken together with the intervening atoms to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; wherein each (a) through (b) is optionally substituted with one or more R ; R is selected from: , , , , , , , , , , , , , , and ; 9k 9l 9m 9n 9o 9p 9q 9r 9s 9t wherein R , R , R , R , R , R , R , R , R , and R are each independently selected from (a) hydrogen, (b) halogen, (c) –CN, (d) –N , (e) –NO , (f) –OCF , (g) –OCH , 3 2 3 3 11 11 11 11 11 (h) –OCF H, (i) –OCFH , (j) –OR , (k) –NH , (l) –NR R , (m) –C(O)R , (n) –C(O)OR , 2 2 2 11 11 11 11 11 (o) –C(O)NR R , (p) –NR C(O)R , (q) –S(O) R , (r) –C –C alkyl, (s) –C –C alkenyl, p 1 8 2 8 (t) –C –C alkynyl, (u) haloalkyl, (v) –3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (w) –3–14 membered saturated, unsaturated, or aromatic carbocycle; wherein each (r) through (w) is optionally substituted with one or more R ; 9k 9l 9m 9n alternatively, one or more pairs of substituents selected from R and R , R and R , 9o 9p 9q 9r 9s 9t R and R , R and R , and R and R are taken together with the carbon atom to which they are attached to form (a) 3–7 membered saturated or unsaturated carbocyclic, (b) 3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (c) an exo carbon-carbon double bond, (d) carbonyl group, or (e) thiocarbonyl group; wherein each (a) through (c) is optionally substituted with one or more R ; 9k 9l 9m 9n 9o 9p 9q 9r 9s alternatively, two substituents selected from R , R , R , R , R , R , R , R , R , and R on different carbon atoms are taken together with the intervening atoms to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; wherein each (a) through (b) is optionally substituted with one or more R ; 9k 9l 9m 9n 9o 9p 9q 9r 9s alternatively, two substituents selected from R , R , R , R , R , R , R , R , R , and R on two adjacent carbon atoms are taken together with the bond between said adjacent carbon atoms form a substituted or unsubstituted carbon-carbon double bond, or four 9k 9l 9m 9n 9o 9p 9q 9r 9s 9t substituents selected from R , R , R , R , R , R , R , R , R , and R on two adjacent carbon atoms are taken together with the bond between said adjacent carbon atoms form a carbon-carbon triple bond; 11 11 11 Z is selected from –O–, –S(O) –, –NR –, –(C=O)–, –NR (C=O)–, –(C=O)NR –, – 11 11 11 11 11 11 S(O) NR –, –NR S(O) –, –NR S(O) NR –, and –NR C(O)NR –; p p p 11 11 11 11 11 11 11 11 11 W is selected from –NR R , –NR (CO)OR , –NR (C=NR )NR R , and –OR ; 11 9k 9l 9m 9n 9o 9p alternatively, one R and one substituent selected from R , R , R , R , R , R , 9q 9r 9s 9t R , R , R , and R are taken together with the intervening atoms to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; wherein each (a) through (b) is optionally substituted with one or more R ; R is independently selected from (a) hydrogen, (b) halogen, (c) –OH, (d) –SH, (e) – (C –C alkyl)OH, (f) –OCF , (g) –OCH , (h) –OCF H, (i) –OCFH , (j) –O(C –C alkyl), (k) – 1 8 3 3 2 2 1 8 CN, (l) –NO , (m) –CONH , (n) C(O)NH(C -C alkyl), (o) C(O)N(C -C alkyl) , (p) –COH, 2 2 1 8 1 8 2 (q) –COCH , (r) –S(O) CH , (s) –S(O) N(C –C alkyl) , (t) –S(C –C alkyl), (u) –C(O)OH, 3 p 3 p 1 8 2 1 8 (v) –C(O)O(C –C alkyl), (w) –N , (x) –NHC(O)(C –C alkyl), (y) –N(C –C alkyl)C(O)(C – 1 8 3 1 8 1 8 1 C alkyl), (z) –NH , (aa) –NH(C –C alkyl), (bb) –N(C –C alkyl) , (cc) –C –C alkyl, (dd) – 8 2 1 8 1 8 2 1 8 C –C alkenyl, (ee) –C –C alkynyl, (ff) –haloalkyl, (gg) –(C –C alkyl)–(3–14 membered 2 8 2 8 1 8 saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (hh) –(C –C alkyl)–(3–14 membered saturated, unsaturated, or aromatic carbocycle), (ii) –3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (jj) –3–14 membered saturated, unsaturated, or aromatic carbocycle, (kk) –(C=NH)NH , (ll) –C(=NH)NH , (mm) –C(O)R , (nn) =O, and (oo) =NR ; wherein each (aa) through (jj) is optionally substituted with one or more R ; R is independently selected from (a) hydrogen, (b) halogen, (c) –C –C alkyl, (d) –C –C 1 8 2 8 alkenyl, (e) –C –C alkynyl, (f) –haloalkyl, (g) –OH, (h) –OC -C alkyl, (i) –OC –C alkenyl, 2 8 1 8 2 8 (j) –OC –C alkynyl, (k) –OCF , (l) –OCH , (m) –OCF H, (n) –OCFH , (o) –NH , (p) –CN, 2 8 3 3 2 2 2 (q) –N , (r) –S(O) C -C alkyl, (s) –3–14 membered saturated, unsaturated, or aromatic 3 p 1 8 heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (t) –3–14 membered saturated, unsaturated, or aromatic carbocycle; p is 0, 1, or 2; and t is 0, 1, or 2.
In some embodiments, the present invention relates to a compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, having the formula: (I), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, wherein 1 2 3 4 5 X is CR or N; X is CR or N; X is CR or N; X is CR or N; X is CR or N; with 1 2 3 4 5 the proviso that X , X , X , X , and X are not all N; 1 2 3 4 5 6 7 8 9 10 Y is CR or N; Y is CR or N; Y is CR or N; Y is CR or N; Y is CR or N; 6 7 8 9 10 with the proviso that Y , Y , Y , Y , and Y are not all N; wherein 6 7 8 9 10 1 2 4 5 6 7 8 10 R , R , R , R , R , R , R and R are each independently selected from (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) –CF , (g) –CF H, (h) –CFH , (i) –OCF , (j) –OCF H, (k) – 2 2 3 2 11 11 11 11 OCFH , (l) –OCH , (m) –CN, (n) –N , (o) –NO , (p) –NR R , (q) –NR (CO)R , (r) – 2 3 3 11 11 11 11 (CO)NR R , (s) –OR , (t) –COH, (u) –CO(C –C alkyl), (v) –COR , (w) – 11 11 11 11 11 11 11 11 NR (CNR )NR R , (x) –S(O) R , (y) –NR S(O) R , (z) –SR , (aa) –SCF , (bb) – p p 3 11 11 11 11 11 C(CF )H-NH-CHR R , (cc) –COOR , (dd) –(OCH CH ) R , (ee) –(OCH CH ) OR , (ff) 3 2 2 t 2 2 t –C –C alkyl, (gg) –C –C alkenyl, (hh) –C –C alkynyl, (ii) –(C –C alkyl)–(3–14 1 8 2 8 2 8 1 8 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (jj) –(C –C alkyl)–(3–14 membered saturated, unsaturated, or aromatic carbocycle), (kk) –haloalkyl, (ll) –3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (mm) –3–14 membered saturated, unsaturated, or aromatic carbocycle, and (nn) –CHR -NH-(3-14 membered saturated, unsaturated, or aromatic heterocycle containing one of more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur); wherein each (ff) through (nn) is optionally substituted with one or more R ; each R is independently selected from (a) hydrogen, (b) halogen, (c) –CF , (d) – CF H, (e) –CFH , (f) –OH, (g) –SH, (h) –(C –C alkyl)OH, (i) –OCF , (j) –OCF H, (k) – 2 2 1 8 3 2 12 12 OCFH , (l) –OCH , (m) –OR , (n) –COR , (o) –CN, (p) –NO , (q) –CONH , (r) – 2 3 2 2 12 12 12 12 12 CONR R , (s) –C(O)CH , (t) –S(O) CH , (u) –S(O) NR R , (v) –SR , (w) –C(O)OH, (x) 3 p 3 p 12 12 12 –C(O)OR , (y) –N , (z) –NH , (aa) –NR C(O)R , (bb) –NH(C –C alkyl), (cc) –N(C –C 3 2 1 8 1 8 alkyl) , (dd) –C –C alkyl, (ee) –C –C alkenyl, (ff) –C –C alkynyl, (gg) –haloalkyl, (hh) – 2 1 8 2 8 2 8 (C –C alkyl)–(3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (ii) –(C –C alkyl)–(3–14 membered saturated, unsaturated, or aromatic carbocycle), (jj) –3– 14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (kk) –3–14 12 12 membered saturated, unsaturated, or aromatic carbocycle, and (ll) –(C=NH)NR R ; wherein each (bb) through (kk) is optionally substituted with one or more R ; alternatively two R subsituents are taken together to form (a) 3–7 membered saturated or unsaturated carbocyclic or (b) 3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, wherein each (a) through (b) is optionally substituted with one or more R ; R is selected from: , , , , , and ; 3a 3b 3c 3d 3e 3f 3g 3h 3i 3j wherein R , R , R , R , R , R , R , R , R , and R are each independently selected from (a) hydrogen, (b) halogen, (c) –CH , (d) –CF , (e) –CF H, (f) –CFH , (g) – 3 3 2 2 OCF , (h) –OCF H, (i) –OCFH , (j) –OCH , (k) –OR , (l) –C –C alkyl, (m) haloalkyl, (n) – 3 2 2 3 1 8 3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (o) –3– 14 membered saturated, unsaturated, or aromatic carbocycle; wherein each (l) through (o) is optionally substituted with one or more R ; 3a 3b 3c 3d alternatively, one or more pairs of substituents selected from R and R , R and R , 3e 3f 3g 3h 3i 3j R and R , R and R , and R and R are taken together with the carbon atom to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic, (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (c) an exo carbon-carbon double bond, (d) carbonyl group, or (e) thiocarbonyl group; wherein each (a) through (b) is optionally substituted with one or more R ; 3a 3b 3c 3d 3e 3f 3g alternatively, wherein two substituents selected from R , R , R , R , R , R , R , 3h 3i 3j R , R , and R on different carbon atoms are taken together with the intervening atoms to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; wherein each (a) through (b) is optionally substituted with one or more R ; 3a 3b 3c 3d 3e 3f 3g alternatively, wherein two substituents selected from R , R , R , R , R , R , R , 3h 3i 3j R , R , and R on two adjacent carbon atoms are taken together with the bond between said adjacent carbon atoms form a substituted or unsubstituted carbon-carbon double bond, or 3a 3b 3c 3d 3e 3f 3g 3h 3i 3j wherein four substituents selected from R , R , R , R , R , R , R , R , R , and R on two adjacent carbon atoms are taken together with the bond between said adjacent carbon atoms form a carbon-carbon triple bond; 11 11 11 U is selected from –O–, –S(O) –, –NR –, –(C=O)–, –NR (C=O)–, –(C=O)NR –, – 11 11 11 11 S(O) NR –, –NR S(O) – and –NR S(O) NR –; p p p 11 11 11 11 11 11 11 11 11 T is selected from –NR R , –NR (C=O)OR , –NR (C=NR )NR R , and OR ; 11 3a 3b 3c 3d 3e 3f alternatively, one R and one substituent selected from R , R , R , R , R , R , 3g 3h 3i 3j R , R , R , and R are taken together with the intervening atoms to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; wherein each (a) through (b) is optionally substituted with one or more R ; R is selected from: , , , , , , , , , , , , , , and ; 9k 9l 9m 9n 9o 9p 9q 9r 9s 9t wherein R , R , R , R , R , R , R , R , R , and R are each independently selected from (a) hydrogen, (b) halogen, (c) –CH , (d) –CF , (e) –CF H, (f) –CFH , (g) – 3 3 2 2 OCF , (h) –OCH , (i) –OCF H, (j) –OCFH , (k) –OR , (l) –C –C alkyl, (m) haloalkyl, (n) – 3 3 2 2 1 8 3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (o) –3– 14 membered saturated, unsaturated, or aromatic carbocycle; wherein each (l) through (o) is optionally substituted with one or more R ; 9k 9l 9m 9n alternatively, one or more pairs of substituents selected from R and R , R and R , 9o 9p 9q 9r 9s 9t R and R , R and R , and R and R are taken together with the carbon atom to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic, (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (c) an exo carbon-carbon double bond, (d) carbonyl group, and (e) thiocarbonyl group; wherein each (a) through (c) is optionally substituted with one or more R ; 9k 9l 9m 9n 9o 9p 9q 9r 9s alternatively, two substituents selected from R , R , R , R , R , R , R , R , R , and R on different carbon atoms are taken together with the intervening atoms to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; wherein each (a) through (b) is optionally substituted with one or more R ; 9k 9l 9m 9n 9o 9p 9q 9r 9s alternatively, two substituents selected from R , R , R , R , R , R , R , R , R , and R on two adjacent carbon atoms are taken together with the bond between said adjacent carbon atoms form a substituted or unsubstituted carbon-carbon double bond, or four 9k 9l 9m 9n 9o 9p 9q 9r 9s 9t substituents selected from R , R , R , R , R , R , R , R , R , and R on two adjacent carbon atoms are taken together with the bond between said adjacent carbon atoms form a carbon-carbon triple bond; 11 11 11 Z is selected from –O–, –S(O) –, –NR –, –(C=O)–, –NR (C=O)–, –(C=O)NR –, – 11 11 11 11 S(O) NR –, –NR S(O) – and –NR S(O) NR –; p p p 11 11 11 11 11 11 11 11 11 W is selected from –NR R , –NR (CO)OR , –NR (C=NR )NR R , and –OR ; 11 9k 9l 9m 9n 9o 9p alternatively, one R and one substituent selected from R , R , R , R , R , R , 9q 9r 9s 9t R , R , R , and R are taken together with the intervening atoms to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; wherein each (a) through (b) is optionally substituted with one or more R ; R is independently selected from (a) hydrogen, (b) halogen, (c) –CF , (d) –CF H, (e) –CFH , (f) –OH, (g) –SH, (h) –(C –C alkyl)OH, (i) –OCF , (j) –OCH , (k) –OCF H, (l) – 2 1 8 3 3 2 OCFH , (m) –O(C –C alkyl), (n) –CN, (o) –NO , (p) –CONH , (q) –C(O)H, (r) –C(O)CH , 2 1 8 2 2 3 (s) –S(O) CH , (t) –S(O) N(C –C alkyl) , (u) –S(C –C alkyl), (v) –C(O)OH, (w) – p 3 p 1 8 2 1 8 C(O)O(C –C alkyl), (x) –N , (y) –NHC(O)(C –C alkyl), (z) –N(C –C alkyl)C(O)(C –C 1 8 3 1 8 1 8 1 8 alkyl), (aa) –NH , (bb) –NH(C –C alkyl), (cc) –N(C –C alkyl) , (dd) –C –C alkyl, (ee) – 2 1 8 1 8 2 1 8 C –C alkenyl, (ff) –C –C alkynyl, (gg) –haloalkyl, (hh) –(C –C alkyl)–(3–14 membered 2 8 2 8 1 8 saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (ii) –(C –C alkyl)–(3–14 membered saturated, unsaturated, or aromatic carbocycle), (jj) –3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (kk) –3–14 membered saturated, unsaturated, or aromatic carbocycle, (ll) –(C=NH)NH , (mm) –C(O)NH(C -C alkyl), (nn) – 2 1 8 C(O)N(C -C alkyl) , and (oo) –C(=NH)NH ; 1 8 2 2 p is 0, 1, or 2; and t is 0, 1, or 2.
In some embodiments, the present invention relates to a compound having the formula: (II), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, wherein X , X , X , X , Y , Y , Y , Y , R and R are as defined 1 2 4 5 6 7 8 10 herein.
In some embodiments, the present invention relates to a compound having the formula: (III), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 1 2 3 4 5 6 7 8 9 10 compound or tautomer, wherein R , R , R , R , R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having the formula: (IV), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 1 2 3a 3b 4 5 6 7 8 9 10 compound or tautomer, wherein R , R , R , R , R , R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (V), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 1 2 3a 3b 4 5 6 7 8 9k 9l 9m 9n 9o compound or tautomer, wherein R , R , R , R , R , R , R , R , R , R , R , R , R , R , 9p 10 R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (VI), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 1 2 3a 3b 4 5 6 7 9k 9l 9m 9n 9o 9p compound or tautomer, wherein R , R , R , R , R , R , R , R , R , R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (VII), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 1 2 3a 3b 4 5 6 8 9k 9l 9m 9n 9o 9p compound or tautomer, wherein R , R , R , R , R , R , R , R , R , R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (VIII), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 1 2 3a 3b 4 5 7 8 9k 9l 9m 9n 9o 9p compound or tautomer, wherein R , R , R , R , R , R , R , R , R , R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (IX), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 1 2 3a 3b 4 5 6 9k 9l 9m 9n 9o 9p compound or tautomer, wherein R , R , R , R ,R , R , R , R , R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (X), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 1 2 3a 3b 4 5 7 9k 9l 9m 9n 9o 9p compound or tautomer, wherein R , R , R , R , R , R , R , R , R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (XI), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 1 2 3a 3b 4 5 8 9k 9l 9m 9n 9o 9p compound or tautomer, wherein R , R , R , R , R , R , R , R , R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (XXa), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 1 2 3a 3b 4 5 9k 9l 9m 9n 9o 9p 10 compound or tautomer, wherein R , R , R , R , R , R , R , R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (XXa1) or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 1 2 3a 3b 4 5 9k 9l 9m 9n 9o 9 compound or tautomer, wherein R , R , R , R , R , R , R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (Va), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 1 2 3a 3b 4 5 6 7 8 9k 9l 9m 9n 9o compound or tautomer, wherein R , R , R , R , R , R , R , R , R , R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (VIa), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 1 2 3a 3b 4 5 6 7 9k 9l 9m 9n 9o compound or tautomer, wherein R , R , R , R , R , R , R , R , R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (VIIa), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 1 2 3a 3b 4 5 6 8 9k 9l 9m 9n 9o compound or tautomer, wherein R , R , R , R , R , R , R , R , R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (VIIIa), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 1 2 3a 3b 4 5 7 8 9k 9l 9m 9n 9o compound or tautomer, wherein R , R , R , R , R , R , R , R , R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (IXa), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 1 2 3a 3b 4 5 6 9k 9l 9m 9n 9o 9p compound or tautomer, wherein R , R , R , R , R , R , R , R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (Xa), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 1 2 3a 3b 4 5 7 9k 9l 9m 9n 9o 9p compound or tautomer, wherein R , R , R , R , R , R , R , R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (XIa) or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 1 2 3a 3b 4 5 8 9k 9l 9m 9n 9o 9p compound or tautomer, wherein R , R , R , R , R , R , R , R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (XII), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 1 2 3a 3b 4 5 6 7 8 9k 9l 9m 9n 9o compound or tautomer, wherein R , R , R , R , R , R , R , R , R , R , R , R , R , R , 9p 9q 9r 10 R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (XIII), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 1 2 3a 3b 4 5 6 7 9k 9l 9m 9n 9o 9p compound or tautomer, wherein R , R , R , R , R , R , R , R , R , R , R , R , R , R , 9q 9r 10 R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (XIV), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 1 2 3a 3b 4 5 6 8 9k 9l 9m 9n 9o 9p compound or tautomer, wherein R , R , R , R , R , R , R , R , R , R , R , R , R , R , 9q 9r 10 R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (XV), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 1 2 3a 3b 4 5 7 8 9k 9l 9m 9n 9o 9p compound or tautomer, wherein R , R , R , R , R , R , R , R , R , R , R , R , R , R , 9q 9r 10 R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (XVI), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 1 2 3a 3b 4 5 6 9k 9l 9m 9n 9o 9p 9q compound or tautomer, wherein R , R , R , R , R , R , R , R , R , R , R , R , R , R , 9r 10 R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (XVII), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 1 2 3a 3b 4 5 7 9k 9l 9m 9n 9o 9p 9q compound or tautomer, wherein R , R , R , R , R , R , R , R , R , R , R , R , R , R , 9r 10 R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (XVIII), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 1 2 3a 3b 4 5 8 9k 9l 9m 9n 9o 9p 9q compound or tautomer, wherein R , R , R , R , R , R , R , R , R , R , R , R , R , R , 9r 10 R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (XXb) or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 1 2 3a 3b 4 5 9k 9l 9m 9n 9o 9p 9q 9r compound or tautomer, wherein R , R , R , R , R , R , R , R , R , R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (XXb1) or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 1 2 3a 3b 4 5 9k 9l 9m 9n 9o 9p 9q compound or tautomer, wherein R , R , R , R , R , R , R , R , R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (XIIa), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 1 2 3a 3b 4 5 6 7 8 9k 9l 9m 9n 9o compound or tautomer, wherein R , R , R , R , R , R , R , R , R , R , R , R , R , R , 9p 9q 9r R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (XIIIa), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 1 2 3a 3b 4 5 6 7 9k 9l 9m 9n 9o 9p compound or tautomer, wherein R , R , R , R , R , R , R , R , R , R , R , R , R , R , 9q 9r R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (XIVa), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 1 2 3a 3b 4 5 6 8 9k 9l 9m 9n 9o 9p compound or tautomer, wherein R , R , R , R , R , R , R , R , R , R , R , R , R , R , 9q 9r R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (XVa), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 1 2 3a 3b 4 5 7 8 9k 9l 9m 9n 9o 9p compound or tautomer, wherein R , R , R , R , R , R , R , R , R , R , R , R , R , R , 9q 9r R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (XVIa), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 1 2 3a 3b 4 5 6 9k 9l 9m 9n 9o 9p 9q compound or tautomer, wherein R , R , R , R , R , R , R , R , R , R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (XVIIa), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 1 2 3a 3b 4 5 7 9k 9l 9m 9n 9o 9p 9q compound or tautomer, wherein R , R , R , R , R , R , R , R , R , R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (XVIIIa) or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 1 2 3a 3b 4 5 8 9k 9l 9m 9n 9o 9p 9q compound or tautomer, wherein R , R , R , R ,R , R , R , R , R , R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, according to any formulae of the invention, wherein at least one substituent 9k 9l 9m 9n 9o 9p 9q 9r 9s 9t selected from R , R , R , R , R , R , R , R , R , and R is not hydrogen.
In some embodiments, the present invention relates to a compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, according to any formulae of the invention, wherein at least two substituents 9k 9l 9m 9n 9o 9p 9q 9r 9s 9t selected from R , R , R , R , R , R , R , R , R , and R are not hydrogen.
In some embodiments, the present invention relates to a compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or 1 2 4 5 tautomer, according to any formulae of the invention, wherein R , R , R and R are each 1 2 4 5 independently selected from hydrogen and F. In some embodiments, R , R , R , and R are each hydrogen.
In some embodiments, the present invention relates to a compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or 3a 3b tautomer, according to any formulae of the invention, wherein R and R are each independently selected from (a) hydrogen, (b) F, (c) Cl, (d) –CH , (e) –CF , (f) –CF H, (g) – 3 3 2 CFH , (h) –OCF , (i) –OCF H, (j) –OCFH , (k) –OCH , and (l) –OH. In some embodiments, 2 3 2 2 3 3a 3b 3a 3b R and R are each hydrogen. In some embodiments, R and R are each hydrogen. In 3a 3b 3a 3b some embodiments, the stereochemistry of R and R is and R is methyl and R is 3a 3b hydrogen. In some embodiments, the stereochemistry of R and R is 3a 3b 3a and R is methyl and R is hydrogen. In some embodiments, the stereochemistry of R and 3b 3a 3b R is and R is hydrogen and R is methyl. In some embodiments, the 3a 3b 3a 3b stereochemistry of R and R is and R is hydrogen and R is methyl.
In some embodiments, the present invention relates to a compound having formula: (A1), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 6 7 8 9k 9l 10 compound or tautomer, wherein R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (A2), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 6 7 9k 9l 10 compound or tautomer, wherein R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (A3), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 6 8 9k 9l 10 compound or tautomer, wherein R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (A4), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 7 8 9k 9l 10 compound or tautomer, wherein R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (A5), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 6 9k 9l 10 compound or tautomer, wherein R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (A6), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 7 9k 9l 10 compound or tautomer, wherein R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (A7); or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 8 9k 9l 10 compound or tautomer, wherein R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (B1), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 6 7 8 9m 9n 10 compound or tautomer, wherein R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (B2), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 6 7 9m 9n 10 compound or tautomer, wherein R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (B3), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 6 8 9m 9n 10 compound or tautomer, wherein R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (B4), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 7 8 9m 9n 10 compound or tautomer, wherein R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (B5), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 6 9m 9n 10 compound or tautomer, wherein R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (B6), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 7 9m 9n 10 compound or tautomer, wherein R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (B7), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 8 9m 9n 10 compound or tautomer, wherein R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (C1), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 6 7 8 9o 9p 10 compound or tautomer, wherein R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (C2), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 6 7 9o 9p 10 compound or tautomer, wherein R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (C3), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 6 8 9o 9p 10 compound or tautomer, wherein R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (C4), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 7 8 9o 9p 10 compound or tautomer, wherein R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (C5), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 6 9o 9p 10 compound or tautomer, wherein R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (C6), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 7 9o 9p 10 compound or tautomer, wherein R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (C7) or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 8 9o 9p 10 compound or tautomer, wherein R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (D1), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 6 7 8 9q 9r 10 compound or tautomer, wherein R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (D2), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 6 7 9q 9r 10 compound or tautomer, wherein R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (D3), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 6 8 9q 9r 10 compound or tautomer, wherein R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (D4), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 7 8 9q 9r 10 compound or tautomer, wherein R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (D5), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 6 9q 9r 10 compound or tautomer, wherein R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (D6), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 7 9q 9r 10 compound or tautomer, wherein R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (D7), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 8 9q 9r 10 compound or tautomer, wherein R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (E1), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 6 7 8 10 compound or tautomer, wherein R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (E2), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 6 7 10 compound or tautomer, wherein R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (E3), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 6 8 10 compound or tautomer, wherein R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (E4), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 7 8 10 compound or tautomer, wherein R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (E5) or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 6 10 compound or tautomer, wherein R and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (E6), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 7 10 compound or tautomer, wherein R and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (E7) or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 8 10 compound or tautomer, wherein R and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (A1a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 6 7 8 9k 9l compound or tautomer, wherein R , R , R , R and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (A2a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 6 7 9k 9l compound or tautomer, wherein R , R , R and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (A3a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 6 8 9k 9l compound or tautomer, wherein R , R , R and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (A4a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 7 8 9k 9l compound or tautomer, wherein R , R , R and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (A5a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 6 9k 9l compound or tautomer, wherein R , R and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (A6a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 7 9k 9l compound or tautomer, wherein R , R and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (A7a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 8 9k 9l compound or tautomer, wherein R , R and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (A8a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 9k 9l 10 compound or tautomer, wherein R , R and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (A9a) or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 9k 9l compound or tautomer, wherein R and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (B1a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 6 7 8 9m 9n compound or tautomer, wherein R , R , R , R and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (B2a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 6 7 9m 9n compound or tautomer, wherein R , R , R and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (B3a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 6 8 9m 9n compound or tautomer, wherein R , R , R and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (B4a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 7 8 9m 9n compound or tautomer, wherein R , R , R and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (B5a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 6 9m 9n compound or tautomer, wherein R , R and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (B6a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 7 9m 9n compound or tautomer, wherein R , R and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (B7a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 8 9m 9n compound or tautomer, wherein R , R and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (B8a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 9m 9n 10 compound or tautomer, wherein R , R and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (B9a) or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 9m 9n compound or tautomer, wherein R and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (C1a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 6 7 8 9o 9p compound or tautomer, wherein R , R , R , R and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (C2a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 6 7 9o 9p compound or tautomer, wherein R , R , R and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (C3a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 6 8 9o 9p compound or tautomer, wherein R , R , R and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (C4a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 7 8 9o 9p compound or tautomer, wherein R , R , R and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (C5a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 6 9o 9p compound or tautomer, wherein R , R and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (C6a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 7 9o 9p compound or tautomer, wherein R , R and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (C7a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 8 9o 9p compound or tautomer, wherein R , R and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (C8a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 9o 9p 10 compound or tautomer, wherein R , R and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (C9a) or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 9o 9p compound or tautomer, wherein R and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (D1a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 6 7 8 9q 9r compound or tautomer, wherein R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (D2a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 6 7 9q 9r compound or tautomer, wherein R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (D3a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 6 8 9q 9r compound or tautomer, wherein R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (D4a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 7 8 9q 9r compound or tautomer, wherein R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (D5a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 6 9q 9r compound or tautomer, wherein R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (D6a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 7 9q 9r compound or tautomer, wherein R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (D7a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 8 9q 9r compound or tautomer, wherein R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (D8a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 9q 9r 10 compound or tautomer, wherein R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (D9a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 9q 9r compound or tautomer, wherein R and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (E1a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 6 7 8 compound or tautomer, wherein R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (E2a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, wherein R and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (E3a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, wherein R and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (E4a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, wherein R and R are as defined herein.
In some embodiments, the present invention relates to a compound having formula: (E5a) or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, wherein R is as defined herein.
In some embodiments, the present invention relates to a compound having formula: (E6a) or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, wherein R is as defined herein.
In some embodiments, the present invention relates to a compound having formula: , (E7a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, wherein R is as defined herein.
In some embodiments, the present invention relates to a compound having formula: (E8a), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, wherein R is as defined herein.
In some embodiments, the present invention relates to a compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, wherein R is selected from hydrogen, F and Cl.
In some embodiments, the present invention relates to a compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or 6 7 8 tautomer, wherein R , R , and R are each independently selected from (a) F, (b) Cl, (c) –CF , (d) –CF H, (e) –CFH , (f) –OCF , (g) –OCF H, (h) –OCFH , (i) –OCH , (j) –CN, (k) –OR , 2 2 3 2 2 3 (l) –S(O) R , (m) –SCF , (n) –C –C alkyl, (o) –3–14 membered saturated, unsaturated, or p 3 1 8 aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (p) –3–14 membered saturated, unsaturated, or aromatic carbocycle, (q) –CHCHCN and (r) –CHCH-C(O)NH-t-butyl.
In some embodiments, the present invention relates to a compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or 6 7 8 tautomer, wherein R , R , and R are each independently selected from (a) F, (b) Cl, (c) –CF , (d) –CF H, (e) –CFH , (f) –OCF , (g) –OCF H, (h) –OCFH , (i) –OCH , (j) –CN, (k) –OR , 2 2 3 2 2 3 (l) –S(O) R , (m) –SCF , (n) –C –C alkyl, (o) –3–14 membered saturated, unsaturated, or p 3 1 8 aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (p) –3–14 membered saturated, unsaturated, or aromatic carbocycle.
In some embodiments, the present invention relates to a compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or 6 7 8 tautomer, wherein R , R , and R are each independently selected from are each independently selected from (a) F; (b) Cl; (c) –CF ; (d) –CF H; (e) –CFH ; (f) –OCF ; (g) – 2 2 3 OCF H; (h) –OCFH ; (i) –OCH ; (j) –O(C -C alkyl); (k) –S(O)CH ; (l) –S(O)CF ; (m) – 2 2 3 1 4 3 3 S(O) CH ; (n) –S(O) CF ; (o) –SCF ; 2 3 2 3 3 (p) –C -C alkyl selected from methyl, ethyl, isopropyl, and t-butyl; (q) –3–7 membered saturated, unsaturated, or aromatic heterocycle selected from oxetanyl, azepanyl, pyridyl, dihydropyridyl, furanyl, tetrahydrofuranyl, tetrahydropyridyl, azetidinyl, pyrrolidinyl, piperidinyl, and piperidenyl; and (r) –3–7 membered saturated, unsaturated, or aromatic carbocycle selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, phenyl, cyclohexenyl, and cyclohexadienyl.
In some embodiments, the present invention relates to a compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or 6 7 8 tautomer, wherein R , R , and R are each independently selected from are each independently selected from (a) F, (b) Cl, (c) –CF , (d) –OCF , (e) –OCH , (f) methyl, (g) ethyl, (h) isopropyl, (i) t-butyl, (j) azepanyl, (k) cyclopropyl, (l) cyclobutyl, (m) cyclohexyl, (n) phenyl, (o) pyridyl, (p) azetidinyl, (q) pyrrolidinyl, (r) piperidinyl, and (s) piperidenyl.
In some embodiments, the present invention relates to a compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or 9k 9l 9m 9n 9o 9p 9q 9r 9s 9t tautomer, wherein R , R , R , R , R , R , R , R , R , and R are each independently selected from (a) hydrogen, (b) halogen, (c) –CF , (d) –CF H, (e) –CFH , (f) –OCF , (g) – 3 2 2 3 OCH , (h) –OCF H, (i) –OCFH , (j) –OR , (k) –C –C alkyl, (l) haloalkyl, (m) –3–14 3 2 2 1 8 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (n) –3– 14 membered saturated, unsaturated, or aromatic carbocycle; 9k 9l 9m alternatively, one or more of pairs of substituents selected from R and R , R and 9n 9o 9p 9q 9r 9s 9t R , R and R , R and R , and R and R are taken together with the carbon atom to which they are attached to form (a) 3–7 membered saturated or unsaturated carbocyclic or (b) 3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; and 9k 9l 9m 9n 9o 9p 9q 9r 9s 9t at least one substituent selected from R , R , R , R , R , R , R , R , R , and R is not hydrogen.
In some embodiments, the present invention relates to a compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or 9k 9l 9m 9n 9o 9p 9q 9r 9s 9t tautomer, wherein R , R , R , R , R , R , R , R , R , and R are each independently selected from (a) hydrogen; (b) halogen; (c) –CF ; (d) –CF H; (e) –CFH ; (f) –OCF ; (g) – 3 2 2 3 OCH ; (h) –OCF H; (i) –OCFH ; (j) –OH; (k) –O(C –C alkyl); 3 2 2 1 4 (l) –C –C alkyl selected from methyl, ethyl, isopropyl, and t-butyl; (m) –3–7 membered saturated, unsaturated, or aromatic heterocycle selected from oxetanyl, azepanyl, pyridyl, dihydropyridyl, furanyl, tetrahydrofuranyl, tetrahydropyridyl, azetidinyl, pyrrolidinyl, piperidinyl, and piperidenyl; and (n) –3–7 membered saturated, unsaturated, or aromatic carbocycle selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, phenyl, cyclohexenyl, and cyclohexadienyl; 9k 9l 9m alternatively, one or more of pairs of substituents are selected from R and R , R 9n 9o 9p 9q 9r 9s 9t and R , R and R , R and R , and R and R are taken together with the carbon atom to which they are attached form cyclopropyl, cyclobutyl, or oxetanyl; and 9k 9l 9m 9n 9o 9p 9q 9r 9s 9t at least one substituent selected from R , R , R , R , R , R , R , R , R , and R is not hydrogen; In some embodiments, the present invention relates to a compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or 9k 9l 9m 9n 9o 9p 9q 9r 9s 9t tautomer, wherein R , R , R , R , R , R , R , R , R , and R are each independently selected from (a) hydrogen, (b) halogen, (d) –CF , (e) –CF H, (f) –CFH , (g) –OCF , (h) – 3 2 2 3 OCH , (i) –OCF H, (j) –OCFH , (k) –OH, (l) –OCH , (l) methyl, (m) ethyl, (n) isopropyl, 3 2 2 3 and (o) t-butyl; and 9k 9l 9m 9n 9o 9p 9q 9r 9s 9t at least one substituent selected from R , R , R , R , R , R , R , R , R , and R is not hydrogen.
In some embodiments, the present invention relates to a compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, wherein is selected from: or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer.
In some embodiments, is selected from In some embodiments, the present invention relates to a compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, wherein R is selected from: In some embodiments, the present invention relates to a compound having the formula: (F1), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 3a 3b 6 7 8 9o 9p 9q 9r compound or tautomer, wherein R , R , R , R , R , Z, R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having the formula: (F2), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 3a 3b 6 7 8 9o 9p 9q 9r compound or tautomer, wherein R , R , R , R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound of formula F1 or F2, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, wherein 11 11 11 Z is selected from –O–, –S(O) –, –NR –, –(C=O)–, –NR (C=O)–, –(C=O)NR –, – 11 11 11 11 S(O) NR –, –NR S(O) –, and –NR S(O) NR –; p p p R is selected from halogen and –C –C alkyl; 3b 11 R is selected from hydrogen, halogen, –OCF , –OCF H, –OCFH , –OCH , –OR , – 3 2 2 3 C –C alkyl, and haloalkyl; 6 7 8 R , R , and R are each independently selected from (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) –CF , (g) –CF H, (h) –CFH , (i) –OCF , (j) –OCF H, (k) –OCFH , (l) –OCH , (m) –CN, 2 2 3 2 2 3 11 11 11 11 11 11 11 (n) –N , (o) –NO , (p) –NR R , (q) –NR (CO)R , (r) –(CO)NR R , (s) –OR , (t) –COH, 11 11 11 11 11 11 (u) –CO(C –C alkyl), (v) –COR , (w) –NR (CNR )NR R , (x) –S(O) R , (y) – 1 8 p 11 11 11 11 11 11 NR S(O) R , (z) –SR , (aa) –SCF , (bb) –C(CF )H-NH-CHR R , (cc) –COOR , (dd) – p 3 3 11 11 (OCH CH ) R , (ee) –(OCH CH ) OR , (ff) –C –C alkyl, (gg) –C –C alkenyl, and (hh) – 2 2 t 2 2 t 1 8 2 8 C –C alkynyl; 9o 9p 9q 9r R , R , R , and R are each independently selected from (a) hydrogen, (b) halogen, (c) –OCF , (d) –OCH , (e) –OCF H, (f) –OCFH , (g) –OR , (h) –C –C alkyl, and (i) 3 3 2 2 1 8 haloalkyl; R is selected from hydrogen, –C –C alkyl, –C –C alkenyl, –C –C alkynyl, and 1 6 2 6 2 6 haloalkyl; p is 0, 1, or 2; and t is 0, 1, or 2.
In some embodiments, the present invention relates to a compound of formula F1, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, wherein Z is O; 9o 9p 9q 9r R , R , R , and R are each independently selected from C -C alkyl and hydrogen; R and R are each independently selected from hydrogen, F, Cl, Br, I, –C -C alkyl, –CH F, 1 6 2 –CHF , and –CF ; R is selected from hydrogen, F, Cl, Br, I, – C -C alkyl, –CH F, –CHF , –CF , –OC -C 1 6 2 2 3 1 6 alkyl, –S(O) -C -C alkyl, –OCH F, –OCHF , –OCF , –S(O) -CH , –S(O) -CH F, and – p 1 6 2 2 3 p 3 p 2 S(O) -CF ; and R is selected from halogen and –C –C alkyl; R is selected from hydrogen, halogen, –CF , –CF H, –CFH , –C –C alkyl, and haloalkyl; 3 2 2 1 6 p is 0, 1, or 2.
In some embodiments, the present invention relates to a compound of formula F2, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or 9o 9p 9q 9r tautomer, wherein R , R , R , and R are each independently selected from –C -C alkyl and hydrogen; R and R are each independently selected from hydrogen, F, Cl, Br, I, –C -C alkyl, –CH F, 1 6 2 –CHF , and –CF ; R is selected from hydrogen, F, Cl, Br, I, –C -C alkyl, –CH F, –CHF , –CF , –OC -C 1 6 2 2 3 1 6 alkyl, –S(O) -C -C alkyl, –OCH F, –OCHF , –OCF , –S(O) -CH , –S(O) -CH F, and – p 1 6 2 2 3 p 3 p 2 S(O) -CF ; and R is selected from halogen and –C –C alkyl; R is selected from hydrogen, halogen, –CF , –CF H, –CFH , –C –C alkyl, and haloalkyl; 3 2 2 1 6 and p is 0, 1, or 2.
In some embodiments, the present invention relates to a compound having the formula: (G1), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 3a 6 7 8 9o 9p 9q 9r compound or tautomer, wherein R , R , R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having the formula: (G2), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 3a 6 7 8 9o 9p 9q 9r compound or tautomer, wherein R , R , R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having the formula: (G3), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 3a 6 7 8 9o 9p 9q 9r compound or tautomer, wherein R , R , R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having the formula: (G4), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 3a 6 7 8 9o 9p 9q 9r compound or tautomer, wherein R , R , R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound of formulae G1, G2, G3, or G4, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug 9o 9p 9q 9r of said compound or tautomer, wherein R , R , R , and R are each independently selected from –C -C alkyl and hydrogen; R and R are each independently selected from hydrogen, F, Cl, Br, I, –C -C alkyl, –CH F, 1 6 2 –CHF , and –CF ; R is selected from hydrogen, F, Cl, Br, I, –C -C alkyl, –CH F, –CHF , –CF , –OC -C 1 6 2 2 3 1 6 alkyl, –S(O) -C -C alkyl, –OCH F, –OCHF , –OCF , –S(O) -CH , –S(O) -CH F, and – p 1 6 2 2 3 p 3 p 2 S(O) -CF ; and R is selected from halogen and –C –C alkyl; and p is 0, 1, or 2.
In some embodiments, the present invention relates to a compound of formulae G1, G2, G3, or G4, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug 9o 9p 9q 9r of said compound or tautomer, wherein R , R , R , and R are each independently selected from –C -C alkyl and hydrogen; R is selected from hydrogen, F, Cl, Br, I, –C -C alkyl, –CH F, –CHF , and –CF ; 1 6 2 2 3 R is selected from hydrogen, F, Cl, Br, I, –C -C alkyl, –CH F, –CHF , –CF , –OC -C 1 6 2 2 3 1 6 alkyl, –S(O) -C -C alkyl, –OCH F, –OCHF , –OCF , –S(O) -CH , –S(O) -CH F, and – p 1 6 2 2 3 p 3 p 2 S(O) -CF ; R is hydrogen; R is selected from halogen and –C –C alkyl; and p is 0, 1, or 2.
In some embodiments, the present invention relates to a compound having the formula: (H1), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 3a 6 7 8 9q 9r compound or tautomer, wherein R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having the formula: (H2), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 3a 6 7 8 9q 9r compound or tautomer, wherein R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having the formula: (H3), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 3a 6 7 8 9q 9r compound or tautomer, wherein R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having the formula: (H4), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 3a 6 7 8 9q 9r compound or tautomer, wherein R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having the formula: (H5), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 3a 6 7 8 9r compound or tautomer, wherein R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having the formula: (H6), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 3a 6 7 8 9r compound or tautomer, wherein R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having the formula: (H7), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 3a 6 7 8 9r compound or tautomer, wherein R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having the formula: (H8), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 3a 6 7 8 9r compound or tautomer, wherein R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having the formula: (H9), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 3a 6 7 8 9r compound or tautomer, wherein R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having the formula: (H10), 3a 6 7 8 9r wherein R , R , R , R , and R are as defined herein, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer.
In some embodiments, the present invention relates to a compound having the formula: (H11), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 3a 6 7 8 9r compound or tautomer, wherein R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having the formula: (H12), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 3a 6 7 8 9r compound or tautomer, wherein R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound of formulae H1, H2, H3, or H4, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug 9q 9r of said compound or tautomer, wherein R and R are each independently selected from – C -C alkyl and hydrogen; R and R are each independently selected from hydrogen, F, Cl, Br, I, –C -C alkyl, –CH F, 1 6 2 –CHF , and –CF ; R is selected from hydrogen, F, Cl, Br, I, –C -C alkyl, –CH F, –CHF , –CF , –OC -C 1 6 2 2 3 1 6 alkyl, –S(O) -C -C alkyl, –OCH F, –OCHF , –OCF , –S(O) -CH , –S(O) -CH F, and – p 1 6 2 2 3 p 3 p 2 S(O) -CF ; and R is selected from halogen and –C –C alkyl; and p is 0, 1, or 2.
In some embodiments, the present invention relates to a compound of formulae H1, H2, H3, or H4, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug 9q 9r of said compound or tautomer, wherein R and R are each independently selected from – C -C alkyl and hydrogen; R is selected from hydrogen, F, Cl, Br, I, –C -C alkyl, –CH F, –CHF , and –CF ; 1 6 2 2 3 R is selected from hydrogen, F, Cl, Br, I, –C -C alkyl, –CH F, –CHF , –CF , –OC -C 1 6 2 2 3 1 6 alkyl, –S(O) -C -C alkyl, –OCH F, –OCHF , –OCF , –S(O) -CH , –S(O) -CH F, and – p 1 6 2 2 3 p 3 p 2 S(O) -CF ; R is hydrogen; R is selected from halogen and –C –C alkyl; and p is 0, 1, or 2.
In some embodiments, the present invention relates to a compound of formulae H5, H6, H7, H8, H9, H10, H11, or H12, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, wherein R is –C -C alkyl; R is selected from hydrogen, F, Cl, Br, I, –C -C alkyl, –CH F, –CHF , and –CF ; 1 6 2 2 3 R is selected from hydrogen, F, Cl, Br, I, –C -C alkyl, –CH F, –CHF , –CF , –OC -C 1 6 2 2 3 1 6 alkyl, –S(O) -C -C alkyl, –OCH F, –OCHF , –OCF , –S(O) -CH , –S(O) -CH F, and – p 1 6 2 2 3 p 3 p 2 S(O) -CF ; R is hydrogen; R is selected from halogen and –C –C alkyl; and p is 0, 1, or 2.
In some embodiments, the present invention relates to a compound of formulae H5, H6, H7, H8, H9, H10, H11, or H12, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, wherein R is –CH ; R is selected from hydrogen, F, Cl, Br, I, –C -C alkyl, –CH F, –CHF , and –CF ; 1 6 2 2 3 R is selected from hydrogen, F, Cl, Br, I, –C -C alkyl, –CH F, –CHF , –CF , –OC -C 1 6 2 2 3 1 6 alkyl, –S(O) -C -C alkyl, –OCH F, –OCHF , –OCF , –S(O) -CH , –S(O) -CH F, and – p 1 6 2 2 3 p 3 p 2 S(O) -CF ; R is hydrogen; R is –CH ; and p is 0, 1, or 2.
In some embodiments, the present invention relates to a compound having the formula: (I1), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 3a 6 7 8 9o 9p compound or tautomer, wherein R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having the formula: (I2), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 3a 6 7 8 9o 9p compound or tautomer, wherein R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having the formula: (I3), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 3a 6 7 8 9o 9p compound or tautomer, wherein R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having the formula: (I4), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 3a 6 7 8 9o 9p compound or tautomer, wherein R , R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having the formula: (I5), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 3a 6 7 8 9o compound or tautomer, wherein R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having the formula: (I6), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 3a 6 7 8 9o compound or tautomer, wherein R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having the formula: (I7), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 3a 6 7 8 9o compound or tautomer, wherein R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having the formula: (I8), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 3a 6 7 8 9o compound or tautomer, wherein R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having the formula: (I9), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 3a 6 7 8 9o compound or tautomer, wherein R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having the formula: (I10), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 3a 6 7 8 9o compound or tautomer, wherein R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having the formula: (I11), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 3a 6 7 8 9o compound or tautomer, wherein R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound having the formula: (I12), or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 3a 6 7 8 9o compound or tautomer, wherein R , R , R , R , and R are as defined herein.
In some embodiments, the present invention relates to a compound of formulae I1, I2, I3, or I4, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 9o 9p compound or tautomer, wherein R and R are each independently selected from –C -C alkyl and hydrogen; R and R are each independently selected from hydrogen, F, Cl, Br, I, –C -C alkyl, –CH F, 1 6 2 –CHF , and –CF ; R is selected from hydrogen, F, Cl, Br, I, –C -C alkyl, –CH F, –CHF , –CF , –OC -C 1 6 2 2 3 1 6 alkyl, –S(O) -C -C alkyl, –OCH F, OCHF , –OCF , S(O) -CH , –S(O) -CH F, and –S(O) - p 1 6 2 2 3 p 3 p 2 p CF ; and R is selected from halogen and –C –C alkyl; and p is 0, 1, or 2.
In some embodiments, the present invention relates to a compound of formulae I1, I2, I3, or I4, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said 9o 9p compound or tautomer, wherein R and R are each independently selected from –C -C alkyl and hydrogen; R is selected from hydrogen, F, Cl, Br, I, C -C alkyl, –CH F, –CHF , and –CF ; 1 6 2 2 3 R is selected from hydrogen, F, Cl, Br, I, –C -C alkyl, –CH F, –CHF , –CF , –OC -C 1 6 2 2 3 1 6 alkyl, –S(O) -C -C alkyl, –OCH F, –OCHF , –OCF , –S(O) -CH , –S(O) -CH F, and – p 1 6 2 2 3 p 3 p 2 S(O) -CF ; R is hydrogen; R is selected from halogen and –C –C alkyl; and p is 0, 1, or 2.
In some embodiments, the present invention relates to a compound of formulae I5, I6, I7, I8, I9, I10, I11, or I12, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, wherein R is –C -C alkyl; R is selected from hydrogen, F, Cl, Br, I, –C -C alkyl, –CH F, –CHF , and –CF ; 1 6 2 2 3 R is selected from hydrogen, F, Cl, Br, I, –C -C alkyl, –CH F, –CHF , –CF , –OC -C 1 6 2 2 3 1 6 alkyl, –S(O) -C -C alkyl, –OCH F, –OCHF , –OCF , –S(O) -CH , –S(O) -CH F, and – p 1 6 2 2 3 p 3 p 2 S(O) -CF ; R is hydrogen; R is selected from halogen and –C –C alkyl; and p is 0, 1, or 2.
In some embodiments, the present invention relates to a compound of formulae I5, I6, I7, I8, I9, I10, I11, or I12, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, wherein R is –CH ; R is selected from hydrogen, F, Cl, Br, I, –C -C alkyl, –CH F, –CHF , and –CF ; 1 6 2 2 3 R is selected from hydrogen, F, Cl, Br, I, –C -C alkyl, –CH F, –CHF , –CF , –OC -C 1 6 2 2 3 1 6 alkyl, –S(O) -C -C alkyl, –OCH F, –OCHF , –OCF , –S(O) -CH , –S(O) -CH F, and – p 1 6 2 2 3 p 3 p 2 S(O) -CF ; R is hydrogen; R is –CH ; and p is 0, 1, or 2.
In some embodiments, the present invention relates to a compound of formulae IV, V, VI, VII, VIII, IX, X, XI, XXa, XXa1, Va, VIa, VIIa, VIIIa, IXa, Xa, XIa, XII, XIII, XIV, XV, XVI, XVII, XVIII, XXb, XXb1, XIIa, XIIIa, XIVa, XVa, XVIa, XVIIa, XVIIIa, F1, or F2, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, wherein the moiety and R is H, is selected from: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , and .
In some embodiments, the present invention relates to a compound of formulae F1 3b 3b (R is H), F2 (R is H), G2, G4, H2, H4, H6, H8, H10, H12, I2, I4, I6, I8, I10, or I12, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, wherein the moiety is selected from: , , , , , , , , , , , , , , , , , , , , and .
In some embodiments, the present invention relates to a compound of formulae F1 3b 3b (R is H), F2 (R is H), G1, G3, H1, H3, H5, H7, H9, H11, I1, I3, I5, I7, I9, or I11, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, wherein the moiety is selected from: , , , , , , , , , , , , , , , , , , and .
In some embodiments, the present invention relates to a compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, according to any one the compounds in Table 1, Table 2, Table 2a, and Table 2aa.
In some embodiments, the present invention relates to a compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer that binds the ribosome. In some embodiments, the ribosome is a bacterial ribosome.
In some embodiments, the present invention relates to a pharmaceutical composition comprising a compound of the invention, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, and a pharmaceutically acceptable carrier. In some embodiments, the present invention relates to a compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer of the invention and a means for delivery.
In some embodiments, the present invention relates to a method of treating, preventing, or reducing the risk of a disease state in a human or animal comprising administering to the human or animal in need thereof an effective amount of a compound of the invention, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer.
In some embodiments, the present invention relates to a method of treating, preventing, or reducing a microbial infection in a human or animal comprising administering to the human or animal an effective amount of a compound of the invention, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer.
In some embodiments, the present invention relates to use of a compound of the invention, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, in the manufacture of a medicament for treating, preventing, or reducing a microbial infection in a human or animal.
In some embodiments, the present invention relates to a compound of the invention, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, for use in treating, preventing, or reducing a microbial infection in a human or animal.
In some embodiments, the present invention relates to a method of treating, preventing, or reducing the risk of a microbial infection in a human or animal comprising administering to the human or animal an effective amount of a compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, wherein said microbial infection is caused by one or more of the following microorganisms: Acinetobacter spp. (Acinetobacter baumanni), Bacteroides distasonis, Bacteroides fragilis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Citrobacter freundii, Citrobacter koser, Clostridium clostridioforme, Clostridium perfringens, Enterobacter aerogenes, Enterobacter cloacae, Enterococcus faecalis, Enterococcus spp. (vancomycin susceptible and resistant isolates), Escherichia coli (including ESBL and KPC producing isolates), Eubacterium lentum, Fusobacterium spp., Haemophilus influenzae (including beta-lactamase positive isolates), Haemophilus parainfluenzae, Klebsiella pneumoniae (including ESBL and KPC producing isolates), Klebsiella oxytoca (including ESBL and KPC producing isolates), Legionella pneumophilia Moraxella catarrhalis, Morganella morganii, Mycoplasma spp., Peptostreptococcus spp., Porphyromonas asaccharolytica, Prevotella bivia, Proteus mirabilis, Proteus vulgaris, Providencia rettgeri, Providencia stuartii, Pseudomonas aeruginosa, Serratia marcescens, Streptococcus anginosus, Staphylococcus aureus (methicillin susceptible and resistant isolates), Staphylococcus epidermidis (methicillin susceptible and resistant isolates), Stenotrophomonas maltophilia, Streptococcus agalactiae, Streptococcus constellatus, Streptococcus pneumoniae (penicillin susceptible and resistant isolates), Streptococcus pyogenes, or Streptococcus pyogenes.
In some embodiments, the present invention relates to a method of treating, preventing, or reducing the risk of a microbial infection in a human or animal comprising administering to the human or animal an effective amount of a compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, wherein said infection is caused by or involves one or more microorganisms selected from: Acinetobacter spp. (Acinetobacter baumanni), Bacteroides distasonis, Bacteroides fragilis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Citrobacter freundii, Citrobacter koser, Clostridium clostridioforme, Clostridium perfringens, Enterobacter aerogenes, Enterobacter cloacae, Enterococcus faecalis, Enterococcus spp., Escherichia coli, Eubacterium lentum, Fusobacterium spp., Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Klebsiella oxytoca, Legionella pneumophilia, Moraxella catarrhalis, Morganella morganii, Mycoplasma spp., Peptostreptococcus spp., Porphyromonas asaccharolytica, Prevotella bivia, Proteus mirabilis, Proteus vulgaris, Providencia rettgeri, Providencia stuartii, Pseudomonas aeruginosa, Serratia marcescens, Streptococcus anginosus, Staphylococcus aureus, Staphylococcus epidermidis, Stenotrophomonas maltophilia, Streptococcus agalactiae, Streptococcus constellatus, Streptococcus pneumoniae, Streptococcus pyogenes, and Streptococcus pyogenes.
In some embodiments, the present invention relates to a method wherein said infection is caused by or involves one or more of aerobic and facultative gram-positive microorganism selected from: Staphylococcus aureus, Streptococcus pneumoniae, Enterococcus spp., Streptococcus agalactiae, Streptococcus pyogenes, and Staphylococcus epidermidis.
In some embodiments, the present invention relates to a method wherein said infection is caused by or involves one or more of aerobic and facultative gram-negative microorganism selected from: Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter aerogenes, Enterobacter cloacae, Morganella morganii, Serratia marcescens, Pseudomonas aeruginosa, Acinetobacter baumanni, Moraxella catarrhalis, Proteus mirabilis, Citrobacter koseri, Haemophilus parainfluenzae, Klebsiella oxytoca, Proteus vulgaris, Providencia rettgeri, and Providencia stuartii.
In some embodiments, the present invention relates to a method wherein, said infection is caused by or involves one or more of anaerobic microorganism: Bacteroides fragilis, Bacteroides distasonis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Clostridium clostridioforme, Eubacterium lentum, Peptostreptococcus spp., Porphyromonas asaccharolytica, Prevotella bivia, Bacteroides vulgatus, Clostridium perfringens, and Fusobacterium spp.
In some embodiments, the present invention relates to a method, wherein the microorganism Enterococcus spp. is selected from vancomycin susceptible isolate and vancomycin resistant isolate.
In some embodiments, the present invention relates to a method wherein, the microorganism Escherichia coli is selected from extended spectrum beta-lactamase (ESBL) producing isolate and Klebsiella pneumoniae carbapenemase (KPC) producing isolate.
In some embodiments, the present invention relates to a method wherein, the microorganism Haemophilus influenzae is a beta-lactamase positive isolate.
In some embodiments, the present invention relates to a method wherein, the microorganism Klebsiella pneumoniae is selected from extended spectrum beta-lactamase (ESBL) producing isolate and Klebsiella pneumoniae carbapenemase (KPC) producing isolate.
In some embodiments, the present invention relates to a method wherein, the microorganism Klebsiella oxytoca selected from extended spectrum beta-lactamase (ESBL) producing isolate and Klebsiella pneumoniae carbapenemase (KPC) producing isolate.
In some embodiments, the present invention relates to a method wherein, the microorganism Staphylococcus aureus is selected from methicillin susceptible isolate and methicillin resistant isolate.
In some embodiments, the present invention relates to a method wherein, the microorganism Staphylococcus epidermidis is selected from methicillin susceptible isolate and methicillin resistant isolate.
In some embodiments, the present invention relates to a method wherein, the microorganism Streptococcus pneumoniae is selected from penicillin susceptible isolate and penicillin resistant isolate.
In some embodiments, the present invention relates to a method of treating, preventing or reducing the risk of a microbial infection in a human or animal comprising administering to the human or animal an effective amount of a compound of the invention, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, or use of a compound of the invention, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, in the manufacture of a medicament for treating, preventing, or reducing the risk of a microbial infection in a human or animal, wherein the microbial infection is selected from the group consisting of: a skin infection, a Gram positive infection, a Gram negative infection, nosocomial pneumonia, community acquired pneumonia, post–viral pneumonia, hospital acquired pneumonia/ventilator associated pneumonia, a respiratory tract infection such as chronic respiratory tract infection (CRTI), acute pelvic infection, a complicated skin and skin structure infection, a skin and soft tissue infection (SSTI) including uncomplicated skin and soft tissue infections (uSSTI)s and complicated skin and soft tissue infections, an abdominal infection, a complicated intra-abdominal infection, a urinary tract infection, bacteremia, septicemia, endocarditis, an atrio–ventricular shunt infection, a vascular access infection, meningitis, surgical prophylaxis, a peritoneal infection, a bone infection, a joint infection, a methicillin–resistant Staphylococcus aureus infection, a vancomycin–resistant Enterococci infection, a linezolid–resistant organism infection, a Bacillus anthracis infection, a Francisella tularensis infection, a Yersinia pestis infection, and tuberculosis.
The compounds of the present invention can be used, for example for the treatment of patients with moderate to severe infections, which may be caused by susceptible isolates of the indicated microorganisms: In some embodiments, the present invention relates to a method of treating, preventing or reducing the risk of a complicated intra-abdominal infection in a human or animal comprising administering to the human or animal an effective amount of a compound of the invention, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, or to the use of a compound of the invention, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, in the manufacture of a medicament for treating, preventing or reducing the risk of a complicated intra-abdominal infection in a human or animal, In some embodiments, the complicated intra-abdominal infection is selected from polymicrobial infections such as abscess due to Escherichia coli, Clostridium clostridioforme, Eubacterium lentum, Peptostreptococcus spp., Bacteroides fragilis, Bacteroides distasonis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Streptococcus anginosus, Streptococcus constellatus, Enterococcus faecalis, Proteus mirabilis, or Clostridium perfringens.
In some embodiments, the present invention relates to a method of treating, preventing or reducing the risk of a complicated skin and skin structure infection (cSSSI, also known as acute bacterial skin and skin structure infections or ABSSSI) in a human or animal comprising administering to the human or animal an effective amount of a compound of the invention, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, or to the use of a compound of the invention, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, in the manufacture of a medicament for treating, preventing or reducing the risk of a complicated skin and skin structure infection, In some embodiments, the complicated skin and skin structure infection is selected from diabetic foot infections without osteomyelitis due to Staphylococcus aureus (methicillin susceptible and resistant isolates), Streptococcus agalactiae, Streptococcus pyogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Bacteroides fragilis, Peptostreptococcus species, Porphyromonas asaccharolytica, or Prevotella bivia.
In some embodiments, the present invention relates to a method of treating, preventing, or reducing the risk of a community acquired pneumonia (CAP) in a human or animal comprising administering to the human or animal an effective amount of a compound of the invention, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, or to the use of a compound of the invention, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, in the manufacture of a medicament for treating, preventing or reducing the risk of community acquired pneumonia, In some embodiment, the community acquired pneumonia is due to Streptococcus pneumoniae (penicillin susceptible and resistant isolates) including cases with concurrent bacteremia, Haemophilus influenzae (including beta-lactamase positive isolates), Moraxella catarrhalis, or atypical bacteria like Mycoplasma spp.
In some embodiments, the present invention relates to a method of treating, preventing, or reducing the risk of a complicated urinary tract infection (cUTI) in a human or animal comprising administering to the human or animal an effective amount of a compound of the invention, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, or to the use of a compound of the invention, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, in the manufacture of a medicament for treating, preventing or reducing the risk of a complicated urinary tract infection, In some embodiment, the complicated urinary tract infection is selected from pyelonephritis due to Escherichia coli, concurrent bacteremia, or Klebsiella pneumoniae.
In some embodiments, the present invention relates to a method of treating, preventing, or reducing the risk of an acute pelvic infection in a human or animal comprising administering to the human or animal an effective amount of a compound of the invention, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, or to the use of a compound of the invention, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, in the manufacture of a medicament for treating, preventing or reducing the risk of an cute pelvic infection, In some embodiments, the acute pelvic infection is selected from postpartum endomyometritis, septic abortion and post surgical gynecologic infections and the infection is due to a microorganism selected from Streptococcus agalactiae, Escherichia coli, Bacteroides fragilis, Porphyromonas asaccharolytica, Peptostreptococcus spp., and Prevotella bivia.
In some embodiments, the present invention relates to a method of treating, preventing, or reducing the risk of a hospital acquired pneumonia (HAP) /ventilator associated pneumonia (VAP) in a human or animal comprising administering to the human or animal an effective amount of a compound of the invention, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, or to the use of a compound of the invention, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, in the manufacture of a medicament for treating, preventing or reducing the risk of hospital acquired pneumonia/ventilator associated pneumonia, In some embodiments, the hospital acquired pneumonia/ventilator associated pneumonia is due to a microorganism selected from Streptococcus pneumoniae (penicillin susceptible and resistant isolates), Staphylococcus aureus (methicillin susceptible and resistant isolates), Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter spp., Stenotrophomonas maltophilia, Haemophilus influenzae (including beta-lactamase positive isolates), and Legionella pneumophilia.
The compounds or tautomers or pharmaceutically acceptable salts, esters or prodrugs of said compounds or tautomers of the present invention may also be useful for the prevention, prophylaxis, or reduction of surgical site infections. In some embodiments, the compounds or tautomers or pharmaceutically acceptable salts, esters or prodrugs of said compounds or tautomers of the present invention are useful following elective colorectal surgery.
Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify the causative organisms and to determine their susceptibility to the compounds of the present invention. Therapy with the compounds or tautomers or pharmaceutically acceptable salts, esters or prodrugs of said compounds or tautomers of the present invention may be initiated empirically before results of these tests are known; once results become available, antimicrobial therapy should be adjusted accordingly.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of the compounds or tautomers or pharmaceutically acceptable salts, esters or prodrugs of said compounds or tautomers of the present invention and other antibacterial drugs, the compounds or tautomers or pharmaceutically acceptable salts, esters or prodrugs of said compounds or tautomers should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
In some embodiments, the present invention relates to a method of treating, preventing, or reducing the risk of a microbial infection due to an aerobic or facultative gram- positive microorganism in a human or animal comprising administering to the human or animal an effective amount of a compound of the invention, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, or to the use of a compound of the invention, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, in the manufacture of a medicament for treating, preventing or reducing the risk of a microbial infection due to an aerobic or facultative gram-positive microorganism.
In some embodiments, the aerobic or facultative gram-positive microorganism is selected from: Staphylococcus aureus (methicillin susceptible and resistant isolates), Streptococcus pneumoniae (penicillin susceptible and resistant isolates), Enterococcus spp. (vancomycin susceptible and resistant isolates), Streptococcus agalactiae, Streptococcus pyogenes, and Staphylococcus epidermidis (methicillin susceptible and resistant isolates).
In some embodiments, the present invention relates to a method of treating, preventing, or reducing the risk of a microbial infection due to an aerobic and facultative gram-negative microorganism in a human or animal comprising administering to the human or animal an effective amount of a compound of the invention, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, or to the use of a compound of the invention, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, in the manufacture of a medicament for treating, preventing or reducing the risk of a microbial infection due to an aerobic or facultative gram-positive microorganism.
In some embodiments, the aerobic and facultative gram-negative microorganism is selected from: Escherichia coli [including extended spectrum beta-lactamase (ESBL) and Klebsiella pneumonia (KPC) producing isolates), Haemophilus influenzae (including Beta- lactamase positive isolates), Klebsiella pneumoniae (including ESBL and KPC producing isolates), Citrobacter freundii, Enterobacter aerogenes, Enterobacter cloacae, Morganella morganii, Serratia marcescens, Pseudomonas aeruginosa, Acinetobacter baumanni, Moraxella catarrhalis, Proteus mirabilis, Citrobacter koseri, Haemophilus parainfluenzae, Klebsiella oxytoca (including ESBL and KPC producing isolates), Proteus vulgaris, Providencia rettgeri, and Providencia stuartii.
In some embodiments, the present invention relates to a method of treating, preventing, or reducing the risk of a microbial infection due to an anaerobic microorganism in a human or animal comprising administering to the human or animal an effective amount of a compound of the invention, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, or to the use of a compound of the invention, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, in the manufacture of a medicament for treating, preventing or reducing the risk of a microbial infection due to an anaerobic microorganism.
In some embodiments, the anaerobic microorganism is selected from: Bacteroides fragilis, Bacteroides distasonis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Clostridium clostridioforme, Eubacterium lentum, Peptostreptococcus species, Porphyromonas asaccharolytica, Prevotella bivia, Bacteroides vulgates, Clostridium perfringens, and Fusobacterium spp.
In some embodiments, the present invention relates to a method of treating or reducing the risk of a microbial infection in a human or animal comprising administering to the human or animal an effective amount of a compound of the invention, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, or to the use of a compound of the invention, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, in the manufacture of a medicament for treating, preventing or reducing the risk of a microbial infection.
In some embodiments, the microorganism is Legionella pneumophilia.
In some embodiments, the microorganism Enterococcus spp. is selected from vancomycin susceptible isolate and vancomycin resistant isolate. In some embodiments, the microorganism Escherichia coli is selected from extended spectrum beta-lactamase (ESBL) producing isolate and Klebsiella pneumoniae carbapenemase (KPC) producing isolate. In some embodiments, the microorganism Haemophilus influenzae is a beta-lactamase positive isolate. In some embodiments, the microorganism Klebsiella pneumoniae is selected from extended spectrum beta-lactamase (ESBL) producing isolate and Klebsiella pneumoniae carbapenemase (KPC) producing isolate. In some embodiments, the microorganism Klebsiella oxytoca selected from extended spectrum beta-lactamase (ESBL) producing isolate and Klebsiella pneumoniae carbapenemase (KPC) producing isolate. In some embodiments, the microorganism Staphylococcus aureus is selected from methicillin susceptible isolate and methicillin resistant isolate. In some embodiments,the microorganism Staphylococcus epidermidis is selected from methicillin susceptible isolate and methicillin resistant isolate. In some embodiments, the microorganism Streptococcus pneumoniae is selected from penicillin susceptible isolate and penicillin resistant isolate.
In some embodiments, the present invention relates to a method, use, or compound of the invention, wherein the amount of compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer comprises from 0.1 mg to 1500 mg.
In some embodiments, the present invention relates to a method, use, or compound of the invention wherein the amount of compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer comprises about 25 mg, or about 50 mg, or about 75 mg, or about 100 mg, or about 125 mg, or about 150 mg, or about 175 mg, or about 200 mg, or about 225 mg, or about 250 mg, or about 275 mg, or about 300 mg, or about 325, or about 350 mg, or about 375 mg, or about 400 mg, or about 425 mg, or about 450 mg, or about 475 mg, or about 500 mg, or about 525 mg, or about 550 mg, or about 575 mg, or about 600 mg, or about 625 mg, or about 650 mg, or about 675 mg, or about 700 mg, or about 725 mg, or about 750 mg, or about 775 mg, or about 800 mg, or about 825 mg, or about 850 mg, or about 875 mg, or about 900 mg, or about 925 mg, or about 950 mg, or about 975 mg, or about 1000 mg, or about 1025 mg, or about 1050, mg, or about 1075 mg, or about 1100 mg, or about 1125 mg, or about 1150 mg, or about 1175 mg, or about 1200 mg, or about 1225 mg, or about 1250 mg, or about 1275 mg, or about 1300 mg, or about 1325 mg, or about 1350 mg, or about 1375 mg, or about 1400 mg, or about 1425 mg, or about 1450 mg, or about 1475 mg, or about 1500 mg.
In some embodiments, the present invention relates to a method, use, or compound of the invention wherein the compound, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, is administered otically, ophthalmically, nasally, orally, parenterally, topically, or intravenously.
In some embodiments, the present invention relates to a method of synthesizing a compound of the invention, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer.
In some embodiments, the present invention relates to a medical device containing a compound of the invention or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer. In some embodiments, the device is a stent. 3. Synthesis of the Compounds of the Invention Compounds of the invention can be prepared according to methods known in the art.
More specifically, compounds of the invention can be prepared according to the procedures and examples described herein. In one aspect, a compound of the invention can be synthesized by coupling two fragments A and B: In one aspect, a compound of the invention can be synthesized as outlined Scheme 1.
Scheme 1 In one aspect, a compound of the invention can be synthesized as outlined in Scheme 2. The scheme depicts the preparation of a compound of formula I having certain values 3 9 9 where X is CR and Y is CR . It is understood that one skilled in the art would be able to readily apply this scheme for the synthesis of compounds having other R and R groups as described herein.
Scheme 2 In one aspect, the transformation of step 1 of the synthesis described above is based on a coupling reaction of Fragments A and B to form the core pyrrolocytosine ring. See e.g., Wojciechowski, F., Hudson, R. H. E. "Peptide Nucleic Acid Containing a Meta-Substituted Phenylpyrrolocytosine Exhibits a Fluorescence Response and Increased Binding Affinity toward RNA." Org. Lett. 2009, 11(21), 4878–4881 and Wojciechowski, F., Hudson, R. H.
E. "Fluorescence and Hybridization Properties of Peptide Nucleic Acid Containing a Substituted Phenylpyrrolocytosine Designed to Engage Guanine with an Additional H-Bond" J. Am. Chem. Soc., 2008, 130(38), 12574-12575. In one aspect, X in Fragment A is I or Br 3a 3b 3e 3f 3g 3h 3i 3j 6 7 8 9k 9l 9o 9p 9q 9p 9q 9r and R , R , R , R , R , R , R , R , R , R , R , R , R , R , R , R , R , R , R , and Z are as described herein.
Fragments A and B can be coupled using a variety of methods known in the art. Step 2 of the synthesis involves the installation of a guanidine functional group using methods known in the art. In one aspect, the protected terminal amine on the left-hand side of the molecule can be deprotected to afford the primary amine. Guanidine can then be installed by selective addition to the primary amine on the basis of steric factors and the diminished reactivity of the benzylic nitrogen. Global deprotection then produces the final compound in the form of a polyamine salt.
In one aspect, a compound of the invention can be synthesized as shown in the Scheme 3. The scheme depicts the preparation of a compound having certain values defined, however one skilled in the art would understand that the methodology outlined below could be readily applied for the preparation of other compounds of the invention described herein.
Scheme 3 3a 9o 9r Although Scheme 3 shown above is depicted with certain values for R , R , R , and Z, it is understood that one skilled in the art would be able to readily apply this scheme for 3a 9o 9r the synthesis of compounds having other R , R , R , and Z groups. Furthermore, it is understood that Scheme 3 above is applicable for the variety of aryl groups described herein e.g., Preparation of Fragment A Fragment A intermediates can be prepared according to methods known in the art.
The schemes below outline strategies that can be applied for the synthesis of Fragment A intermediates and used to prepare compounds of the invention. Procedures for the preparation of Fragment A intermediates are also found in the examples provided herein. In one aspect, Fragment A can be synthesized using a 4 step process as outlined below.
Step 1 uses a reductive amination strategy to form a benzyl amine intermediate. The amine and aldehyde groups can be on either one of the compounds involved in the reductive amination reaction. Reductive amination is a well known procedure in the chemical arts and thus, the skilled person would be able to optimize Step 1 for the preparation of a compound of the invention.
Scheme 4 Following formation of the benzyl amine intermediate, Step 2 is a coupling reaction to form a pinacol borane compound, which is then coupled in Step 3 with an iodocytosine moiety. Step 4 involves acylation of the amine group of the pyrimidinone to form a Fragment A intermediate.
Scheme 5 Scheme 6 and Scheme 7 below show a 4-step for the synthesis of the Fragment A intermediate: Although the schemes depict the preparation of compounds having certain values defined, one skilled in the art would understand that the methodology outlined below could be readily applied for the preparation of other compounds of the invention described herein. The scheme below shows two alternative procedures for Step 1 in the synthesis of the Fragment A intermediate above. In the first procedure, the resulting benzyl amine intermediate does not have a substituent at the benzylic position (i.e., R = H). In the second procedure, the resulting benzyl amine intermediate has at least one substituent (R is not H) in the benzylic position. It is understood that the second procedure can be used to prepare a variety of different benzyl amine intermediates e.g., intermediates with R selected from ethyl, propyl, alkenyl, cyclopropyl, CO H, CO Me, alkyl substituted with CO Me, CO H, etc. 2 2 2 2 Scheme 6 Steps 2-4 are shown below for the preparation of Fragment A. The steps are the same for compounds having R as H or CH . Although the steps are depicted with compounds having R defined as H or CH , one skilled in the art could readily apply the procedures described herein and in the examples for the preparation of a different Fragment A e.g., a Fragment A with R selected from ethyl, propyl, alkenyl, cyclopropyl, CO H, CO Me, alkyl substituted with CO Me, CO H, etc.
Scheme 7 Preparation of Fragment B Fragment B intermediates can be prepared according to methods known in the art.
The schemes below outline strategies that can be applied for the synthesis of Fragment B intermediates and used to prepare compounds of the invention. Procedures for the preparation of Fragment B intermediates are also found in the examples provided herein.
Scheme 8 below is a retro-synthetic analysis which shows the strategy for attaching a R group to the aryl moiety. The strategy involves the coupling of an aryl halide with an aminoalkene moiety. This strategy is applicable for the synthesis of Fragment B intermediates where the R group is an all carbon chain (i.e., Z is CH ). Although the Scheme 8 illustrates a transformation to form a Fragment B intermediate with a certain R group, it is understood that the strategy can be applied to prepare different Fragment B intermediates with a different R group as described herein, where Z is CH .
Scheme 8 An example of the preparation of the aminoalkene compound is shown below.
Further details regarding the preparation of this aminoalkene compound are found in the examples herein.
Alternatively, Scheme 9 below depicts a retro-synthetic strategy for the synthesis of Fragment B intermediates that have an oxygen atom in the R chain. In one aspect, the synthesis of the Fragment B intermediate begins with a dibromide or dihalide (Br and I) aryl compound (labeled A and B below). The synthesis involves conversion of an aryl bromide or iodide to an aldehyde group, reduction of the aldehyde to a primary alcohol, which is next converted to a leaving group (LG). The R chain is then elaborated by the displacement of the OLG group with a primary alcohol. The primary alcohol has functionality that can be unmasked and elaborated to a nitrogen group using chemistry known in the art.
Scheme 9 Alternatively, the R chain can be installed to produce a Fragment B intermediate starting with an aldehyde aryl compound (labeled C in Scheme 9). The synthesis can involve a Wittig olefination reaction to install the R chain as shown in Scheme 10, which depicts the retro-synthesis of fragment B.
Scheme 10 It is understood that the synthetic procedures described above and in the examples can be used to prepare compounds of the invention having a variety of different aryl groups.
Some representative aryl groups include e.g., It is understood that the synthetic procedures described above and in the examples can be used to prepare compounds of the invention having a variety of different R chains. Some representative R chains include e.g., In the last R chain, there is no CH group between the aryl group and cyclic group.
Precursors for the preparation of the R chain include e.g., The three schemes (Schemes 11-13) below illustrate several general strategies for preparing Fragment B intermediates. Scheme 11 illustrates how the dihalide aryl comopund (labelled compound 8) is a key intermediate which can be coupled with a variety of different R chains to synthesize a Fragment B intermediate and used to prepare many of the compounds of the invention. Synthetic procedures for the preparation of dihalide aryl intermediates used to prepare compounds of the invention are found in the examples herein.
Scheme 11 Scheme 12 shows a key transformation of the dihalide aryl intermediate compound 8 to compound 21, which can be elaborated to many different Fragment B intermediates.
Scheme 12 Scheme 13 emphasizes the utility of the aniline moiety for the regioselective installation of either iodide or bromide either in a stepwise manner (eg. 2 6 7) or in one pot (2 3). The diversity of aniline compounds, either commercially available or prepared from other starting materials (eg. 1 2), allows access to a variety of substitution patterns.
Scheme 13 Scheme 14 below shows the preparation of a Fragment B intermediate having a ring in the R chain. In one aspect, the process of attaching the R group to the aryl moiety includes coupling of a dihalide aryl intermediate compound 8 with an aminoalkene moiety having a ring structure e.g., Scheme 14 illustrates a strategy for preparing R chains having any size ring incorporated into the chain e.g., a 3-, 4-, 5-, 6-, etc. membered ring. In one aspect, the amino group can be installed via either a Curtius rearrangement (2 3) or a nitrile reduction (1 7).
In one aspect, the aminoalkene moiety can be attached to the aryl moiety via the Suzuki- coupling reaction. For example, the aminoalkene can first be converted to a alkylborane by treatment with 9-BBN and then reacted with compound 8, replacing the more reactive iodide first. The terminal alkyne can be installed by a variety of methods know in the art. Reagents such as trimethylsilyl acetylene can be employed to generate fragment B.
Scheme 14 4. Characterization of Compounds of the Invention Compounds designed, selected and/or optimized by methods described above, once produced, can be characterized using a variety of assays known to those skilled in the art to determine whether the compounds have biological activity. For example, the molecules can be characterized by conventional assays, including but not limited to those assays described below, to determine whether they have a predicted activity, binding activity and/or binding specificity.
Furthermore, high–throughput screening can be used to speed up analysis using such assays. As a result, it can be possible to rapidly screen the molecules described herein for activity, for example, as anti–cancer, anti–bacterial, anti–fungal, anti–parasitic or anti–viral agents. Also, it can be possible to assay how the compounds interact with a ribosome or ribosomal subunit and/or are effective as modulators (for example, inhibitors) of protein synthesis using techniques known in the art. General methodologies for performing high– throughput screening are described, for example, in Devlin (1998) High Throughput Screening, Marcel Dekker; and U.S. Patent No. 5,763,263. High–throughput assays can use one or more different assay techniques including, but not limited to, those described below. (1) Surface Binding Studies. A variety of binding assays can be useful in screening new molecules for their binding activity. One approach includes surface plasmon resonance (SPR) that can be used to evaluate the binding properties of molecules of interest with respect to a ribosome, ribosomal subunit or a fragment thereof.
SPR methodologies measure the interaction between two or more macromolecules in real–time through the generation of a quantum–mechanical surface plasmon. One device, (BIAcore Biosensor RTM from Pharmacia Biosensor, Piscataway, N.J.) provides a focused beam of polychromatic light to the interface between a gold film (provided as a disposable biosensor "chip") and a buffer compartment that can be regulated by the user. A 100 nm thick "hydrogel" composed of carboxylated dextran that provides a matrix for the covalent immobilization of analytes of interest is attached to the gold film. When the focused light interacts with the free electron cloud of the gold film, plasmon resonance is enhanced. The resulting reflected light is spectrally depleted in wavelengths that optimally evolved the resonance. By separating the reflected polychromatic light into its component wavelengths (by means of a prism), and determining the frequencies that are depleted, the BIAcore establishes an optical interface which accurately reports the behavior of the generated surface plasmon resonance. When designed as above, the plasmon resonance (and thus the depletion spectrum) is sensitive to mass in the evanescent field (which corresponds roughly to the thickness of the hydrogel). If one component of an interacting pair is immobilized to the hydrogel, and the interacting partner is provided through the buffer compartment, the interaction between the two components can be measured in real time based on the accumulation of mass in the evanescent field and its corresponding effects of the plasmon resonance as measured by the depletion spectrum. This system permits rapid and sensitive real–time measurement of the molecular interactions without the need to label either component. (2) Fluorescence Polarization. Fluorescence polarization (FP) is a measurement technique that can readily be applied to protein–protein, protein–ligand, or RNA–ligand interactions in order to derive IC s and Kds of the association reaction between two molecules. In this technique one of the molecules of interest is conjugated with a fluorophore. This is generally the smaller molecule in the system (in this case, the compound of interest). The sample mixture, containing both the ligand–probe conjugate and the ribosome, ribosomal subunit or fragment thereof, is excited with vertically polarized light.
Light is absorbed by the probe fluorophores, and re–emitted a short time later. The degree of polarization of the emitted light is measured. Polarization of the emitted light is dependent on several factors, but most importantly on viscosity of the solution and on the apparent molecular weight of the fluorophore. With proper controls, changes in the degree of polarization of the emitted light depends only on changes in the apparent molecular weight of the fluorophore, which in–turn depends on whether the probe–ligand conjugate is free in solution, or is bound to a receptor. Binding assays based on FP have a number of important advantages, including the measurement of IC s and Kds under true homogenous equilibrium conditions, speed of analysis and amenity to automation, and ability to screen in cloudy suspensions and colored solutions. (3) Protein Synthesis. It is contemplated that, in addition to characterization by the foregoing biochemical assays, the compound of interest can also be characterized as a modulator (for example, an inhibitor of protein synthesis) of the functional activity of the ribosome or ribosomal subunit.
Furthermore, more specific protein synthesis inhibition assays can be performed by administering the compound to a whole organism, tissue, organ, organelle, cell, a cellular or subcellular extract, or a purified ribosome preparation and observing its pharmacological and inhibitory properties by determining, for example, its inhibition constant (IC ) for inhibiting 3 35 protein synthesis. Incorporation of H leucine or S methionine, or similar experiments can be performed to investigate protein synthesis activity. A change in the amount or the rate of protein synthesis in the cell in the presence of a molecule of interest indicates that the molecule is a modulator of protein synthesis. A decrease in the rate or the amount of protein synthesis indicates that the molecule is a inhibitor of protein synthesis. (4) Antimicrobial assays and other evaluation. Furthermore, the compounds can be assayed for anti–proliferative or anti–infective properties on a cellular level. For example, where the target organism is a microorganism, the activity of compounds of interest can be assayed by growing the microorganisms of interest in media either containing or lacking the compound. Growth inhibition can be indicative that the molecule can be acting as a protein synthesis inhibitor. More specifically, the activity of the compounds of interest against bacterial pathogens can be demonstrated by the ability of the compound to inhibit growth of defined strains of human pathogens. For this purpose, a panel of bacterial strains can be assembled to include a variety of target pathogenic species, some containing resistance mechanisms that have been characterized. Use of such a panel of organisms permits the determination of structure–activity relationships not only in regards to potency and spectrum, but also with a view to obviating resistance mechanisms.
The in vitro activity of the compounds of the present invention can be determined.
Antimicrobial testing is typically performed to determine the minimum inhibitory concentration (MIC). Minimum inhibitory concentrations (MICs) are determined by the microdilution method in a final volume of 100 μl according to protocols outlined by The Clinical and Laboratory Standards Institute (CLSI). Performance standards for reference strains are assessed within the same experimental design to maintain quality control. See, for example, Clinical Laboratory Standards Institute: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically M7-A8. Approved Standard-Eighth Edition. Wayne, PA: CLSI; December 2008; and Clinical Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing M100-S20; Approved Standard-Twentieth Edition. Wayne, PA: CLSI; June 2010.
The antimicrobial and other drug properties of the compounds can further be evaluated in various in vivo mammalian assays, such as a mouse or rat peritonitis infectious models, skin and soft tissue models (often referred to as the thigh model), or a mouse pneumonia model. There are septicemia or organ infection models known to those skilled in the art. These efficacy models can be used as part of the evaluation process and can be used as a guide of potential efficacy in humans. Endpoints can vary from reduction in bacterial burden to lethality. For the latter endpoint, results are often expressed as a PD value, or the dose of drug that protects 50% of the animals from mortality.
To further assess a compound’s drug–like properties, measurements of inhibition of cytochrome P450 enzymes and phase II metabolizing enzyme activity can also be measured either using recombinant human enzyme systems or more complex systems like human liver microsomes. Further, compounds can be assessed as substrates of these metabolic enzyme activities as well. These activities are useful in determining the potential of a compound to cause drug–drug interactions or generate metabolites that retain or have no useful antimicrobial activity.
To get an estimate of the potential of the compound to be orally bioavailable, one can also perform solubility and Caco–2 assays. The latter is a cell line from human epithelium that allows measurement of drug uptake and passage through a Caco–2 cell monolayer often growing within wells of a 24–well microtiter plate equipped with a 1 micron membrane. Free drug concentrations can be measured on the basolateral side of the monolayer, assessing the amount of drug that can pass through the intestinal monolayer. Appropriate controls to ensure monolayer integrity and tightness of gap junctions are needed. Using this same system one can get an estimate of P–glycoprotein mediated efflux. P–glycoprotein is a pump that localizes to the apical membrane of cells, forming polarized monolayers. This pump can abrogate the active or passive uptake across the Caco–2 cell membrane, resulting in less drug passing through the intestinal epithelial layer. These results are often done in conjunction with solubility measurements and both of these factors are known to contribute to oral bioavailability in mammals. Measurements of oral bioavailability in animals and ultimately in man using traditional pharmacokinetic experiments will determine the absolute oral bioavailability.
Experimental results can also be used to build models that help predict physical– chemical parameters that contribute to drug–like properties. When such a model is verified, experimental methodology can be reduced, with increased reliance on the model predictability. (5) Animal Pharmacology and Toxicology. The compounds of the present invention can be evaluated for efficacy in well-known animal models. The following table provides representative animal models for various infection indications.
Target Infection Indication Animal Model of Efficacy HAP/VAP Efficacy in mouse and/or rat pneumoniae model vs. respiratory tract infection pathogens of interest (Streptococcus pneumoniae, including multi-drug resistant Streptococcus pneumoniae, H. influenzae, methicillin resistant Staphylococcus aureus (MRSA), and Pseudomonas. aeruginosa) cSSSI Efficacy in mouse model against pathogens of interest (MRSA, K. pneumoniae) Sepsis Efficacy in mouse peritonitis model vs. pathogens of interest (E. coli, K. pneumoniae, E. faecalis, MRSA) cUTI Efficacy in mouse model against E. coli, K. pneumoniae and/or MRSA) Febrile neutropenia Efficacy in mouse peritonitis model against S. aureus, S. epidermidis, S. pneumoniae, S. pyogenes, P. aeruginosa Animal Model for Complicated Skin and Skin Structure Infections (cSSSI): Murine Skin and Soft Tissue Infection Model of Klebsiella pneumoniae 1705966 in Thighs of Neutropenic Female CD-1 Mice This model is useful to assess the efficacy of compounds of the present invention in a Klebsiella pneumoniae 1705966 neutropenic mouse thigh infection model using female ICR (CD-1) mice.
Study Design: Species: Female ICR (CD-1) Mice, 8 to 9 weeks old, weighting 25-29g.
Inoculum: Klebsiella pneumoniae 17059663 was streaked from frozen stock onto Blood agar (Tryptic Soy Agar + 5% Sheep Blood), BD, #221261) and incubated overnight at °C. After overnight incubation, enough bacteria (approx. 1 full loop) to measure OD =0.990 was transferred from plate and diluted into 10 ml pre-warmed Mueller-Hinton broth. This culture was further diluted 1:1000 into pre-warmed MH broth and grown for approximately 2 hrs at 35°C with shaking. Each mouse was given 0.1mL of 1:1000 dilution culture injected into both caudal thigh muscles under isoflurane inhalation anesthesia.
Dilution Initial O.D. Final O.D. (after ~2 hr. incubation) 1:10 0.135 0.424 1:100 0.014 0.215 1:1000 0.001 0.035 Neutropenia is induced by intraperitoneal (I.P.) administration of Cyclophosphamide monohydrateon Day -4 (150mg/kg) and Day -1 (100mg/kg).
Vehicle: 0.9% sodium chloride Dosing: Each mouse in the treated groups was given the appropriate dose of the compound to be tested in a volume of 0.2ml, 2 and 8 hrs. post bacterial inoculation.
Time points: Controls: 0, 2, 6, and 24 hrs.
Treated: 24 hrs.
Sampling: 2 or 3 mice/time point were euthanized via CO , and their caudal thigh muscles excised and homogenized. The thigh muscles were placed in 5 ml sterile PBS in Stomacher Filter bag and homogenized with MicroBiomaster80 (Brinkmann) for 60seconds, normal setting and 1:10 dilutions were made per standard protocol in a 96-well plate.
Aliquots of 25ul for each dilution, as well as the homogenate, were plated on blood agar plates and incubated at 35°C to determine the CFU/mL over the time course. After overnight incubation, colonies were counted.
Animal Model for Sespsis: Murine peritonitis model (E. coli, K. pneumoniae, E. faecalis, MRSA) This model is used to evaluate the effect of subcutaneous (SC) treatment with compounds of the present invention on growth of Escherichia coli ATCC 25922 in a mouse peritonitis model using female Swiss Webster mice.
Controls: Negative: Inoculum only Inoculum Vehicle Intraperitoneal Positive: Ciprofloxacin Study Design: Species: Female Swiss Webster Mice Inoculation: Escherichia coli ATCC 25922 is made by adding 1ml (4/6/07) stock to 9ml 0.25% Brewer’s Yeast to make (1:10), then 1ml of the (1:10) will be added to 9ml 0.25% Brewer’s Yeast to make (1:100), then 1ml of the (1:100) will be added to 9ml 0.25% Brewer’s Yeast to make (1:1000), then 2.5 ml of the (1:1000) will be added to 122.5ml 0.25% Brewer’s Yeast to make (1:50,000), 1ml/mouse will by inoculated intraperitoneally (IP).
Route of Administration: SC Dosing: Vehicle for compounds of the present invention: Saline or 50mM Sodium phosphate buffer in 10% Captisol in water, pH=7.2.
Dose Administration: Q3H x 3 beginning at 30 min post bacterial inoculation Study Duration: 24 hrs. 0.25% Brewer’s Yeast Extract (BYE): Dilute 2% prepared on 11/12/09 (Lot.2158K, MP Biomedicals) 25ml 2% + 175ml 1x PBS.
Outcome Measures: Colony Forming Unit’s from peritoneal wash and spleen homogenate and drug levels from wash, spleen homogenate, and plasma.
Blood is collected via cardiac puncture while mouse is under CO narcosis. The whole blood sample is placed in heparinized eppendorf tubes and kept on wet ice until centrifuged (4 min @ 14,000rpm). Plasma is transferred to 96 deep-well block on dry ice and stored at -20º C. Immediately following blood collection, 2 ml of sterile PBS (phosphate buffered saline) was injected into the peritoneal cavity with a 25G needle. The abdomen was gently massaged, and a small incision was made to allow access to the peritoneal cavity. The peritoneal wash fluid was collected using sterile technique, serially diluted 1:10, plated on blood agar plates, and incubated overnight at 35 C.
Spleens were harvested and placed in 1 ml sterile PBS in Stomacher bag and homogenized with MicroBiomaster80 (Brinkmann) for 60 seconds, normal setting and 1:10 dilutions were made. 25ul of each dilution, as well as the homogenate, was plated on blood agar plates and incubated at 35°C to determine the CFU/mL over the time course. After overnight incubation, colonies were counted.
Other Animal Models Similarly, other animal infection models can be used for hospital acquired pneumonia (HAP)/ ventilator acquired pneumonia (VAP), complicated urinary tract infections (cUTI), and febrile neutropenia.
. Formulation and Administration The compositions and methods of the present invention can be practiced by delivering the compounds of the present invention using a means for delivery e.g., any suitable carrier.
The dose of active compound, mode of administration and use of suitable carrier will depend upon the intended patient or subject and the targeted microorganism, e.g., the target bacterial organism. The formulations, both for human medical use and veterinary use, of compounds according to the present invention typically include such compounds in association with a pharmaceutically acceptable carrier.
The carrier(s) should be "acceptable" in the sense of being compatible with compounds of the present invention and not deleterious to the recipient. Pharmaceutically acceptable carriers, in this regard, are intended to include any and all solvents, dispersion media, coatings, absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds (identified or designed according to the invention and/or known in the art) also can be incorporated into the compositions. The formulations can conveniently be presented in dosage unit form and can be prepared by any of the methods well known in the art of pharmacy/microbiology. In general, some formulations are prepared by bringing the compound into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation.
A pharmaceutical composition of the invention should be formulated to be compatible with its intended route of administration. Solutions or suspensions can include the following components: a sterile diluent such as water, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.
The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
A wide variety of formulations and administration methods, including, e.g., intravenous formulations and administration methods can be found in S.K. Niazi, ed., Handbook of Pharmaceutical Formulations, Vols. 1-6 [Vo1. 1 Compressed Solid Products, Vol. 2 Uncompressed Drug Products, Vol. 3 Liquid Products, Vol. 4 Semi-Solid Products, Vol. 5 Over the Counter Products, and Vol. 6 Sterile Products], CRC Press, April 27, 2004.
Useful solutions for oral or parenteral administration can be prepared by any of the methods well known in the pharmaceutical art, described, for example, in Remington's Pharmaceutical Sciences, 18th ed. (Mack Publishing Company, 1990). Formulations for parenteral administration can also include glycocholate for buccal administration, methoxysalicylate for rectal administration, or citric acid for vaginal administration. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic. Suppositories for rectal administration also can be prepared by mixing the drug with a non-irritating excipient such as cocoa butter, other glycerides, or other compositions which are solid at room temperature and liquid at body temperatures.
Formulations also can include, for example, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, and hydrogenated naphthalenes. Formulations for direct administration can include glycerol and other compositions of high viscosity. Other potentially useful parenteral carriers for these drugs include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation administration can contain as excipients, for example, lactose, or can be aqueous solutions containing, for example, polyoxyethylenelauryl ether, glycocholate and deoxycholate, or oily solutions for administration in the form of nasal drops, or as a gel to be applied intranasally. Retention enemas also can be used for rectal delivery.
Formulations of the present invention suitable for oral administration can be in the form of: discrete units such as capsules, gelatin capsules, sachets, tablets, troches, or lozenges, each containing a predetermined amount of the drug; a powder or granular composition; a solution or a suspension in an aqueous liquid or non-aqueous liquid; or an oil- in-water emulsion or a water-in-oil emulsion. The drug can also be administered in the form of a bolus, electuary or paste. A tablet can be made by compressing or molding the drug optionally with one or more accessory ingredients. Compressed tablets can be prepared by compressing, in a suitable machine, the drug in a free-flowing form such as a powder or granules, optionally mixed by a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets can be made by molding, in a suitable machine, a mixture of the powdered drug and suitable carrier moistened with an inert liquid diluent.
Oral compositions generally include an inert diluent or an edible carrier. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients. Oral compositions prepared using a fluid carrier for use as a mouthwash include the compound in the fluid carrier and are applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose; a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). It should be stable under the conditions of manufacture and storage and should be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filter sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation include vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
Formulations suitable for intra-articular administration can be in the form of a sterile aqueous preparation of the drug that can be in microcrystalline form, for example, in the form of an aqueous microcrystalline suspension. Liposomal formulations or biodegradable polymer systems can also be used to present the drug for both intra-articular and ophthalmic administration.
Formulations suitable for topical administration, including eye treatment, include liquid or semi-liquid preparations such as liniments, lotions, gels, applicants, oil-in-water or water-in-oil emulsions such as creams, ointments or pastes; or solutions or suspensions such as drops. Formulations for topical administration to the skin surface can be prepared by dispersing the drug with a dermatologically acceptable carrier such as a lotion, cream, ointment or soap. Useful are carriers capable of forming a film or layer over the skin to localize application and inhibit removal. For topical administration to internal tissue surfaces, the agent can be dispersed in a liquid tissue adhesive or other substance known to enhance adsorption to a tissue surface. For example, hydroxypropylcellulose or fibrinogen/thrombin solutions can be used to advantage. Alternatively, tissue-coating solutions, such as pectin-containing formulations can be used.
For inhalation treatments, inhalation of powder (self-propelling or spray formulations) dispensed with a spray can, a nebulizer, or an atomizer can be used. Such formulations can be in the form of a fine powder for pulmonary administration from a powder inhalation device or self-propelling powder-dispensing formulations. In the case of self-propelling solution and spray formulations, the effect can be achieved either by choice of a valve having the desired spray characteristics (i.e., being capable of producing a spray having the desired particle size) or by incorporating the active ingredient as a suspended powder in controlled particle size. For administration by inhalation, the compounds also can be delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
Systemic administration also can be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants generally are known in the art, and include, for example, for transmucosal administration, detergents and bile salts.
Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds typically are formulated into ointments, salves, gels, or creams as generally known in the art.
The active compounds can be prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. Liposomal suspensions can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.
Oral or parenteral compositions can be formulated in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.
Furthermore, administration can be by periodic injections of a bolus, or can be made more continuous by intravenous, intramuscular or intraperitoneal administration from an external reservoir (e.g., an intravenous bag).
Where adhesion to a tissue surface is desired the composition can include the drug dispersed in a fibrinogen-thrombin composition or other bioadhesive. The compound then can be painted, sprayed or otherwise applied to the desired tissue surface. Alternatively, the drugs can be formulated for parenteral or oral administration to humans or other mammals, for example, in effective amounts, e.g., amounts that provide appropriate concentrations of the drug to target tissue for a time sufficient to induce the desired effect.
Where the active compound is to be used as part of a transplant procedure, it can be provided to the living tissue or organ to be transplanted prior to removal of tissue or organ from the donor. The compound can be provided to the donor host. Alternatively or, in addition, once removed from the donor, the organ or living tissue can be placed in a preservation solution containing the active compound. In all cases, the active compound can be administered directly to the desired tissue, as by injection to the tissue, or it can be provided systemically, either by oral or parenteral administration, using any of the methods and formulations described herein and/or known in the art. Where the drug comprises part of a tissue or organ preservation solution, any commercially available preservation solution can be used to advantage. For example, useful solutions known in the art include Collins solution, Wisconsin solution, Belzer solution, Eurocollins solution and lactated Ringer's solution.
In conjunction with the methods of the present invention, pharmacogenomics (i.e., the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) can be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, a physician or clinician can consider applying knowledge obtained in relevant pharmacogenomics studies in determining whether to administer a drug as well as tailoring the dosage and/or therapeutic regimen of treatment with the drug.
Generally, an effective amount of dosage of active compound will be in the range of from about 0.1 to about 100 mg/kg of body weight/day, more preferably from about 1.0 to about 50 mg/kg of body weight/day. The amount administered will also likely depend on such variables as the type of surgery or invasive medical procedure, the overall health status of the patient, the relative biological efficacy of the compound delivered, the formulation of the drug, the presence and types of excipients in the formulation, and the route of administration. Also, it is to be understood that the initial dosage administered can be increased beyond the above upper level in order to rapidly achieve the desired blood-level or tissue level, or the initial dosage can be smaller than the optimum.
Nonlimiting doses of active compound comprise from about 0.1 to about 1500 mg per dose. Nonlimiting examples of doses, which can be formulated as a unit dose for convenient administration to a patient include: about 25 mg, about 50 mg, about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, about 500 mg, about 525 mg, about 550 mg, about 575 mg, about 600 mg, about 625 mg, about 650 mg, about 675 mg about 700 mg, about 725 mg, about 750 mg, about 775 mg, about 800 mg, about 825 mg, about 850 mg, about 875 mg, about 900 mg, about 925 mg, about 950 mg, about 975 mg, about 1000 mg, about 1025 mg, about 1050, mg, about 1075 mg, about 1100 mg, about 1125 mg, about 1150 mg, about 1175 mg, about 1200 mg, about 1225 mg, about 1250 mg, about 1275 mg, about 1300 mg, about 1325 mg, about 1350 mg, about 1375 mg, about 1400 mg, about 1425 mg, about 1450 mg, about 1475 mg, and about 1500 mg. The foregoing doses are useful for administering the compounds of the present invention according to the methods of the present invention.
As is understood by one of ordinary skill in the art, generally, when dosages are described for a pharmaceutical active, the dosage is given on the basis of the parent or active moiety. Therefore, if a salt, hydrate, or another form of the parent or active moiety is used, a corresponding adjustment in the weight of the compound is made, although the dose is still referred to on the basis of the parent or active moiety delivered. As a nonlimiting example, if the parent or active moiety of interest is a monocarboxylic acid having a molecular weight of 250, and if the monosodium salt of the acid is desired to be delivered to be delivered at the same dosage, then an adjustment is made recognizing that the monosodium salt would have a molecular weight of approximately 272 (i.e. minus 1H or 1.008 atomic mass units and plus 1 Na or 22.99 atomic mass units). Therefore, a 250 mg dosage of the parent or active compound would correspond to about 272 mg of the monosodium salt, which would also deliver 250 mg of the parent or active compound. Said another way, about 272 mg of the monosodium salt would be equivalent to a 250 mg dosage of the parent or active compound.
Formulation Examples I. Formulation for Intravenous Administration Ingredients Amount ____________________________________________________________________ Antimicrobial Compound 0.1 - 1500 total mg of the present invention Dextrose, USP 50 mg/ml Sodium citrate, USP 1.60-1.75 mg/ml Citric Acid, USP 0.80-0.90 mg/ml Water, USP q.s This formulation for intravenous administration is formulated by heating water for injection to about 60 ºC. Next the sodium citrate, citric acid and dextrose are added and stirred until dissolved. A solution or aqueous slurry of the antimicrobial compound is added to the previous mixture and stirred until dissolved. The mixture is cooled to 25 ºC with stirring.
The pH is measured and adjusted if necessary. Lastly the mixture is brought to the desired volume, if necessary, with water for injection. The mixture is filtered, filled into the desired container (vial, syringe, infusion container, etc.), over wrapped and terminally moist heat sterilized.
This formulation is useful for intravenous administration, either bolus or infusion, to a patient for treating, preventing, or reducing the risk of infection.
II. Lyophilisate for Reconstitution Alternatively, the antimicrobial compound can be provided as a lyophilisate which can be reconstituted before intravenous or intramuscular administration.
Ingredient mg per injection vial Antimicrobial Compound 0.1 – 1500 of the present invention Cyclodextin 1500 Reconstitution solution for a volume to be administered of 50 ml (infusion): 5% aqueous glucose solution.
Reconstitution solution for a volume to be administered of 15 ml (bolus): 3.3% aqueous glucose solution.
The foregoing lyophilisate is useful for reconstitution and intravenous administration, either bolus or infusion, to a patient for treating, preventing, or reducing the risk of infection.
III. Lyophilisate for Reconstitution Ingredient mg per injection vial Antimicrobial Compound 0.1 -1500 of the present invention soya lecithin 2250 Sodium cholate 1500 Reconstitution solution for a volume to be administered of 50 ml (infusion): 4% aqueous glucose solution.
Reconstitution solution for a volume to be administered of 15 ml (bolus): 2% aqueous glucose solution The foregoing lyophilisate is useful for reconstitution and intravenous administration, either bolus or infusion, to a patient for treating, preventing, or reducing the risk of infection.
IV. Lyophilisate for Reconstitution Ingredient mg per injection vial Antimicrobial Compound 0.1-1500 of the present invetnion soya lecithin 900 Sodium glycocholate 540 Reconstitution solution for a volume to be administered of 15 ml (bolus): 3.3% aqueous glucose solution.
The foregoing lyophilisate is useful for reconstitution and intravenous administration, either bolus or infusion, to a patient for treating, preventing, or reducing the risk of infection.
V. Tablet for Oral Administration Ingredients Per Tablet Per 4000 Tablets ____________________________________________________________________ Antimicrobial Compound 0.1 - 1500 mg 0.4 - 6000 g of the present invention Anhydrous Lactose, NF 110.45 mg 441.8 g Microcrystalline 80.0 mg 320.0 g Cellulose NF Magnesium Stearate 1.00 mg 4.0 g Impalpable Powder NF Croscarmellose Sodium 2.00 mg 8.0 g NF Type A ___________________________________________________________________ The antimicrobial compound (any of the compounds equivalent to the desired delivery strength, e.g., 50 to 1500 mg per tablet) is premixed with 1/3 of the microcrystalline cellulose NF and 1/2 of the anhydrous lactose NF in a ribbon blender for 5 minutes at 20 RPM. To the premix is added the remaining 2/3 of the microcrystalline cellulose NF and the remaining 1/2 of the anhydrous lactose NF. This is blended for 10 minutes at 20 RPM.
Crosscarmellose sodium is added to the blended powders and mixed for 5 minutes at 20 RPM. Finally the magnesium stearate is added to the mixture by passing through a 90 mesh screen and blended for an additional 5 minutes at 20 RPM. The lubricated mixture is compressed to provide tablets of 500 mg active ingredient.
These tablets are useful for oral administration to a patient for treating, prevention, or reducing the risk of infection. 6. Examples Nuclear magnetic resonance (NMR) spectra were obtained on a Bruker Avance 300 or Avance 500 spectrometer, or in some cases a GE–Nicolet 300 spectrometer. Common reaction solvents were either high performance liquid chromatography (HPLC) grade or American Chemical Society (ACS) grade, and anhydrous as obtained from the manufacturer unless otherwise noted. "Chromatography" or "purified by silica gel" refers to flash column chromatography using silica gel (EM Merck, Silica Gel 60, 230–400 mesh) unless otherwise noted.
The compounds or tautomers thereof, or pharmaceutically acceptable salts, esters or prodrugs of said compounds or tautomers of the present invention can be prepared using known chemical transformations adapted to the particular situation at hand.
Some of the abbreviations used in the following experimental details of the synthesis of the examples are defined below: h or hr = hour(s); min = minute(s); mol = mole(s); mmol = millimole(s); M = molar; M = micromolar; g = gram(s); g = microgram(s); rt = room temperature; L = liter(s); mL = milliliter(s); Et O = diethyl ether; THF = tetrahydrofuran; DMSO = dimethyl sulfoxide; EtOAc = ethyl acetate; Et N = triethylamine; i–Pr NEt or DIPEA = diisopropylethylamine; CH Cl = methylene chloride; 2 2 2 CHCl = chloroform; CDCl = deuterated chloroform; CCl = carbon tetrachloride; 3 3 4 MeOH = methanol; CD OD = deuterated methanol; EtOH = ethanol; DMF = dimethylformamide; BOC = t–butoxycarbonyl; CBZ = benzyloxycarbonyl; TBS = t– butyldimethylsilyl; TBSCl = t–butyldimethylsilyl chloride; TFA = trifluoroacetic acid; DBU = diazabicycloundecene; TBDPSCl = t–butyldiphenylchlorosilane; Hunig’s Base = N,N–diisopropylethylamine; DMAP = 4–dimethylaminopyridine; CuI = copper (I) iodide; MsCl = methanesulfonyl chloride; NaN = sodium azide; Na SO = sodium sulfate; 3 2 4 NaHCO = sodium bicarbonate; NaOH = sodium hydroxide; MgSO = magnesium sulfate; K CO = potassium carbonate; KOH = potassium hydroxide; NH OH = ammonium 2 3 4 hydroxide; NH Cl = ammonium chloride; SiO = silica; Pd–C = palladium on carbon; Pd(dppf)Cl = dichloro[1,1’–bis(diphenylphosphino)ferrocene] palladium (II).
Exemplary compounds synthesized in accordance with the invention are listed in Table 1, Table 2, Table 2a and Table 2aa. A bolded or dashed bond is shown to indicate a particular stereochemistry at a chiral center, whereas a wavy bond indicates that the substituent can be in either orientation or that the compound is a mixture thereof. It should also be known that in the interest of conserving space, the chemical structures of some compounds have been split into two parts with the two points of connection each being indicated by a bond crossed by a wavy line. See, e.g. compound 1, which was drawn in two parts as: H N N N but corresponds to the complete chemical structure: .
The compounds of the present invention can be prepared, formulated, and delivered as salts, esters, and prodrugs. For convenience, the compounds are generally shown without indicating a particular salt, ester, or prodrug form.
Compounds of the present invention are shown in Table 1, Table 2, Table 2a, and Table 2aa. LCMS (liquid chromatography mass spectral) data are provided, where available.
When data is not available this is indicated by "NA". The LCMS data are provided using the convention for m/z in the format, [M + H]+, except where otherwise indicated.
Table 1 Comp. Structure LCMS 1 543.1 H N N N 2 563.1 H N N N 3 531.1 H N N N 4 542.1 H N N N 505.2 H N N N 6 541.1 H N N N 7 523.1 H N N N 8 589.1 H N N N 9 501.1 H N N N 555.1 H N N N 11 561.1 H N N N S CH 12 589.1 H N N N 13 628.2 H N N N 14 517.1 H N N N O CH 555.1 H N N N 16 621.1 H N N N 17 569.1 H N N N 18 527.2 H N N N 19 585.1 NH CH H N N N 627.2 NH CH H N N N 21 586.1 H N N N 22 593.1 H N N N 23 539.1 H N N N 24 507.1 H N N 585.1 H N N N 26 558.3 H N N N 27 569.2 H N N N 28 628.1 H N N N 29 571.2 H N N N 607.1 H N N N 31 599.1 H N N N H C CH 32 549.1 H N N N S CH 33 565.1 H N N N S CH 34 585.1 H N N N 585.1 H N N N 36 573.0 H N N N 37 539.0 H N N N Cl F 38 581.1 H N N N 39 589.0 H N N N 40 541.1 H N N N 41 544.4 42 587.1 43 666.9 44 601.1 H N N N 45 659.0 H N N N 46 529.1 H N N N 47 631.1 H N N 48 580.0 H N N N HN S O 49 545.0 H N N N 50 571.1 H N N N F CO 51 537.0 H N N N 52 607.1 NH F H N N N 53 541.1 H N N N 54 523.1 NH F H N N N 55 554.1 H N N N 56 596.1 H N N N H N N N 58 589.0 H N N N 59 553.0 H N N N 60 558.1 61 564.3 H N N N 62 555.1 H N N N Cl Cl 63 535.0 H N N N Cl CH 64 589.0 H N N N Cl CF 65 605.0 H N N N Cl OCF 66 474.1 H N N N 67 553.1 NH CH H N N N Cl F 68 605.3 NH F H N N N 69 601.0 NH CH H N N N 70 587.1 NH CH H N N N 71 557.0 NH F H N N N Cl F H N N 73 519.1 H N N 74 561.1 H N N N 75 587.0 H N N N 76 587 H N N N 77 547.1 NH F H N N N 78 543.1 NH CH H N N N 79 503.2 H N N N 80 573.1 NH F H N N N 81 539.0 H N N N 82 508.0 H N N N 83 535.1 H N N N 84 523.0 H N N N 85 585.1 H N N N 86 599.1 NH CH H N N N 87 603.3 NH F H N N N 88 587.0 H N N N 89 585.0 H N N N 90 589.1 H N N 91 539.0 H N N N 92 621.0 H N N N Cl SCF 93 585.1 H N N N 94 585.5 H N N N 95 583.5 H N N N 96 611.0 H N N N 97 557.0 H N N N 98 539.0 H N N N 99 587.1 H N N N 100 583.1 NH CH H N N N 101 587.1 NH F H N N N 102 585.0 H N N N 103 569.0 H N N N 104 599.0 H N N N 105 553.1 H N N N Cl F 106 519.1 H N N N 107 589.0 H N N N F OCF 108 535.1 H N N N 109 535.1 H N N N 110 553.1 H N N N 111 573.1 H N N N F CF 112 607.1 H N N N 113 519.1 H N N N 114 546.0 H N N N 115 566.1 H N N N Cl NO 116 545.0 H N N N 117 533.0 H N N N 118 546.0 H N N N 119 553.1 H N N N F Cl 120 546.1 H N N N H C NO 121 546.0 H N N N 122 530.1 H N N N F CN 123 515.1 H N N N H N N N 125 567.0 H N N N Cl F 126 613.1 H N N N i-Pr 127 613.1 H N N N i-Pr 128 553.1 H N N N Cl F 129 552.9 H N N N 130 533.1 H N N N 131 599.0 H N N N 132 553.0 H N N N F Cl 133 519.0 H N N N F CH 134 526.1 H N N N H C CN 135 533.1 H N N N 136 531.0 H N N N 137 597.0 H N N N 138 579.0 H N N N Cl F 139 571.0 H N N N OCHF 140 589.0 H N N N 141 529.0 H N N 142 589.0 H N N N 143 511.0 H N N N F Cl 144 576.1 H N N N H N N N Cl i-Pr 146 611.1 H N N N 147 519.1 H N N N H C F 148 525.0 H N N N Cl F 149 555.0 H N N N i-Pr 212 569.0 H N N N H C CF 213 568.1 H N N N H CO 214 587.1 H N N N Cl OCHF 215 642.3 H N N N NHtBu H CO 216 601.0 H N N N 217 549.1 H N N N Cl Et 218 573.0 H N N N F C F 219 533.1 H N N N F CH 220 637.0 H N N N Cl S(O)CF 221 570.1 H C N N 222 569.0 H N N N F C CH 223 565.0 H N N N Cl F 224 541.0 H N N N Cl Cl 225 591.0 H N N N Cl OCF 226 589.0 [M] H N N N F C Cl 227 624.1 NH CH H N N N N N NH 228 525.0 H N N N F Cl 229 599.1 H N N N F C OEt 230 599.0 NH CH H N N N NH CH H N N N 232 657.0 NH CH H N N N 233 583.1 H N N N F C Et 234 567.2 NH CH H N N N F Cl 235 601.0 H N N N 236 583.0 NH CH H N N N 237 567.1 H N N N H C OCHF 238 587.0 H N N N 239 587.0 H N N N 240 587.0 H N N N 241 571.0 H N N N 242 555.0 H N N N 243 567.0 H N N N F Cl 244 587.1 245 549.1 H N N N F OEt 246 585.1 H N N N F C CH OH 247 615.1 NH CH H N N N 248 569.1 H N N N 249 569.1 H N N N 250 584.3 H N N N F C CH NH 251 613.1 H N N N F C OPr 252 587.0 H N N N H N N N F Cl H N N N F Cl H N N N H N N N F Cl H N N N F Cl H N N N H N N N H N N N 261 577.1 H N N N Cl iPr 262 601.1 H N N N F C SMe 263 556.1 H N N OCF3 264 613.2 NH CH H N N N 265 585.1 H N N N F C OMe 266 549.1 H N N N 267 539.1 H N N N 268 553.3 H N N N F Cl 269 567.3 NH CH H N N N H N N N H N N N NH CH H N N N H N N N 274 602.2 NH CH H N N N F CF 275 588.2 H N N N 276 625.0 NH CH [M/2]+1 H N N N 277 314.4 [M+1]/2 H N N N N N NH H N N N F Cl H N N N F CF H N N N F CF 281 310.3 [M+2H]/2 H N N N Cl OCF 282 317.2 NH CH [M+2H]/2 H N N N Cl OCF 283 563.1 H N N N Cl Et 284 605.1 H N N N Cl Et 285 591.1 H N N N 286 603.0 H N N N F OCF 287 583.0 H N N N 288 635.2 H N N N 289 649.1 NH CH H N N N Cl SCF 290 597.0 NH CH H N N N 291 553.1 H N N N F CF 292 567.2 H N N N 293 623.2 H N N N F C CF 294 615.1 H N N N 295 567.1 H N N N F Cl 296 581.1 NH CH H N N N F Cl 297 585.1 H N N N OCHF 298 581.1 H N N N F Cl 299 599.1 NH CH H N N N F OCHF 300 561.4 NH CH H N N N 301 547.1 H N N N F Et 302 629.1 H N N N 303 615.1 H N N N 304 629.1 NH CH H N N N 305 583.0 H N N N SCHF 306 583.1 H N N N 307 613.1 (m/e) H N N N 308 597.0 309 597.0 H N N N N CH 310 627.4 NH CH (m/e) H N N N 311 587.3 (m/e) H N N N 312 551.1 (m/e) H N N N 313 549.1 H N N N Cl CH 314 571.2 H N N N 315 585.1 NH CH H N N N 316 617.0 NH CH H N N N F OCF 317 583.1 H N N N 318 597.2 NH CH H N N N 319 581.1 H N N N 320 579.3 NH CH H N N N F Cl 321 619.8 H N N N F CO 322 585.3 NH CH H N N N 323 571.3 H N N N 324 567.0 H N N N 325 581.0 NH CH H N N N 326 603.3 H N N N 327 617.3 NH CH H N N N 328 565.5 H N N N CF CH 329 579.1 NH CH H N N N CF CH 330 543.3 H N N N C(O)CH 331 557.7 NH CH H N N N C(O)CH Table 2 Comp. Structure LCMS 150 689.0 H N N 151 543.0 H N N N NH 152 587.0 H N N N NH 153 597.0 H N N N NH 154 598.0 H N N 155 626.0 H N N N N NH 156 601.0 H N N N N NH 157 693.0 H N N N N NH 158 603.0 H N N 159 619.0 H N N N 160 585.0 H N N N N NH 161 590.0 H N N N NH 162 652.0 H N N N NH 163 522.0 H N N N 164 613.0 H N N N NH 165 522.0 H N N N 166 522.0 H N N N 3 O N 167 538.0 H N N N 168 633.0 H N N 169 615.0 H N N N NH 170 526.0 H N N N 171 526.0 H N N N 172 542.0 H N N N 173 526.0 H N N N 174 576.0 H N N N 175 542.0 H N N N 176 550.0 H N N N H C CH 177 576.0 H N N N 178 538.0 H N N N 179 538.0 H N N O NH 180 537.0 H N N O NH 181 548.0 H N N O NH 182 550.0 H N N N O NH 183 592.0 H N N N O NH 184 548.0 H N N N O NH 185 538.0 H N N N 186 550.0 H N N N 187 542.0 H N N N 188 558.0 H N N N 189 548.0 H N N N 190 538.0 H N N N H N NH 332 580.3 NH O O N N Table 2a Comp. Structure LCMS 333 552.0 H N N N F Cl 334 566.0 NH CH H N N N F Cl 335 516.0 336 619.1 H N N N 337 632.9 NH CH H N N N 338 569.3 H N N N H CH 339 583.4 H N N N H CH 340 597.1 NH CH H N N N CH CF 341 567.2 H N N N F Cl H C NH 342 569.2 H N N N F Cl HO NH 343 566.9 NH CH H N N N F Cl 344 603.1 H N N N 345 617.1 NH CH H N N N 346 621.4 N CH H N N N F Cl 347 695.5 N CH H N N N F Cl 348 581.0 N CH H N N N F Cl 349 581.0 H N N N 350 595.0 NH CH H N N N 351 536.1 Cl SCF 352 550.1 Cl SCF 353 428.0 354 496.3 355 486.3 356 500.2 357 514.1 358 528.1 359 565.0 H N N N 360 579.0 NH CH H N N N 361 541.4 H N N N 362 595.4 N CH H N N N F Cl 363 555.2 NH CH H N N N 364 609.1 N CH CH H N N N F Cl 365 569.0 H N N 366 552.0 367 584.0 H CO N 368 621.2 N CH H N N N F Cl 369 516.1 NH CH H N N N 370 502.1 H N N N 371 530.2 372 468.2 F Cl 373 482.2 F Cl 374 581.2 NH CH H N N N F Cl H C NH 375 555.0 H N N N F Cl 376 569.0 NH CH H N N N F Cl 377 647.5 NH CH H N N N 378 554.6 H N N N H CH F Cl 379 568.1 H N N N H CH F Cl 380 615.1 H N N N H C NH 381 629.5 NH CH H N N N H C NH 382 567.1 H N N N F Cl 383 622.3 N CH H N N N F Cl 384 579.1 NH CH H N N N F Cl 385 571.0 NH CH H N N N 386 553.1 H C N N F Cl 387 530.2 H N N N 388 544.1 NH CH H N N N 389 570.1 H N N N 390 584.1 NH CH H N N N 391 583.1 NH CH H N N N F Cl HO NH 392 581.3 H N N N F Cl 393 555.2 NH CH H N N N 394 598.1 H N N N F Cl 395 581.0 NH CH H N N N 396 581.1 NH CH H N N N 397 587.6 H N N N 398 601.7 NH CH H N N N 399 550.1 H N N N 400 597.2 H N N N 401 627.1 NH CH H N N N 402 627.1 NH CH H N N N 403 627.1 NH CH H N N N 404 544.4 H N N N 405 500.1 O CF 406 468.1 F Cl 407 629.1 H N N N 408 561.4 H N N N 409 550.0 Cl SCF 410 569.1 NH CH H N N N 411 553.1 NH CH H N N N F Cl 412 641.0 NH CH H N N N 413 593.1 NH CH H N N N F Cl 414 579.1 H N N N F Cl 415 595.1 NH CH H N N N F Cl 416 643.3 NH CH H N N N 417 569.2 NH CH H N N N 418 601.0 H N N N 419 615.1 NH CH H N N N 420 627.3 NH CH H N N N 421 579.2 NH CH H N N N F Cl 422 599.0 H N N N 423 613.0 NH CH H N N N 424 631.2 H N N N MeO NH 425 581.1 H N N N 426 595.1 NH CH H N N N 427 611.2 NH CH H N N N 428 550.1 NH CH H N N N 429 595.1 H N N N 430 609.1 NH CH H N N N 431 575.0 H N N N 432 589.0 NH CH H N N N 433 595.2 H C CH H N N N F Cl 434 571.2 NH CH H N N N t-Bu 435 599.0 436 613.1 437 599.1 438 613.1 439 557.1 H N N N t-Bu 440 641.0 NH CH H N N N 441 557.0 NH CH H N N N 442 543.1 H N N N 443 557.1 NH CH H N N N 444 543.1 H N N N 445 583.1 H N N N F Cl MeO NH 446 557.1 H N N N H C CH 447 575.1 NH CH H N N N F CH 448 579.2 H N N N F Cl 449 593.0 NH CH H N N N F Cl 450 579.0 H N N N F Cl 451 593.0 NH CH H N N N F Cl 452 571.0 H N N N 453 585.0 NH CH H N N N 454 585.1 H N N N 455 599.1 NH CH H N N N 456 585.2 NH CH H N N N 457 553.1 NH CH H N N N 458 603.0 NH CH H N N N H C CH 459 615.0 H N N N H N O 460 629.0 NH CH H N N N 461 569.1 NH CH H N N N 462 551.1 NH CH H N N N 463 537.0 H N N N 464 551.1 NH CH H N N N 465 537.1 H N N N 466 603.1 NH CH H N N N 467 529.1 H N N N H C CH 468 543.1 NH CH H N N N H C CH Table 2aa Comp. Structure LCMS 469 573.1 NH CH H N N N 470 551.1 NH CH H N N N 471 633.1 NH CH H N N N F SCF 472 593.1 H N N N F Cl 473 627.2 H N N N 474 609.1 H N N N 475 579.1 H N N N F Cl 476 613.1 H N N N H N O 477 627.2 NH CH H N N N H N O 478 599.2 NH CH H N N N 479 599.1 H N N N H C NH 480 613.1 NH CH H N N N H C NH 481 579.1 H N N N F Cl 482 595.1 H N N N 483 569.3 H N N N 484 583.1 NH CH H N N N 485 595.1 H N N N 486 579.1 H N N N F Cl 487 625.1 CO Me H N N N F Cl 488 641.0 CO Me H N N N 489 611.1 CO H H N N N F Cl 490 627.1 CO H H N N N 491 673.2 CO Me H N N N 492 659.1 CO H H N N N 493 585.1 NH CH H N N N F Cl 494 611.1 NH CO Me H N N N F Cl 495 597.0 NH CO H H N N N F Cl 496 627.1 NH CO Me H N N N 497 613.0 NH CO H H N N N 498 659.2 NH CO Me H N N N 499 571.0 H N N N F Cl 500 627.0 H N N N 501 595.1 H N N 502 627.1 H N N N 503 645.1 NH CO H H N N N 504 306.9 [M+1]/2 NH CH H N N N 505 613.1 H N N N 506 597.1 H N N N 507 645.3 H N N N 508 707.1 H N N N In one embodiment, the invention is not the compound selected from: Table AA NH CHF H N N N H N N N H N N N H N N N H N N N H N N N H N N H N N N H N N N H N N N H N N N H N N N H N N N OCHF H N N N H N N N H N N N H N N S CF H N N N O S CF O CF H N N S CF H N N N H N N N H N N N 2 CF H N N N H N N N H N N S NH The compounds of the present invention can be made using synthetic chemical techniques well known to those of skill in the art.
EXAMPLES Example 1 Synthesis of Alkyne Intermediate The alkyne intermediate can generally be synthesized according to the scheme: N 1) MsCl, TEA DCM, 0 C O O 2) NaN , DMF 70 C Br NHCBz Br OH Br OH 3) PPh , THF/H 0 Cl O 4) CbzCl, THF/H 0 1) TMS NaBH , THF NaHCO Pd(PPh ) , CuI -10 C to 0 C TEA, THF, 70 C 2) MeOH,K CO NHCBz Alkyne Intermediate Example 2 Synthesis of Pyrrolocytosines Compound 37 (R =Cl, R =F) and Compound 91 (R =F, R =Cl) Compounds 37 and 91 can be synthesized according to the scheme. Compound 37 can be synthesized according to the procedures detailed below. Similar procedures can be used to synthesize compound 91. Variables R and R in the scheme are not the same as in the claims, and they are used in this scheme for purposes of this particular example.
Synthesis of Compound 31 from 1,5-dibromochlorofluoro-benzene (2a): A solution of 2,6-dibromochlorofluoro-phenylamine (1a, 4.85 g, 16 mmol, 1 eq.) in DMF (20 mL) was added to a solution of isoamylnitrite (3.46 mL, 25.6 mmol, 1.6 eq.) in DMF (12 mL) at 70 °C. The mixture was heated at 70 °C for 3 h before it was cooled to room temperature, quenched with 1 N NaOH aqueous solution (150 mL), and extracted with EtOAc (200 mL). The EtOAc extract was washed with brine (100 mL x 2), dried over MgSO , filtered and concentrated. The residue was purified by flash chromatography (heptane) to give desired product 2a as colorless oil (3.70 g, 80%).
Synthesis of [4-(3-bromochlorofluoro-phenyl)-butyl]-carbamic acid benzyl ester (3a): A solution of butenyl-carbamic acid benzyl ester (5.00 g, 24.36 mmol, 1 eq) in anhydrous toluene (60 mL) was cooled under argon to 0-5 °C. 9-BBN (0.50 M, solution in THF; 54.6 mL, 26.80 mmol, 1.1 eq.) was added dropwise, and the mixture was allowed to reach room temperature. After 24 h, the resulting solution was added dropwise at room temperature to a mixture of 2a (7.03 g, 24.36 mmol, 1 eq.), 1N NaOH/H O (40 mL, 40 mmol, 1.6 eq.), and toluene (20 mL). The mixture was then degassed with argon and Pd(PPh ) (1.13 g, 0.98 mmol, 0.04eq.) was added. The mixture was rapidly stirred under argon at 60 °C for 24 h, before cooling to room temperature. The mixture was partitioned between EtOAc (150 mL) and brine (150 mL). The organic phase was washed with brine (200 mL), dried over Na SO , filtered and concentrated. The crude product was purified by flash chromatography on silica gel (0-50% EtOAc in Heptane) to afford 3a as a colorless oil (3.54 g, 35%).
Synthesis of [4-(4-chlorofluorotrimethylsilanylethynyl-phenyl)-butyl]-carbamic acid benzyl ester (4a): A mixture of 3a (4.78 g, 11.51 mmol, 1 eq.), CuI (175 mg, 0.92 mmol, 0.08 eq.), Pd(PPh ) Cl (323 mg, 0.46 mmol, 0.04 eq.) and DMF (30 mL) was degassed. 3 2 2 Trimethsilylacetylene (4.23 mL, 21.02 mmol, 2 eq.) was added under argon, followed by Et N (4.81 mL, 34.53 mmol, 3 eq.). The resulting mixture was heated at 70 °C for 24 h. After cooling to room temperature, the reaction mixture was diluted with EtOAc (250 mL) was washed with brine (150 mL x 2 containing 15 mL 28% NH OH). The EtOAc solution was dried over MgSO , filtered and concentrated. The crude product was purified by flash chromatography (0-50%, EtOAc in heptane) to afford 4a (4.50 g, 90%).
Synthesis of [4-(4-Chloroethynylfluoro-phenyl)-butyl]-carbamic acid benzyl ester (5a): K CO (2.76 g, 20 mmol, 2 eq.) was added to a solution of 4a (4.50 g, 10.36 mmol, 1 eq.) in degassed MeOH (200 mL). The suspension was stirred at room temperature for 30 min. before concentration. The residue was partitioned between EtOAc (200 mL) and brine (200 mL). The EtOAc layer was separated and washed further with brine (100 mL), dried over MgSO , filtered and concentrated. The crude product was purified by flash chromatography (0-50%, EtOAc in heptane) to afford 5a as a colorless oil (3.60 g, 96%).
Synthesis of 6a: Intermediate 6a can generally be synthesized according to the scheme: Synthesis of compound 3b: Compound 2b (65.0 g, 373 mmol) was dissolved in ethanol (150 mL). The flask was purged with argon. Compound 1b (55.93 g, 373 mmol) was then added and the mixture was stirred at room temperature for 2 h. The reaction solution was then added via addition funnel, over 20 minutes, to a suspension of NaBH (14.18 g, 373 mmol) in toluene (150 mL), at 0 C.
The ice bath was removed, and the resulting mixture was stirred at room temperature for 3h. 1N HCl (750 mL) was added to the solution, and the mixture was stirred at room temperature for 30 min. K CO (205.9 g, 1.49 mol), Boc O (81.41 g, 373 mmol), and THF (200 mL) were 2 3 2 added to the solution, and stirred at room temperature for 23 h. Reaction solution was partitioned between EtOAc and 1:1 brine/H O. The aqueous layer was washed with EtOAc (2 x 300 mL). The combined organic layers were washed with brine (500 mL); dried over Na SO ; filtered, and concentrated. The crude product was purified by Combi Flash chromatography, in 3 portions, affording the product as a white solid (119.43 g, 78 %); H– NMR (300 MHz, CDCl ) δ 1.43 (bs, 18H), 1.63 (m, 2H), 2.95–3.30 (m, 4H), 4.45 (m, 2H), .93 (bs, 1H), 7.22 (bs, 1H), 7.34 (bs, 1H), 7.78 (d: 8Hz, 1H), 8.19 (d: 8Hz, 1H).
Synthesis of compound 5b: To a mixture of compound 3b (42.28 g, 103.5 mmol) and compound 4b (24.54 g, 103.5 mmol) were added MeOH (3 L) and H O (750 mL). The mixture was stirred vigorously open to air, at room temperature, for 30 min. Cu(OAc) •H O (20.67g, 103.5 mmol) was then added followed by TMEDA (18.63 mL, 124.3 mmol). The solution was stirred open to air, at room temperature, for 5 h. Once the reaction was complete, the solution was concentrated to 0.7 L, and then partitioned between CH Cl (700 mL) and 20% NH OH/H O saturated with NH Cl (500 mL). The aqueous layer was washed with CH Cl 4 2 4 2 2 (500 mL, 200 mL). The combined organic layers were dried over MgSO , filtered, and concentrated. The crude product was purified by Combi Flash chromatography: A: CH Cl B: :1 CH Cl / 2N NH /MeOH, 0–100 % B over 85 min. (two 330g columns). This gave the 2 2 3 product as a white solid (35.52 g, 58 %); LCMS (ESI): m/e 600 (M+H) .
Synthesis of compound 6a: Compound 5b (10.0 g, 16.68 mmol) was dissolved in THF (40 mL). The flask was purged with argon. Pyridine (40 mL) was then added followed by BzCl (3.10 mL, 26.69 mmol). The solution was stirred at room temperature under argon atmosphere for 3 h.
MeOH (4 mL) was added, the mixture was stirred at room temperature for 10 min, and then it was partitioned between EtOAc (200 mL), heptane (100 mL), and 5% KHCO /H O (200 mL). The aqueous layer was washed with EtOAc (100 mL, 50 mL). The combined organic layers were washed with 5% KHCO /H O (300 mL); dried over Na SO ; filtered, and 3 2 2 4 concentrated. The crude product was purified by Combi Flash chromatography: 0–100% EtOAc / heptane, over 55 min. (330 g column). The product was obtained as an off–white powder (9.81 g, 84%); LCMS (ESI): m/e 704 (M+H) .
Synthesis of 7a: Pyrrolocytosine 7a was prepared from the coupling of common intermediate 6a and alkyne 5a according to the procedure describing this type of reaction. For example: compound 6a (1 eq) and compound 5a (1 eq) were placed in a pressure vessel, and anhydrous DMF was added. The solution was purged with argon, and then CuI (0.1 eq), Pd(PPh ) (0.05 eq), and Et N (6 eq) were added, the vessel was sealed, and the mixture was stirred at 22 ºC, for 15 min. Subsequently, the temperature was increased to 80–85 °C, and the mixture was stirred for 14 h. It was cooled to ambient temperature, MeOH was added, the vessel was sealed, and the mixture was stirred at 90 °C for 3 h. After cooling to ambient temperature, the mixture was partitioned between sat. KH PO /H O and EtOAc, the organic phase was 2 4 2 washed with brine, dried over Na SO , filtered and concentrated. The crude product was purified by flash chromatography on silica gel using 5% (2.5M NH /MeOH)/CH Cl . Starting 3 2 2 from 360 mg of 5a, 600 mg of the desired compound 7a was obtained as an orange-brown solid (72%); LCMS (ESI) m/e 813.2 (M+1) .
Synthesis of 8a: Boc-deprotection of 7a (0.60 g, 0.72 mmol) was accomplished with 8 mL of 6N HCl in 25 mL EtOH at 60 C (2 h). Following solvent evaporation, the crude residue was taken to the next step without further purification. LCMS (ESI) m/e 613.0 (M+1) .
Synthesis of 9a: Guanidine formation was carried out by dissolving 8a in a 5:1 DMF/MeOH (0.1 M) at rt. After treating with diisopropylethylamine (8 eq), N,N-bis-boc-guanylpyrrazole (1.3 eq) was added as a solid. The reaction mixture was stirred for 6 h, and upon completion the solvents were removed by rotary evaporation. Crude 9a was used without further purification.
Synthesis of 10a (Compound 31): Under argon, fully protected guanidine 9a (0.60-0.80 mmol) was dissolved in 25 mL of trifluoroacetic acid. Thioanisole (0.5 mL) was added dropwise and the solution was stirred at rt for 4 h. Upon completion, solvent was evaporated affording an oil. Diethyl ether was added and the liquid layer containing most of the residual thioanisole was decanted. Crude 10a was then dissolved in [(20% MeOH- 80% H2O)+0.15%TFA] (10 mL). An aliquot (10 mL) was injected on a Dynamax 41.4 mm, C-18 prep HPLC Unit (guard+column), which was eluted with a gradient of solvents of 20% - 80% (MeOH/H2O + 0.15% TFA), over 45 min. The pure fractions were combined and concentrated with EtOH to dryness. This sample was treated with 1N HCl/H2O (5 mL) and EtOH (70 mL), and concentrated. This operation was repeated; the solid thus obtained was lyophilized from H2O-MeCN (4:1), affording compound 10a as a yellow powder (250 mg); LCMS (ESI) m/e 539.0 (M+1) ; H NMR (300 MHz, D O) 1.50-1.60 (m, 4H), 1.82-1.95 (m, 2H), 2.57 (t, J=6.9 Hz, 2H), 2.86 (t, J=6.9 Hz, 2H), 3.06 (t, J=6.9 Hz, 2H), 3.17 (t, J=6.9 Hz, 2H), 4.23 (s, 2H), 6.78 (s, 1H), 7.08 (d, J=8.5 Hz,, 1H), 7.18 (s, 1H), 7.44 (d, J=8.7, 2H), 7.58 (d, J=8.7 Hz, 2H), 8.48 (s, 1H).
Example 3: Synthesis of a benzylic methylated Fragment A intermediate Py.SO / Et N BocHN BocHN OH O DMSO/CH Cl Pyridine sulfurtrioxide complex (20 g, 125 mmol, 2.5 eq.) was added to a mixture of (3-hydroxy-propyl)-carbamic acid tert-butyl ester (8.75 g, 50 mmol, 1 eq.), Et N (17.67 g, 175 mmol, 2.5 eq.), DMSO (25 mL) and CH Cl (100 mL) at 0 °C. The resulted mixture was stirred at 0 °C for 1h and warmed up to room temperature and continuously stirred for 3 h.
After concentration, the residue was diluted with EtOAc (200 mL) and washed with H O (200 mL), brine (100 mL), dried over MgSO , filtered and concentrated to give desired aldehyde as colorless oil (8.60 g, 99%). i) MeOH BocHN N BocHN ii) NaBH Br iii) Boc O/Et N/EtOAc A mixture of (3-oxo-propyl)-carbamic acid tert-butyl ester (8.94 g, 51.7 mmol, 1 eq.), (S)-(-)(4-bromo-phenyl)-ethylamine (10.33 g, 51.7 mmol, 1.0 eq.) and MeOH (50 mL) was stirred at RT for 18h. NaBH (1.98 mg, 52.1 mmol, 1.01 eq.) was added slowly to the above solution. The resulted mixture was stirred at RT for 1h, additional (3-oxo-propyl)- carbamic acid tert-butyl ester (0.8 g, 4.6 mmol) was added and stirred for 2h. additional NaBH (0.21g, 5.53 mmol) was added and stirred for 1 h. EtOAc (120 mL) was added and washed with 1N NaOH (40 mL x 2), 1N HCl (60 mL) and water, dried over MgSO , filtered and concentrated. The crude product was dissolved in EtOAc (120 mL) and MeOH (20 mL), Et N (10.8 mL, 77.52 mmol, 1.5 eq.) was added, followed by Boc O (11.3 g, 51.8 mmol, 1.0 eq.). The resulted mixture was stirred at RT for 3 days (weekend), washed with H O, dried over MgSO , filtered and concentrated. The crude product was purified by flash chromatography (EtOAc:Heptane/1:5) to afford (3-{[1-(4-bromo-phenyl)-ethyl]-tert- butoxycarbonyl-amino}-propyl)-carbamic acid tert-butyl ester (17.5 g, 74%).
Pd(dppf)Cl /KOAc BocHN N BocHN N B Boc Dioxane B A mixture of (3-{[1-(4-bromo-phenyl)-ethyl]-tert-butoxycarbonyl-amino}-propyl)- carbamic acid tert-butyl ester (15.73 g, 34.42 mmol), bis(pinacolato)diborane (9.18 g, 36.14 mmol, 1.05 eq.), Pd(dppf)Cl .CH Cl (843 mg, 1.026 mmol, 0.03 eq.), KOAc (10.6g, 108.42 2 2 2 mmol, 3.15 eq.) and dioxane (60 mL) was degassed and heated at 100 °C at Argon atmosphere overnight. The mixture was diluted with CH Cl (150 mL), washed with H O, 2 2 2 dried over MgSO , filtered and concentrated. The crude product was purified by chromatography (EtOAc:Heptane/1:5) to afford [3-(tert-butoxycarbonyl-{1-[4-(4,4,5,5- tetramethyl-[1,3,2]dioxaborolanyl)-phenyl]-ethyl}-amino)-propyl]-carbamic acid tert- butyl ester ( 16.77 g, 97%).
BocHN N BocHN N MeOH/H O Boc I Cu(OAc) /TMEDA O N NH O N NH References for above rxn: Jacobsen, M. F.; Knudsen, M. M.; Gothelf, K. V. "Efficient N- Arylation and N-Alkenylation of the Five DNA/RNA Nucleobases" J. Org. Chem. 2006, 71, 9183-9190.
Dai, Q.; Ran, C.; Harvey, R. G. "Regioselective Arylation of 2’Deoxyribonucleosides on Amido or Imino Sites by Copper(II)-Mediated Direct Coupling with Arylboronic Acids" Tetrahedron 2006, 62, 1764-1771.
Cu(OAc) (6.02g, 33.13 mmol, 1.1 eq.) was added to a mixture of [3-(tert- butoxycarbonyl-{1-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolanyl)-phenyl]-ethyl}-amino)- propyl]-carbamic acid tert-butyl ester (15.18 g, 30.12 mmol, 1 eq.), 4-aminoiodo-1H- pyrimidinone (7.85 g, 33.13 mmol, 1.1 eq.), MeOH (400 mL) and H O (100 mL), followed by N,N,N',N'-tetramethyl-ethane-1,2-diamine (7.69 g, 66.26 mmol, 2.2 eq.). The Mixture was stirred at RT under air for 48 h (weekend) before concentrated to a volume ca. 130 mL. The residue was diluted with CH Cl (200 mL). The CH Cl extract was washed 2 2 2 2 with brine and concentrated. The crude product was purified by flash chromatography (CH Cl :MeOH:NH OH/35:1:0.01) to afford [3-({1-[4-(4-aminoiodooxo-2H- 2 2 4 pyrimidinyl)-phenyl]-ethyl}-tert-butoxycarbonyl-amino)-propyl]-carbamic acid tert-butyl ester (16.06 g, 87%).
Benzoic anhydride (5.26 g, 23.25 mmol, 1.05 eq.) was added to a solution of [3-({1- [4-(4-aminoiodooxo-2H-pyrimidinyl)-phenyl]-ethyl}-tert-butoxycarbonyl-amino)- propyl]-carbamic acid tert-butyl ester (13.58 g, 22.15 mmol) in DMF (60 mL). The mixture was heated at 70 °C for 2 h and at RT for 20h. EtOAc (150 mL) was added to the mixture and washed with saturated sodium bicarbonate and brine, dried over MgSO , filtered and concentrated. The crude product was purified by chromatography (CH Cl :MeOH:NH OH/50:1:0.01) to afford benzoic acid 1-(4-{1-[tert-butoxycarbonyl-(3-tert- butoxycarbonylamino-propyl)-amino]-ethyl}-phenyl)iodooxo-1,2-dihydro-pyrimidin yl ester (15.5 g, 98%).
Example 4: Synthesis of the Fragment B intermediates The preparation of the Fragment B intermediates 5b and 5c was carried out as described below. The Wittig Olefination can be performed according to methods known in the art or according to Gerpe, A., Convenient Route to Primary (Z)-Allyl Amines and Homologs." Synth. Commun. 2009, 39, 29-47. In one aspect, the intermediates 5b and 5c were used to prepare compounds 27 and 100.
Synthesis of Phosphonium Bromide XXb Synthesis of Phosphonium Bromide XXc Synthesis of Fragment B intermediates via Wittig Olefination Example 5: Synthesis of Compound 234 The preparation of compound 234 was carried out by coupling Fragment A (5) and Fragment B (H). The preparation of Fragment B involves the coupling of intermediates 1 and 2.
Synthesis of N-Cbz (S)aminopentene 1 intermediate OH 3 yield / 4 steps = 93.2% 2 HN .6 g; purity 99% (heptane 1%) (R)Hydroxypentene A (15.00 g, 174.15 mmol) was dissolved in CH Cl (180 mL). To the solution, stirred /Ar at 0°C was added triethylamine (30.4 mL, 217.69 mmol), followed by dropwise addition of methanesulfonyl chloride (14.43 mL, 186.35 mmol), over min. After 5 min, the cold bath was removed and the mixture was stirred for 75 min, concentrated to 50 mL, and partitioned between heptane (80 mL), EtOAc (200 mL), H O (100mL) and brine (100 mL). The phases were separated, the organic phase was washed with H O-brine (2:1; 150 mL), dried over Na SO , filtered and concentrated, affording 2 2 4 intermediate B (28.6 g, yield= 100%).
Compound B (28.6g, 174.15 mmol) was dissolved in anhydrous DMF (250 mL) and NaN (48.46 g; 745.4 mmol) was added. The mixture was stirred/Ar at RT for 5 min, and then at 70-75 °C for 90 min. Afterwards, the mixture was cooled to RT and partitioned between ice (150 g), water (500 mL) and Et O (150 mL). The phases were separated, the aqueous phase was extracted with Et O (3x 100 mL) (Note: Et O could be substituted by 2- Me-THF). The organic extracts were combined and washed with brine (2x 150 mL), resulting in a solution of compound C, which was used directly in the next step.
To the solution of C (174.15 mmol) was added THF (100 mL), followed by H O (35 mL). The mixture was stirred at RT/Ar, and triphenylphosphine 58.65 g, 223.6 mmol) was added in small portions, over 5 min. Afterwards, the flask was equipped with a reflux condenser and the mixture was stirred at 40-42 °C, for 16 hrs. Water (60 mL) was added, followed by dropwise addition of 3N HCl/H O (57 mL) to achieve pH= ca. 2.0. The phases were separated, and the organic phase was washed with a mixture of H O (40 mL) and 3N HCl/H O (3.5 mL). The aqueous phases were combined and washed with EtOAc (2x 70 mL), resulting in a solution of salt D, which was used directly in the next step.
The aqueous solution of D (174 mmol) was stirred under argon, while the flask was cooled in a water bath at 20 °C. Na CO (18.44 g, 174 mmol) was added in small portions, followed by KHCO (34.84 g, 348 mmol), and THF (150 mL). To this mixture, stirred rapidly, was dropwise added benzyl chloroformate (27.3 mL; 191.4 mmol), over 10 min. The mixture was stirred for 2 hrs. Next, water (150 mL) and EtOAc (200 mL) were added, and the mixture was stirred for 10 min. The phases were separated and the aqueous phase was extracted with EtOAc (2x 70 mL). The organic layers were combined, washed with brine (100 mL), dried over Na SO , filtered and concentrated (50.5 g).This sample was purified by flash chromatography on Si-gel (230-400mesh; 750 g), using 5% EtOAc/heptane (4L) and then 10% EtOAc / heptane (5L). This gave a colorless viscous oil of compound 1, which solidified upon standing (35.6 g; purity (NMR) 99% - conatins 1% of heptane; yield = 93.2% over 4 steps).
Synthesis of 1-bromochlorofluoroiodo-benzene 2 intermediate I Br I Br 2 NH E F G N-Iodosuccinimide (286.2 g, 1.272 mol) was slowly added under argon to rapidly stirred DMF (0.85 L) (Note: It is important to do it in this order because if DMF is added to NIS, a very insoluble solid forms), and then methanesulfonic acid (1.90 mL, 29.3 mmol) was added. The mixture was stirred for 5 min and filtered, which gave a clear solution.
Separately, 4-chlorofluoroaniline E (176.3 g, 1.211 mol) was dissolved / Ar in DMF (1.10 L), the solution was cooled to 0 °C, and methanesulfonic acid (2.03 mL, 31.3 mmol) was added. The mixture was stirred at 0 °C / Ar and the above described solution of NIS in DMF was added dropwise, at 0-5 °C, over 1h 20 min. Subsequently, the mixture was stirred at 0-3 °C for 2.5 h, and then a solution of monosodium ascorbate (24.0 g, 0.121 mol) in H O (70 mL) was added dropwise at 0-5 °C, over 10 min. The mixture was stirred at 0-5 °C for 20 min, and then EtOAc (1.3 L) and heptane (0.2 L) are added, followed by 5% KHCO /H O (1.4 L). After 5 minutes of stirring, the phases are separated, and the aqueous phase is extracted with EtOAc (500 mL). The organic phases are combined, washed with water (1L), dried /Na SO , filtered and concentrated (401 g). This material is purified by flash chromatography on Si-gel (230-400mesh; 3.0 kg), using 7% - 9% EtOAc / heptane. During the concentration of fractions, the product F precipitates; the solid was filtered and dried in vacuo to give aniline F as a crystalline solid (206.68 g, yield: 77.5%).
N-Bromosuccinimide (142.29 g, 799.43 mmol) was dissolved under argon in DMF- AcOH (5:1; 0.40 L), stirred for 5 min, which resulted in a clear solution.
Separately, compound F (206.68 g, 761.36 mmol) was dissolved under argon in DMF-AcOH (5:1; 1.40 L). The solution was cooled to 0-4 °C and the above described solution of NBS was added dropwise, at 0-4 °C, over 20 min. The mixture was stirred at 0-4 °C for 30 min, and then at 12-14 °C (Note: it is important not to exceed the specified temperature range due to a sudden drop in selectivity at higher temperatures), for 5 h, with HPLC monitoring. Subsequently, the mixture was cooled to 0-5 °C and a solution of monosodium ascorbate (15.08 g, 76.14 mmol) in water (40 mL) is added at 0-10 °C, over 10 min. The mixture is stirred at 5-10 °C for 10 min, and then EtOAc (1.6 L), heptane (0.2 L), H O (3.2 L), and brine (0.6 L) are added, the mixture is stirred for 5 min, and the phases are separated. The aqueous phase is extracted with EtOAc (0.40 L), the organic phases are combined and washed with 10% KHCO / H O (2x 1.1 L), dried over Na SO4, and 3 2 2 concentrated (320 g). The crude material is dissolved in minimal amount of CH Cl , and purified by flash chromatography on Si-gel (3.0 kg) using 2% EtOAc in heptane. The fractions are concentrated to ca. 600 g, at which point a solid precipitates. The mixture is cooled at 10-15 °C and stirred for 1 hr, the product is filtered, and dried to give aniline G (124.15g, yield: 46.5%).
A solution of isoamyl nitrite (94.9 mL, 708.7 mmol) in DMF (500 mL) was stirred and heated under argon, at 65 °C. To this solution was added dropwise a solution of aniline G in DMF (200 mL), over 40 min, while maintaining the temperature at 65-75 °C. The mixture was stirred at 65-70 °C for 30 min, and then cooled to 30-40 °C. Heptane (0.80 L), EtOAc (0.40 L) and 0.5 N HCl/H O (1.6 L) were added, after extraction the phases were separated, and the aqueous phase was washed with a mixture of heptane (0.20 L) and EtOAc (0.30 L).
The organic phases were combined, washed with 2N HCl/H O (0.70 L), and then with water (0.50 L), dried over Na SO , filtered, and concentrated (brown oil, 160 g). This sample was purified by flash chromatography on Si-gel (3.0 kg) using 100% heptane as the eluent. This gave a solidifying, thick oil (90.5 g), which was dissolved at 40 °C in heptane (100 mL), and then crystallized from the solution at 0°C. After filtration, the filtrate was recrystallized under similar conditions, and the crystals were combined. This gave compound 2 (67.0 g, yield: 56.4%; HPLC purity (PDA) > 93%) as colorless crystals (Note: The major impurity (3-5%) is identified as 1,5-dibromochlorofluoro-benzene, which is expected to show utility in the present synthesis, essentially similar to compound 2).
Synthesis of alkyne Fragment B intermediate 5 I Br 9-BBN The Suzuki-coupling reaction is preformed according to methods known in the art e.g., Al-Hellani, R.; Schluter, A. D. "On the Synthesis and Selective Deprotection of Low- Generation Dendrons with Orthogonally Protected Peripheral Amine Groups and a Possible Impact of the Deprotection Conditions on the Stability of Dendronized Polymers’ Skeletons." Helv. Chim. Acta. 2006, 89, 2745-2763.
A solution of olefin 1 (18.62g, 84.06 mmol) in dry toluene (185 mL) was purged with argon, and then cooled to 0 °C under argon, at which point 9-BBN (11.08 g, 90.80 mmol) was added in a few portions. The mixture was stirred at 0-5 °C for 20 min, and then at RT for 21 h, which gave a solution of the trialkylborane.
To a solution of iodide 2 (28.19 g, 84.06 mmol) in toluene (65 mL) was added 1N NaOH/H O (142.9 mL, 142.9 mmol). The mixture was purged with argon, and the above described solution of trialkylborane was added under argon, followed by tetrakis(triphenylphosphine)Pd(0) (4.86 g, 4.20 mmol). The mixture was purged with argon, the flask was transferred to an oil bath (60-64 °C), and the mixture was stirred under argon for 9 h. After cooling to RT, EtOAc (150 mL) and brine (150 mL) were added, the phases were separated, the organic phase was washed with 1N NaOH/H O (100 mL), and with brine (100 mL). The organic layer was dried over Na SO , filtered, and concentrated (56.1 g). This sample was purified by flash chromatography on Si-gel (750 g) using 15% EtOAc in heptane as the eluent. The fractions were combined and concentrated to ca. 300 mL, at which point crystallization occurred. The solid was filtered and dried. This gave compound 3 as a white solid (27.9 g; yield: 77.4 %).
The bromide 3 (27.85 g; 64.96 mmol) was dissolved in DMF (220 mL), the solution was purged with argon. Under a gentle stream of argon, trimethylsilyl acetylene (27.5 mL, 194.9 mmol) was added, followed by CuI (990 mg, 5.2 mmol), Pd (PPh ) (3.0 g, 2.6 mmol) and triethylamine (stored under argon; 72.5 mL, 519.7 mmol). The flask was equipped with a reflux condenser, and the mixture was stirred under argon, at 70 °C for 2.5 h. After cooling the mixture to RT, brine (300 mL), water (1.0 L) and EtOAc (0.75 L) were added, and after extraction the phases were separated. The organic layer was washed with H O (0.75 L), dried over Na SO , filtered and concentrated. The crude product was purified by flash chromatography on Si-gel (750 g) using 15% EtOAc in heptane. This purification was repeated under the same conditions (Note: due to the potential for ready dimer formation in the next step, it is essential to eliminate from 4 as much transition metal residues as possible).
This gave compound 4 as a pale-yellow, thick oil (29.8 g).
This sample was dissolved in MeOH (previously purged with argon; 350 mL), K CO (19 g, 137.47 mmol) was added, the mixture was stirred under a stream of argon for 5 min, and then it was stirred in darkness, under argon, at 45 °C. After 35 min the mixture was cooled / Ar to RT, concentrated, and purified by flash chromatography on Si-gel (750 g) using 17% EtOAc in heptane (Note: these operations are performed quickly to avoid alkyne dimerization; after chromatographic purification the alkyne is stable). This afforded alkyne 5 as a white, crystalline solid (20.20 g, yield: 83.2 %).
Synthesis of compound 234 The Fragment A intermediate H was prepared according to methods described herein.
H (38.77 g, 54.03 mmol) and alkyne 5 (20.20 g, 54.03 mmol) were dissolved in acetonitrile and the solution was stirred under gentle stream of argon. Copper(I) iodide (617 mg, 3.24 mmol) and Pd(PPh ) (1.87 g, 1.62 mmol) were added, followed by diisopropylethyl amine (26.8 mL, 162.1 mmol). The mixture was stirred under Ar, at RT, for 5 min, and then it was heated at 72-75 °C for 4.5 h. Afterwards, MeOH (100 mL) was added and the mixture was stirred / Ar, at 72-75 °C, for 15 h. After cooling to RT, the mixture was concentrated, the gummy solid thus obtained was dissolved in EtOAc (300 mL), and the solution was washed with NH Cl/NH OH (3x 200 mL). The organic phase was concentrated and purified by flash chromatography on Si-gel (750 g) using 5% (2.5M NH /MeOH) in CH Cl . The 3 2 2 chromatography was repeated under similar conditions, thus affording a red-brown, gummy solid (41.5 g). To a solution of this sample in MeOH (300 mL), was added charcoal (Aldrich No. 242276; 45 g) and the mixture was stirred for 2 h at RT. Afterwards, the mixture was filtered through a silica gel plug prepared in MeOH, the solids were washed with MeOH (1.0 L), concentrated, and dried in vacuo to give compound 6 as a light-brown solid (32.5 g, 70%).
The pyrrolocytosine 6 (32.5g, 37.82 mmol) was dissolved under argon in EtOH (200 proof; 200 mL), 6N HCl/H O 75.6 mL, 453.8 mmol) was added, and the mixture was stirred under argon, at 70-72 °C, for 1h 40 min. Afterwards, the mixture was cooled to 40-45 °C, and IPA (200 mL) was added. After 3 min, abundant precipitation occurred – more IPA (350 mL) was added, the mixture was stirred for 10 min, and then filtered. The solid was washed with IPA (2x 80 mL), and dried in vacuo overnight, affording salt 7 as a crystalline solid (20.7 g, yield: 75%).
Salt 7 (20.7g, 28.3 mmol) was added under argon to rapidly stirred MeOH (350mL), followed by addition of triethylamine (15.8 mL, 113.2 mmol). After the solid dissolved completely (pH ca. 9.5), N,N’-bis-Bocguanylpyrazole (10.54 g, 33.96 mmol) was added and the mixture was stirred for 1 h, at which time more N,N’-bis-Bocguanylpyrazole (0.88 g, 2.83 mmol) was added. The stirring was continued for 1 h; the mixture was concentrated, and the thus obtained semi-solid was purified by flash chromatography on Si-gel (750 g) using 3% MeOH-2% Et N-95% CH Cl . (Note: it is believed that during this 3 2 2 chromatography most of palladium residues are removed in the form of a complex with the by-product pyrazole) This gave a partially purified product (29.0 g) which was additionally purified by flash chromatography on Si-gel (750 g) using 3% (2.5M NH /MeOH) in CH Cl . 3 2 2 This gave compound 8 as a bright-yellow, solid foam (21.6 g, yield: 84.5%); ICP-OES Pd: 8 ppm, Cu < 1 ppm.
Compound 8 (21.30 g) was placed under argon in a 1L round-bottom flask. With stirring, a pre-formed mixture of thioanisole (8.32 mL, 70.9 mmol) and TFA (300 mL) was added. The reaction mixture was stirred / Ar, at 40-45 °C, for 2h 40 min, and then it was cooled to RT, concentrated, and dried in vacuo. The thus obtained glassy solid was treated with 6N HCl/H O (50 mL) and EtOH (200 proof, 200 mL), and the mixture was concentrated to a semi-solid. This material was again treated with 6N HCl/H O (50 mL) and EtOH (200 mL), and the mixture was concentrated, and dried to a solid. This solid was dissolved in 3N HCl/H O (45 mL), the solution was stirred / Ar, and THF (80 mL) was added dropwise to precipitate an oil. The mixture was rapidly stirred for 5 min, and then the phases were separated. The bottom phase (64.5 g) was placed under argon in a 500 mL flask, stirred at RT under argon, and then the product was precipitated by addition of EtOH (150 mL) and isopropanol (50 mL), and the mixture was stirred at RT for 1 h. The solid was filtered, washed with IPA (4 x 40 mL), dried with suction, and then dried in vacuo (1 mm Hg, RT) overnight. This gave the product (14.40 g), which contained 1 equivalent IPA (by H-NMR), in addition to some ethanol and THF. This sample (14.0 g) was dissolved in 1N HCl/H O (21 mL), and solvents (5 mL) were distilled-off. The sample remaining in the flask was diluted with EtOH (40 mL), and solvents (35 mL) were distilled-off. The residue was stirred/Ar at RT, EtOH (150 mL) was added dropwise, the resulting thick suspension was stirred for 1.5 h at RT, and then filtered. The canary-yellow solid was washed with EtOH (3x 30 mL), dried in vacuo at RT for 2 h, and then dried in an oven at 70 °C, for 40 h. This gave compound 234 as a yellow powder (11.94 g; Yield: 75% from 8; HPLC Purity (PDA): 98.9 %; Solvents: EtOH 0.3 % ).
Example 6: Synthesis of compound 248 The preparation of compound 248 was carried out by coupling Fragment A (10) and Fragment B (9).
Synthesis of Fragment B intermediate 9 Synthesis of 7: A solution of (S)-N-Cbzaminopentene (16.425 g, 75 mmol,) and 9-BBN (dimer, .065 g, 41.25 mmol) in toluene was stirred at RT under argon for 16 hrs. 1N NaOH (120 mL,.), compound 6 (22.79 g, 75 mmol) in toluene (100 mL) and Pd(PPh ) (3.5 g, 3.0mmol) was added. The mixture was stirred under argon at 60 °C for 18 hrs, The mixture was diluted with EtOAc (150 mL), washed with brine (150 mL), dried over MgSO , filtered and concentrated. The crude product was purified by chromatography on silica gel (0-20% EtOAc in Heptane) to afford 7 as a colorless oil (31.5 g, 95%). Note the procedure to prepare the starting material (S)-N-Cbzaminopentene is described herein.
Synthesis of 8: A mixture of 7 (31.5 g, 70.96 mmol.), CuI (674 mg, 3.55mmol), PdCl (PPh ) 2 3 2 (996mg, 1.42 mmol) and DMF (110 mL) was degassed. Et N (19.8 mL, 142.12 mmol) and trimethsilylacetylene (10.43 g, 106.42 mmol) was added under argon. The resulting mixture was heated at 70 °C for 24 h. After cooling to room temperature, the reaction mixture was diluted with EtOAc (250 mL), washed with 15% NH OH and brine (100 mL x 2). The EtOAc solution was dried over MgSO , filtered and concentrated. The crude product was purified by flash chromatography (0-10%, EtOAc in heptane) to afford 8 as a light yellow oil (28.10 g, 86%).
Synthesis of 9: The suspension of 8 (28.10 g, 60.96 mmol) and K CO (4.4 g, 31.88 mmol) in MeOH (100 mL) was stirred at room temperature for 1 h. The reaction was diluted with CH Cl (150 mL), washed with water, dried over MgSO , filtered and concentrated. The 2 2 4 crude product was purified by flash chromatography (5-20%, EtOAc in heptane) to afford 9 as a light brown oil (22.60 g, 95%).
Synthesis of 11: Compound 9 (13.0 g, 33.38 mmol) and compound 10 (23.47 g, 33.38mmol) were dissolved in anhydrous DMF (80 mL). The solution was purged with argon, and then CuI (381 mg, 2.0mmol), Pd(PPh ) (1.157g, 1.0mmol), and Et N (13.95 mL, 100.15mmol) 3 4 3 were added. After stirring at 70 °C for 18 h, MeOH (30 mL) was added, and the mixture was stirred at 90 °C for 3 h. After cooling to ambient temperature, the mixture was diluted with EtOAc (200 mL), washed with 15% NH OH and brine (150 mL), dried over MgSO , filtered and concentrated. The crude product was purified by flash chromatography (1-4%, 2.5M NH /MeOH in CH Cl ) to give product 11 (22.94g, 80%). 3 2 2 Synthesis of 12: To a solution of 11 (20.94 g, 24.38 mmol) in MeOH (200 mL) and CH Cl (200 mL) was added 4N HCl in dioxane (150 mL) at 0 °C. The reaction was concentrated after stirring at RT for 16h. The residue was dissolved in DMF (200 mL). Diisopropylethyl amine (21 mL) was added, followed by N,N-bis-boc-guanylpyrrazole (7.56 g, 24.38 mmol). After stirring at RT for 2 days, the reaction was diluted with EtOAc (250 mL) , washed with brine (100 mL x 2), The EtOAc solution was dried over MgSO , filtered and concentrated. The crude product was purified by flash chromatography (0-5%, 2.5M NH /MeOH in CH Cl ) to give product 12 (15.76 g, 72%) as a yellow foam. 12 was 3 2 2 further treated with charcoal (1.5 g) in EtOAc (200 mL) at RT for 4 hrs before next step use.
Synthesis of 13: To a solution of 12 (10.42 g, 11.55 mmol) in CH Cl (70 mL) was added Boc O 2 2 2 (3.07 g, 14.07 mmol). The reaction was concentrated after stirring at RT for 3h. The residue was purified by flash chromatography (25-90%, EtOAc in Heptane) to give product 13 (11.08 g, 96%) as a yellow foam.
Synthesis of compound 248: To a solution of 13 (10.42 g, 10.40 mmol) in TFA (20 mL) was added thioanisole (3.9 g, 31.45 mmol). The reaction was concentrated after stirring at 50 °C for 8h. MeOH (20 mL) and 3N HCl/H O (40 mL) were added, the resulted solution was concentrated (this sequence was repeated once). The residue was dissolved in 1N HCl (120 mL), washed with diethyl ether (80 mL x 3). The acidic aqueous solution was concentrated and recrystallized from MeOH/water/ethanol (2 mL/2 mL/20 mL) to afford the final product 248 (5.8 g, >99% purity, 82% yield).
Example 7: Synthesis of compounds 387 and 388 Compounds 387 and 388 were prepared according to the procedure below.
Example 8: Synthesis of compounds 389 and 390 Compounds 389 and 390 were prepared according to the procedure below.
Example 9: Synthesis of compound 399 Compound 399 was prepared according to the procedure below.
Example 10: Synthesis of compound 404 Compound 404 was prepared according to the procedure below.
Example 11: Synthesis of compound 390 3 CF 9-BBN NHCbz N NaOH, Pd(PPh ) THF/Toluene NHCbz Synthesis of [1-Methyl(4-trifluoromethyl-pyridinyl)-butyl]-carbamic acid benzyl ester (2): A solution of butenyl-carbamic acid benzyl ester (3.06 g, 14.0 mmol, 1 eq) in anhydrous toluene (40 mL) was cooled under argon to 0-5 °C. 9-BBN (0.50 M, solution in THF; 30.8 mL, 1504 mmol, 1.1 eq.) was added dropwise, the mixture was stirred and allowed to reach room temperature. After 24 h, 1N NaOH/H O (23.8 mL, 23.8 mmol, 1.7 eq.) was added, followed by 2-bromotrifluoromethyl-pyridine (3.16 g, 14.0 mmol, 1 eq.) and toluene (25 mL). The resulting mixture was degassed and Pd(PPh ) (0.89 g, 0.70 mmol, 0.05eq.) was added. The mixture was rapidly stirred under argon at 60 °C for 24 h, and then it was cooled to room temperature. Afterwards, the mixture was partitioned between EtOAc (100 mL) and brine (100 mL). The organic phase was washed with brine (100 mL), dried over Na SO , filtered and concentrated. The crude product was purified by flash chromatography on silica gel (0-50% EtOAc in Heptane) to afford 2 as colorless oil (5.1 g, 99%). m-CPBA CH Cl NHCbz NHCbz i) POCl 110 C,16h ii) CbzCl/Et N CH Cl i) CF 3 TMS Pd(PPh ) ,CuI,Et N 3 4 3 ii) K CO /MeOH NHCbz NHCbz Synthesis of [1-methyl(1-oxytrifluoromethyl-pyridinyl)-butyl]-carbamic acid benzyl ester (3): To a solution of 2 (5.1 g, 13.94 mmol, 1 eq.) in CH Cl (50 ml) was added m- chloroperoxybenzoic acid (2.88g, 16.72 mmol, 1.2 eq.). The mixture was stirred at room temperature for 18 h before quenching with NaHCO (sat. 50 ml). The organic solution was washed with brine (50 mL x 2), dried over MgSO , filtered and concentrated. The crude product was purified by flash chromatography (0-10%, MeOH in CH Cl ) to afford 3 (5.30 g, 99%).
Synthesis of [4-(6-Chlorotrifluoromethyl-pyridinyl)methyl-butyl]-carbamic acid benzyl ester (4): A solution of 3 (1.52 g, 4.0 mmol) in POCl (6 ml) was heated at 110 C for 15 h before cooling to room temperature. The reaction mixture was quenched with ice, basified with NaOH to pH ca. 10, and extracted with EtOAc (50 mL x 2). The EtOAc solution was washed with brine (50 mL x 2), dried over MgSO , filtered and concentrated. The crude product was purified by flash chromatography (0-10%, MeOH in CH Cl ) to afford the 2- chloropyridine derivative (360 mg). The resulting product was dissolved in CH Cl (10 ml).
Hunig’s base (520 mg, 4.03 mmol) was added at 0 C followed by CbzCl (343 mg, 2.02 mmol). The mixture was stirred for 3 h at 0 C, then concentrated and purified by flash chromatography (0-50%, EtOAc in heptane) to afford 4 (470 mg, 32%).
Synthesis of [4-(6-Ethynyltrifluoromethyl-pyridinyl)methyl-butyl]-carbamic acid benzyl ester (5) A mixture of 4 (470 mg, 1.17 mmol, 1 eq), CuI (23 mg, 0.117 mmol, 0.1 eq.), Pd(PPh ) (68 mg, 0.058 mmol, 0.05 eq.) and DMF (8 mL) was degassed.
Trimethsilyacetylene (173 mg, 1.760 mmol, 1.5 eq.) was added under Argon, followed by Et N (356 mg, 4.81 mL, 3.52 mmol, 3 eq.). The mixture was heated at 70 °C for 24 h. After being cooled to room temperature, the reaction mixture was diluted with EtOAc (50 mL) and washed with brine (20 mL x 2). The EtOAc solution was dried over MgSO , filtered and concentrated. The crude product was purified by flash chromatography (0-30%, EtOAc in heptane) to afford the desired trimethsilyacetylene derivative (500 mg, 92%). The product was dissolved in MeOH (20 mL), and K CO (138 mg, 1 mmol,) was added. The reaction mixture was stirred at room temperature for 30 min before concentration. The residue was partitioned between EtOAc (20 mL) and H O (20 mL). The EtOAc layer was washed with brine (10 mL), dried over MgSO , filtered and concentrated. The crude product was purified by flash chromatography (0-50%, EtOAc in heptane) to afford 5 as colorless oil (423 mg, 100%).
Synthesis of 7: Pyrrolocytosine 7 was prepared from the coupling of common intermediate 6 and alkyne 5 according to the procedure described previously. Starting from 230 mg of 5, 320 mg of the desired compound was obtained as an orange-brown solid (62%); LCMS (ESI) m/e 876.2 (M+1) .
Synthesis of compound 390: Boc-deprotection of 7 (0.32 g) was accomplished with 2 mL of 4N HCl in dioxane and CH Cl (10 mL) at room temperature (2 h). Following solvent evaporation, the crude residue was taken to the next step without further purification. LCMS (ESI) m/e 613.0 (M+1) . Guanidine formation was carried out according to the protocol used to prepare the other described compounds (bis-Boc-guanylpyrrazole, Et N, MeOH, RT). Deprotection was found to work best using a stepwise procedure to first remove the Boc-groups (trifluoroacetic acid in 10 mL of CH Cl ). Following concentration, the Cbz group was removed by redissolving the yellow-brown solid in 5 mL of trifluoroacetic acid and adding thioanisole (0.1 mL) dropwise. The solution was stirred at rt overnight, and upon completion solvent was evaporated affording the final compound as a brown oil. Diethyl ether was added and the liquid layer containing most of the residual thioanisole was decanted. Crude product was then dissolved in [(20% MeOH-90% H2O)+0.15%TFA] (10 mL). An aliquot (10 mL) was injected on a Dynamax 41.4 mm, C-18 prep HPLC Unit (guard+column), which was eluted with a gradient of solvents of 15% - 70% (MeOH/H2O + 0.15% TFA), over 45 min. The pure fractions were combined and concentrated with EtOH to dryness. This sample was treated with 1N HCl/H2O (5 mL) and EtOH (10 mL), and concentrated. This operation was repeated; the solid thus obtained was lyophilized from H2O-MeCN (4:1), affording compound 390 as a yellow powder (86 mg); LCMS (ESI) m/e 584.1 (M+1) ; H NMR (300 MHz, D O) 1.20 (d, J = 6.6 Hz, 3H), 1.56 (m, 2H), 1.65 (d, J = 6.8 Hz, 3 H), 1.85 (m, 2H), 2.87 (m, 1H), 2.89 (t, J = 6.9 Hz, 2H), 3.00 ( m, 1H), 3.15 (t, J=6.9 Hz, 2H), 3.31 (q, J = 6.8 Hz, 1H), 4.47 (q, J = 6.6 Hz, 1H), 7.05 (s, 1H), 7.50 (d, J = 8.1 Hz, 2H), 7.51 (s, 1H), 7.61 (d, J = 8.1 Hz, 2H), 7.94 (s, 1H), 8.51 (s, 1H).
Example 12: Syntheis of compound 322 Synthesis of Mesylate 2 from Aldehyde 1 Aldehyde 1 (11.8 g, 46.6 mmol) was dissolved in MeOH (70 mL) and the solution was cooled to 0 C. NaBH (2.13 g, 56 mmol) was added slowly as a solid in several portions. After 30 minutes, the mixture was warmed to RT, resulting in the formation of a clear solution. Stirring for an addition 1.5 h at RT led to complete consumption of starting material. MeOH was then evaporated and the residue was partitioned between EtOAc and H O. The organic layer was collected, dried over MgSO , and concentrated to a viscous, colorless oil (12.5 g, 99%). This oil was then redissolved in CH Cl at 0 C, and Et N was 2 2 3 added. The dropwise addition of MsCl produced a slightly yellow solution that was allowed to gradually warm to RT. Upon completion, the reaction was quenched with NaHCO . The organic layer was separated and the aqueous phase was extracted 2X with fresh CH Cl The 2 2. combined organics were dried over Na SO and concentrated to give an oil (8.10 g, 53%) that was used directly in the next step.
Synthesis of aryl THP ether 4 To a flask containing NaH (4.2 g, 105.7 mmol, 60% dispersion in oil) in 20 mL of THF at 0 C was added THP-protected ether 3 (16.9 g, 105.7 mmol) in 30 mL THF. An additional 20 mL of solvent was added to reduce foaming. After 5 min, the ice bath was removed and the mixture was brought to RT and stirring was continued for 1 h. Mesylate 2 (4.4 g, 13.21 mmol) in 50 mL of THF was then added dropwise at RT and the resulting solution was heated for 1.5 h at 45-50 C. Complete conversion was observed by LCMS, so the reaction was quenched with NH Cl. EtOAc was added and the phases were separated.
The aqueous layer was extracted 2X with fresh EtOAc and the combined organics were dried over MgSO and concentrated. The crude material was purified by column chromatography (5-30% EtOAc in heptanes) to provide 2.10 g of product (40%).
Synthesis of aryl alcohol 5 THP-protected aryl ether 4 (2.10 g, 5.28 mmol) was dissolved in 35 mL of MeOH and treated with cat. TsOH (0.1 eq). After 5 h at RT, the reaction was complete as indicated by LCMS and TLC. MeOH was removed and the mixture was partitioned between EtOAc and H O. The organic layer was separated, dried over MgSO , and concentrated to a slightly yellow-colored oil (1.54 g, 93%). This material was used without further purification.
Synthesis of Cbz-protected aryl amine 6 The same procedure for mesylation was used that was part of the two step conversion starting from aldehyde 1. From 0.86 g (2.73 mmol) of alcohol 5, 1.29 g of crude mesylate was obtained and used directly for azide formation.
This residue (1.29 g) was dissolved in DMF (10 mL) and treated with a single portion of NaN (0.6 g. 9.3 mmol). The resulting mixture was then allowed to stir overnight at RT.
Upon completion, ether was added and the organic layer was separated. The aqueous phase was washed 3X with additional ether and the organics were combined, washed 4X with H O, dried over MgSO , and concentrated. The crude oil (~1g) was used directly in the next step without purification.
For the reduction to amine, the azide material (~3 mmol) was then dissolved in 10 mL THF along with 1 mL of H O and triphenylphosphine (1.6 g, 6.0 mmol). The contents were heated from 55-60 C overnight to obtain complete consumption of starting material. THF was then removed in vacuo.
Cbz-protection was then accomplished by placing the amine in 15 mL of CH Cl and mL of sat. NaHCO . The solution was cooled to 0 C prior to the addition of CbzCl (0.64 mL, 4.5 mmol, 1.5 eq). After 4 h at RT, the organic layer was separated. The aqueous phase was washed 2X with fresh CH Cl and the combined organics were dried over Na SO and 2 2 2 4 concentrated. The crude material was purified by column chromatography (3:1 heptanes/EtOAc) to produce 1.2 g of desired compound (97% yield from aryl alcohol 5).
Note: The remainder of the synthesis (i.e. alkyne formation, Sonogashira/cyclization, and guanidine installation) is according the procedures described above for compounds 234 and 248).
Example 13 – Antimicrobial activity The compounds of the present invention were tested for antimicrobial activity. These data are presented in Table 3, Table 4, Table 5, and Table 6. The compounds were run against Eschericia coli strain ATCC25922 using a standard microdilution assay to determine minimum inhibitory concentrations (MICs). The data is presented whereby a "+" indicates that the compound has an MIC value of 16 micrograms/ml or less and a "–" indicates that the compound has an MIC value greater than 16 micrograms/ml. A "N/A" means that data is unavailable. It will be recognized by one skilled in the art that the compounds can be assessed against other bacterial organisms and that the presentation of data for activity against Eschericia coli is illustrative and in no way is intended to limit the scope of the present invention. The compounds of the present invention can be assayed against a range of other microorganisms depending upon the performance activity desired to be gathered.
Furthermore, the "+", "–", and "N/A" representation and the selection of a cutoff value of 16 micrograms/ml is also illustrative and in no way is intended to limit the scope of the present invention. For example, a "–" is not meant to indicate that the compound necessarily lacks activity or utility, but rather that its MIC value against the indicated microorganism is greater than 16 micrograms/ml.
Table 3 Compound no. E. coli ATCC25922 + 11 + 12 + 13 + 14 + + 16 + 17 + 18 + 19 + + 21 + 22 + 23 + 24 + + 26 + 27 + 28 + 29 + + 31 + 32 + 33 + 34 + + 36 + 37 + 38 + 39 + 40 + 41 + 42 + 43 + 44 + 45 + 46 + 47 + 48 + 49 + 50 + 51 + 52 + 53 + 54 + 55 + 56 + 57 + 58 + 59 + 60 - 61 + 62 + 63 + 64 + 65 + 66 - 67 + 68 + 69 + 70 + 71 + 72 + 73 + 74 + 75 + 76 + 77 + 78 + 79 + 80 + 81 + 82 + 83 + 84 + 85 + 86 + 87 + 88 + 89 + 90 + 91 + 92 + 93 + 94 + 95 + 96 + 97 + 98 + 99 + 100 + 101 + 102 + 103 + 104 + 105 + 106 + 107 + 108 + 109 + 110 + 111 + 112 + 113 + 114 + 115 + 116 + 117 + 118 + 119 + 120 + 121 + 122 + 123 + 124 + 125 + 126 + 127 + 128 + 129 + 130 + 131 + 132 + 133 + 134 + 135 + 136 + 137 + 138 + 139 + 140 + 212 + 213 + 214 + 215 + 216 + 217 + 218 + 219 + 220 + 221 + 222 + 223 + 224 + 225 + 226 + 227 + 228 + 229 + 230 + 231 + 232 + 233 + 234 + 235 + 236 + 237 + 238 + 239 + 240 + 241 + 242 + 243 + 244 + 245 + 246 + 247 + 248 + 249 + 250 + 251 + 252 + 253 + 254 + 255 + 256 + 257 + 258 + 259 + 260 + 261 + 262 + 263 + 264 + 265 + 266 + 267 + 268 + 269 + 270 + 271 + 272 + 273 + 274 + 275 + 276 + 277 + 278 + 279 + 280 + 281 + 282 + 283 + 284 + 285 + 286 + 287 + 288 + 289 + 290 + 291 + 292 + 293 + 294 + 295 + 296 + 297 + 298 + 299 + 300 + 301 + 302 + 303 + 304 + 305 + 306 + 307 + 308 + 309 + 310 + 311 + 312 + 313 + 314 + 315 + 316 + 317 + 318 + 319 + 320 + 321 + 322 + 323 + 324 + 325 + 326 + 327 + Table 4 Compound no. E. coli ATCC25922 150 - 151 + 152 + 153 + 154 + 155 + 156 + 157 + 158 + 159 + 160 + 161 + 162 + 163 + 164 + 165 - 166 + 167 + 168 + 169 + 170 + 171 + 172 + 173 + 174 + 175 + 176 + 177 - 178 + 179 + 180 + 181 + 182 + 183 - 184 + 185 187 - 188 + 189 Table 5 Compound E. coli no. ATCC25922 333 + 334 + 335 + 336 + 337 + 338 + 339 + 340 + 341 + 342 + 343 + 344 + 345 + 346 + 347 + 348 + 349 + 350 + 351 353 355 357 359 + 360 + 361 + 362 + 363 + 364 + 365 367 - 368 + 369 + 370 + 371 373 - 374 + 375 + 376 + 377 + 378 + 379 + 380 + 381 + 382 + 383 + 384 + 385 + 386 - 387 + 388 + 389 + 390 + 391 + 392 + 393 + 394 + 395 + 396 + 397 + 398 + 399 + 400 + 401 + 402 + 403 + 404 + 405 407 + 408 + 409 - 410 + 411 + 412 + 413 + 414 + 415 + 416 + 417 + 418 + 419 + 420 + 421 + 522 + 423 + 424 + 425 + 426 + 427 + 428 + 429 + 430 + 431 + 432 + 433 + 434 + 435 + 436 + 437 + 438 + 439 + 440 + 441 + 442 + 443 + 444 + 445 + 446 + 447 + 448 + 449 + 450 + 451 + 452 + 453 + 454 + 455 + 456 + 457 + 458 + 459 + 460 + 461 + 462 + 463 + 464 + 465 + 466 + 467 + 468 + Table 6 E. coli Compound ATCC25922 469 + 470 + 471 + 472 + 473 + 474 + 475 + 476 + 477 + 478 + 479 + 480 + 481 + 482 + 483 + 484 + 485 + 486 + 487 + 488 + 489 + 490 - 491 + 492 - 493 + 494 + 495 + 496 + 497 - 498 + 499 + 500 + 501 + 502 + 503 - 504 + 505 + 506 + 507 + INCORPORATION BY REFERENCE The entire disclosure of each of the patent documents and scientific articles referred to herein is incorporated by reference for all purposes.
EQUIVALENTS The invention can be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting on the invention described herein.
Scope of the invention is thus indicated by the appended claims rather than by the foregoing description, and all changes that come within the meaning and range of equivalency of the claims are intended to be embraced therein.
Claims (26)
1. A compound having the formula: (II) or a tautomer thereof, or a pharmaceutically acceptable salt, or ester of said compound or tautomer, wherein 1 2 4 5 X is CR or N; X is CR or N; X is CR or N; X is CR or N; 1 2 4 5 1 2 4 5 R , R , R , and R are each independently selected from (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) –CF , (g) –CF H, (h) –CFH , (i) –OCF , (j) –OCF H, (k) –OCFH , (l) –OCH , (m) 2 2 3 2 2 3 11 11 11 11 11 11 11 –CN, (n) –N , (o) –NO , (p) –NR R , (q) –NR C(O)R , (r) –C(O)NR R , (s) –OR , (t) – 11 11 11 11 11 11 COH, (u) –CO(C –C alkyl), (v) –COR , (w) –NR (CNR )NR R , (x) –S(O) R , (y) – 1 8 p 11 11 11 11 11 11 NR S(O) R , (z) –SR , (aa) –SCF , (bb) –C(CF )H-NH-CHR R , (cc) –COOR , (dd) – p 3 3 11 11 (OCH CH ) R , (ee) –(OCH CH ) OR , (ff) –C –C alkyl, (gg) –C –C alkenyl, (hh) –C –C 2 2 t 2 2 t 1 8 2 8 2 8 alkynyl, (ii) –(C –C alkyl)–(3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (jj) –(C –C alkyl)–(3–14 membered saturated, unsaturated, or aromatic carbocycle), (kk) –haloalkyl, (ll) –3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (mm) –3–14 membered saturated, unsaturated, or aromatic carbocycle, and (nn) –CHR -NH-(3-14 membered saturated, unsaturated, or aromatic heterocycle containing one of more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur); wherein each (ff) through (nn) is optionally substituted with one or more R ; wherein: is selected from the group consisting of: each R is independently selected from (a) hydrogen, (b) halogen, (c) –OH, (d) –SH, (e) 12 12 –(C –C alkyl)OH, (f) –OCF , (g) –OCF H, (h) –OCFH , (i) –OCH , (j) –OR , (k) –COR , (l) 1 8 3 2 2 3 12 12 –CN, (m) –NO , (n) –CONH , (o) –CONR R , (p) –COCH , (q) –S(O) CH , (r) 2 2 3 p 3 12 12 12 12 –S(O) NR R , (s) –SR , (t) –C(O)OH, (u) –C(O)OR , (v) –N , (w) –NH , (x) – p 3 2 12 12 NR C(O)R , (y) –NH(C –C alkyl), (z) –N(C –C alkyl) , (aa) –C –C alkyl, (bb) –C –C 1 8 1 8 2 1 8 2 8 alkenyl, (cc) –C –C alkynyl, (dd) –haloalkyl, (ee) –(C –C alkyl)–(3–14 membered saturated, 2 8 1 8 unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (ff) –(C –C alkyl)–(3–14 membered saturated, unsaturated, or aromatic carbocycle), (gg) –3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (hh) –3–14 membered saturated, unsaturated, or aromatic carbocycle, and (ii) 12 12 –(C=NH)NR R ; wherein each (y) through (hh) is optionally substituted with one or more R ; alternatively two R substituents are taken together to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, wherein each (a) through (b) is optionally substituted with one or more R ; R is selected from: , , , , , , , and ; 3a 3b 3c 3d 3e 3f 3g 3h 3i 3j 3k 3l wherein R , R , R , R , R , R , R , R , R , R , R , and R are each independently selected from (a) hydrogen, (b) halogen, (c) –CN, (d) –N , (e) –NO , (f) –OCF , (g) –OCF H, 3 2 3 2 11 11 11 11 11 11 (h) –OCFH , (i) –OCH , (j) –OR , (k) –C(O)R , (l) –C(O)NR R , (m) –NH , (n) –NR R , 2 3 2 11 11 11 11 (o) –NR C(O)R , (p) –S(O) R , (q) –C(O)OH, (r) –C(O)OR , (s) –C –C alkyl, (t) –C –C p 1 8 2 8 alkenyl, (u) –C –C alkynyl, (v) haloalkyl, (w) –3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (x) –3–14 membered saturated, unsaturated, or aromatic carbocycle; wherein each (s) through (x) is optionally substituted with one or more R ; 3a 3b 3c 3d alternatively, one or more pairs of substituents selected from R and R , R and R , 3e 3f 3g 3h 3i 3j 3k 3l R and R , R and R , R and R , and R and R are taken together with the carbon atom to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic, (b) – 3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (c) an exo carbon-carbon double bond, (d) carbonyl group, or (e) thiocarbonyl group; wherein each (a) through (b) is optionally substituted with one or more R ; 3a 3b 3c 3d 3e 3f 3g alternatively, wherein two substituents selected from R , R , R , R , R , R , R , 3h 3i 3j 3k 3l R , R , R , R , and R on different carbon atoms are taken together with the intervening atoms to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; wherein each (a) through (b) is optionally substituted with one or more R ; 3a 3b 3c 3d 3e 3f 3g alternatively, wherein two substituents selected from R , R , R , R , R , R , R , 3h 3i 3j 3k 3l R , R , R , R , and R on two adjacent carbon atoms are taken together with the bond between said adjacent carbon atoms form a substituted or unsubstituted carbon-carbon double 3a 3b 3c 3d 3e 3f 3g 3h 3i 3j bond, or wherein four substituents selected from R , R , R , R , R , R , R , R , R , R , 3k 3l R , and R on two adjacent carbon atoms are taken together with the bond between said adjacent carbon atoms form a carbon-carbon triple bond; 11 11 11 U is selected from –O–, –S(O) –, –NR –, –(C=O)–, –NR (C=O)–, –(C=O)NR –, 11 11 11 11 11 11 –S(O) NR –, –NR S(O) – , –NR S(O) NR –, and –NR C(O)NR -; p p p 11 11 11 11 11 11 11 11 11 T is selected from –NR R , –NR (C=O)OR , –NR (C=NR )NR R , and OR ; 11 3a 3b 3c 3d 3e 3f 3g alternatively, one R and one substituent selected from R , R , R , R , R , R , R , 3h 3i 3j 3k 3l R , R , R , R , and R are taken together with the intervening atoms to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; wherein each (a) through (b) is optionally substituted with one or more R ; R is selected from: , , , , , , , , , , , and 9k 9l 9m 9n 9o 9p 9q 9r 9s 9t wherein R , R , R , R , R , R , R , R , R , and R are each independently selected from (a) hydrogen, (b) halogen, (c) –CN, (d) –N , (e) –NO , (f) –OCF , (g) –OCH , (h) 3 2 3 3 11 11 11 11 11 –OCF H, (i) –OCFH , (j) –OR , (k) –NH , (l) –NR R , (m) –C(O)R , (n) –C(O)OR , (o) 2 2 2 11 11 11 11 11 –C(O)NR R , (p) –NR C(O)R , (q) –S(O) R , (r) –C –C alkyl, (s) –C –C alkenyl, (t) – p 1 8 2 8 C –C alkynyl, (u) haloalkyl, (v) –3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (w) –3–14 membered saturated, unsaturated, or aromatic carbocycle; wherein each (r) through (w) is optionally substituted with one or more R ; 9k 9l 9m 9n alternatively, one or more pairs of substituents selected from R and R , R and R , 9o 9p 9q 9r 9s 9t R and R , R and R , and R and R are taken together with the carbon atom to which they are attached to form (a) 3–7 membered saturated or unsaturated carbocyclic, (b) 3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (c) an exo carbon-carbon double bond, (d) carbonyl group, or (e) thiocarbonyl group; wherein each (a) through (c) is optionally substituted with one or more R ; 9k 9l 9m 9n 9o 9p 9q 9r 9s alternatively, two substituents selected from R , R , R , R , R , R , R , R , R , and R on different carbon atoms are taken together with the intervening atoms to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; wherein each (a) through (b) is optionally substituted with one or more R ; 9k 9l 9m 9n 9o 9p 9q 9r 9s alternatively, two substituents selected from R , R , R , R , R , R , R , R , R , and R on two adjacent carbon atoms are taken together with the bond between said adjacent carbon atoms form a substituted or unsubstituted carbon-carbon double bond, or four 9k 9l 9m 9n 9o 9p 9q 9r 9s 9t substituents selected from R , R , R , R , R , R , R , R , R , and R on two adjacent carbon atoms are taken together with the bond between said adjacent carbon atoms form a carbon-carbon triple bond; 11 11 11 Z is selected from –O–, –S(O) –, –NR –, –(C=O)–, –NR (C=O)–, –(C=O)NR –, 11 11 11 11 11 11 –S(O) NR –, –NR S(O) –, –NR S(O) NR –, and –NR C(O)NR –; p p p 11 11 11 11 11 11 11 11 11 W is selected from –NR R , –NR (CO)OR , –NR (C=NR )NR R , and –OR ; 11 9k 9l 9m 9n 9o 9p 9q alternatively, one R and one substituent selected from R , R , R , R , R , R , R , 9r 9s 9t R , R , and R are taken together with the intervening atoms to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; wherein each (a) through (b) is optionally substituted with one or more R ; R is independently selected from (a) hydrogen, (b) halogen, (c) –OH, (d) –SH, (e) – (C –C alkyl)OH, (f) –OCF , (g) –OCH , (h) –OCF H, (i) –OCFH , (j) –O(C –C alkyl), (k) – 1 8 3 3 2 2 1 8 CN, (l) –NO , (m) –CONH , (n) C(O)NH(C -C alkyl), (o) C(O)N(C -C alkyl) , (p) –COH, (q) 2 2 1 8 1 8 2 –COCH , (r) –S(O) CH , (s) –S(O) N(C –C alkyl) , (t) –S(C –C alkyl), (u) –C(O)OH, (v) 3 p 3 p 1 8 2 1 8 –C(O)O(C –C alkyl), (w) –N , (x) –NHC(O)(C –C alkyl), (y) –N(C –C alkyl)C(O)(C –C 1 8 3 1 8 1 8 1 8 alkyl), (z) –NH , (aa) –NH(C –C alkyl), (bb) –N(C –C alkyl) , (cc) –C –C alkyl, (dd) –C – 2 1 8 1 8 2 1 8 2 C alkenyl, (ee) –C –C alkynyl, (ff) –haloalkyl, (gg) –(C –C alkyl)–(3–14 membered 8 2 8 1 8 saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (hh) –(C –C alkyl)–(3–14 membered saturated, unsaturated, or aromatic carbocycle), (ii) –3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (jj) –3–14 membered saturated, unsaturated, or aromatic carbocycle, (kk) 13 13 –(C=NH)NH , (ll) –C(=NH)NH , (mm) –C(O)R , (nn) =O, and (oo) =NR ; wherein each (aa) through (jj) is optionally substituted with one or more R ; R is independently selected from (a) hydrogen, (b) halogen, (c) –C –C alkyl, (d) –C –C 1 8 2 8 alkenyl, (e) –C –C alkynyl, (f) –haloalkyl, (g) –OH, (h) –OC -C alkyl, (i) –OC –C alkenyl, 2 8 1 8 2 8 (j) –OC –C alkynyl, (k) –OCF , (l) –OCH , (m) –OCF H, (n) –OCFH , (o) –NH , (p) –CN, (q) 2 8 3 3 2 2 2 –N , (r) –S(O) C -C alkyl, (s) –3–14 membered saturated, unsaturated, or aromatic heterocycle 3 p 1 8 containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (t) –3–14 membered saturated, unsaturated, or aromatic carbocycle; p is 0, 1, or 2; and t is 0, 1, or 2; and wherein the nitrogen and sulfur heteroatoms in any heterocycle in the compound are unoxidized or oxidized (N→O and S(O) , wherein p = 1 or 2).
2. The compound or a tautomer thereof, or a pharmaceutically acceptable salt, or ester of said compound or tautomer, according to claim 1, wherein 9k 9l 9m 9n 9o 9p 9q 9r 9s 9t (i) R , R , R , R , R , R , R , R , R , and R are each independently selected from (a) hydrogen, (b) halogen, (c) –CF , (d) –CF H, (e) –CFH , (f) –OCF , (g) –OCH , (h) – 3 2 2 3 3 OCF H, (i) –OCFH , (j) –OR , (k) –C –C alkyl, (l) haloalkyl, (m) –3–14 membered saturated, 2 2 1 8 unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (n) –3–14 membered saturated, unsaturated, or aromatic carbocycle; 9k 9l 9m alternatively, one or more of pairs of substituents selected from R and R , R and 9n 9o 9p 9q 9r 9s 9t R , R and R , R and R , and R and R are taken together with the carbon atom to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; 9k 9l 9m 9n 9o 9p 9q 9r 9s 9t (ii) at least one substituent selected from R , R , R , R , R , R , R , R , R , and R is 9k 9l 9m 9n 9o 9p 9q 9r 9s not hydrogen; or at least two substituents selected from R , R , R , R , R , R , R , R , R , and R are not hydrogen; 1 2 4 5 (iii) R , R , R and R are each independently selected from hydrogen and F; 3a 3b (iv) R and R are each independently selected from (a) hydrogen, (b) F, (c) Cl, (d) –CH , (e) –CF , (f) –CF H, (g) –CFH , (h) –OCF , (i) –OCF H, (j) –OCFH , (k) –OCH , and (l) –OH; 3 2 2 3 2 2 3 and wherein the nitrogen and sulfur heteroatoms in any heterocycle in the compound are unoxidized or oxidized (N→O and S(O) , wherein p = 1 or 2).
3. The compound or a tautomer thereof, or a pharmaceutically acceptable salt, or ester of said compound or tautomer, according to claim 2, wherein 9k 9l 9m 9n 9o 9p 9q 9r 9s 9t (i) R , R , R , R , R , R , R , R , R , and R are each independently selected from (a) hydrogen; (b) halogen; (c) –CF ; (d) –CF H; (e) –CFH ; (f) –OCF ; (g) – 3 2 2 3 OCH ; (h) –OCF H; (i) –OCFH ; (j) –OH; (k) –O(C –C alkyl); (l) –C –C alkyl 3 2 2 1 4 1 4 selected from methyl, ethyl, isopropyl, and t-butyl; (m) –3–7 membered saturated, unsaturated, or aromatic heterocycle selected from oxetanyl, azepanyl, pyridyl, dihydropyridyl, furanyl, tetrahydrofuranyl, tetrahydropyridyl, azetidinyl, pyrrolidinyl, piperidinyl, and piperidinyl; and (n) –3–7 membered saturated, unsaturated, or aromatic carbocycle selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, phenyl, cyclohexenyl, and cyclohexadienyl; 9k 9l alternatively, one or more of pairs of substituents are selected from R and R , 9m 9n 9o 9p 9q 9r 9s 9t R and R , R and R , R and R , and R and R are taken together with the carbon atom to which they are attached form cyclopropyl, cyclobutyl, or oxetanyl.
4. The compound or a tautomer thereof, or a pharmaceutically acceptable salt, or ester of said compound or tautomer, according to claim 2, wherein 9k 9l 9m 9n 9o 9p 9q 9r 9s 9t (i) R , R , R , R , R , R , R , R , R , and R are each independently selected from (a) hydrogen, (b) halogen, (d) –CF , (e) –CF H, (f) –CFH , (g) –OCF , (h) – 3 2 2 3 OCH , (i) –OCF H, (j) –OCFH , (k) –OH, (l) –OCH , (l) methyl, (m) ethyl, (n) 3 2 2 3 isopropyl, and (o) t-butyl.
5. The compound or a tautomer thereof, or a pharmaceutically acceptable salt, or ester of 1 2 4 5 said compound or tautomer, according to any one of claims 2 to 4, wherein R , R , R , and R are each hydrogen.
6. The compound of claim 1, wherein the compound is selected from: Structure H N N H N N N H N N N Cl Cl H N N N Cl CF NH CH H N N N Cl F H N N N Cl F H N N N H N N N F Cl H N N N Cl SCF H N N N Cl F H N N N H C Cl H N N N H N N N Cl CN H N N N Cl NO H N N N F Cl H N N N H C NO H N N N F CN H N N N Cl F H N N N Cl F H N N N F Cl H N N N H C CN H N N N F Et H N N N Cl F H N N N F Cl H N N N H N N N Cl i-Pr H N N N H C F H N N N Cl F H N N N H C CF H N N N H CO H N N N Cl OCHF H N N N Cl Et H N N N F C F H N N N Cl F H N N N Cl Cl H N N N F Cl NH CH H N N N F Cl H N N N H C OCHF H N N N F Cl H N N N F Cl H N N N F Cl H N N N F Cl H N N N F Cl H N N N Cl iPr H N N N F Cl NH CH H N N N F Cl NH CH H N N N F Cl NH CH H N N N F CF H N N N F CF H N N N F Cl H N N N F CF H N N N F CF H N N N Cl Et H N N N H N N N Cl Et H N N N Cl SCF NH CH H N N N Cl SCF H N N N F CF H N N N H N N N F Cl NH CH H N N N F Cl H N N N NH CH H N N N F Et H N N N F Et H N N N F Cl NH CH H N N N F Cl H N N N F Cl NH CH H N N N H N N N F Cl H C NH H N N N F Cl HO NH NH CH H N N N F Cl N CH H N N N F Cl N CH H N N N F Cl N CH H N N N F Cl Cl SCF N CH H N N N F Cl N CH CH H N N N F Cl H N N N F Cl F Cl F Cl NH CH H N N N F Cl H C NH H N N N F Cl NH CH H N N N H N N N H CH F Cl H N N N H CH F Cl H N N N F Cl N CH H N N N F Cl NH CH H N N N F Cl H C N N NH CH H N N N F Cl HO NH H N N N F Cl H N N N F Cl F Cl H N N N Cl SCF NH CH H N N N F Cl NH CH H N N N F Cl H N N N F Cl NH CH H N N N F Cl NH CH H N N N F Cl H C CH H N N N H N N N MeO NH H N N N H C CH NH CH H N N N F CH H N N N F Cl NH CH H N N N F Cl H N N N F Cl NH CH H N N N F Cl NH CH H N N N H N N N H N N N H C CH NH CH H N N N H C CH H N N N F Cl H N N N F Cl H N N N F Cl H N N N F Cl CO Me H N N N F Cl CO H H N N N NH CO Me H N N N F Cl NH CO H H N N N H N N N F Cl or a tautomer thereof, or a pharmaceutically acceptable salt, or ester of said compound or tautomer.
7. A pharmaceutical composition comprising a compound according to any one of claims 1-6 or a tautomer thereof, or a pharmaceutically acceptable salt, or ester of said compound or tautomer, and a pharmaceutically acceptable carrier.
8. Use of a compound according to any one of claims 1-6, or a tautomer thereof, or a pharmaceutically acceptable salt, or ester of said compound or tautomer, in the manufacture of a medicament for treating, preventing, or reducing a microbial infection in a human or animal.
9. The use according to claim 8, wherein the microbial infection is selected from the group consisting of: a skin infection, a Gram positive infection, a Gram negative infection, nosocomial pneumonia, community acquired pneumonia, post–viral pneumonia, hospital acquired pneumonia/ventilator associated pneumonia, a respiratory tract infection such as chronic respiratory tract infection (CRTI), acute pelvic infection, a skin infection including an acute bacterial skin and skin structure infection (ABSSSI) and an uncomplicated skin and skin structure infection (uSSSI), a complicated intra-abdominal infection, a urinary tract infection, bacteremia, septicemia, endocarditis, an atrio–ventricular shunt infection, a vascular access infection, meningitis, surgical prophylaxis, a peritoneal infection, a bone infection, a joint infection, a methicillin–resistant Staphylococcus aureus infection, a vancomycin–resistant Enterococci infection, a linezolid–resistant organism infection, a Bacillus anthracis infection, a Francisella tularensis infection, a Yersinia pestis infection, and tuberculosis.
10. The use according to claim 8 or claim 9, wherein the microbial infection is Gram positive infection.
11. The use according to claim 8 or claim 9, wherein the microbial infection is Gram negative infection.
12. The use according to claim 8 or claim 9, wherein the microbial infection is caused by or involves one or more microorganisms selected from: Acinetobacter spp. (Acinetobacter baumanni), Bacteroides distasonis, Bacteroides fragilis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Citrobacter freundii, Citrobacter koser, Clostridium clostridioforme, Clostridium perfringens, Enterobacter aerogenes, Enterobacter cloacae, Enterococcus faecalis, Enterococcus spp., Escherichia coli, Eubacterium lentum, Fusobacterium spp., Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Klebsiella oxytoca, Legionella pneumophilia, Moraxella catarrhalis, Morganella morganii, Mycoplasma spp., Peptostreptococcus spp., Porphyromonas asaccharolytica, Prevotella bivia, Proteus mirabilis, Proteus vulgaris, Providencia rettgeri, Providencia stuartii, Pseudomonas aeruginosa, Serratia marcescens, Streptococcus anginosus, Staphylococcus aureus, Staphylococcus epidermidis, Stenotrophomonas maltophilia, Streptococcus agalactiae, Streptococcus constellatus, Streptococcus pneumoniae, and Streptococcus pyogenes.
13. The use according to claim 8 or claim 9, wherein the microbial infection is caused by or involves one or more of aerobic and facultative gram-positive microorganism selected from: Staphylococcus aureus, Streptococcus pneumoniae, Enterococcus spp., Streptococcus agalactiae, Streptococcus pyogenes, and Staphylococcus epidermidis.
14. The use according to claim 8 or claim 9, wherein the microbial infection is caused by or involves one or more of aerobic and facultative gram-negative microorganism selected from: Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter aerogenes, Enterobacter cloacae, Morganella morganii, Serratia marcescens, Pseudomonas aeruginosa, Acinetobacter baumanni, Moraxella catarrhalis, Proteus mirabilis, Citrobacter koseri, Haemophilus parainfluenzae, Klebsiella oxytoca, Proteus vulgaris, Providencia rettgeri, and Providencia stuartii.
15. The use according to claim 8 or claim 9, wherein the microbial infection is caused by or involves one or more of anaerobic microorganism: Bacteroides fragilis, Bacteroides distasonis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Clostridium clostridioforme, Eubacterium lentum, Peptostreptococcus spp., Porphyromonas asaccharolytica, Prevotella bivia, Bacteroides vulgatus, Clostridium perfringens, and Fusobacterium spp.
16. The use according to claim 9, wherein the microorganism Enterococcus spp. is selected from vancomycin susceptible isolate and vancomycin resistant isolate.
17. The use according to claim 12 or claim 14, wherein the microorganism Escherichia coli is selected from extended spectrum beta-lactamase (ESBL) producing isolate and Klebsiella pneumoniae carbapenemase (KPC) producing isolate.
18. The use according to claim 12 or claim 14, wherein the microorganism Haemophilus influenzae is a beta-lactamase positive isolate.
19. The use according to claim 12 or claim 14, wherein the microorganism Klebsiella pneumoniae is selected from extended spectrum beta-lactamase (ESBL) producing isolate and Klebsiella pneumoniae carbapenemase (KPC) producing isolate.
20. The use according to claim 12 or claim 14, wherein the microorganism Klebsiella oxytoca selected from extended spectrum beta-lactamase (ESBL) producing isolate and Klebsiella pneumoniae carbapenemase (KPC) producing isolate.
21. The use according to claim 12 or claim 13, wherein the microorganism Staphylococcus aureus is selected from methicillin susceptible isolate and methicillin resistant isolate.
22. The use according to claim 12 or claim 13, wherein the microorganism Staphylococcus epidermidis is selected from methicillin susceptible isolate and methicillin resistant isolate.
23. The use according to claim 12 or claim 13, wherein the microorganism Streptococcus pneumoniae is selected from penicillin susceptible isolate and penicillin resistant isolate.
24. The use according to any one of claims 8 to 23, wherein the medicament comprises from 0.1 mg to 1500 mg of the compound or a tautomer thereof, or a pharmaceutically acceptable salt, or ester of said compound or tautomer.
25. The use according to claim 24, wherein the medicament comprises 25 mg, or 50 mg, or 75 mg, or 100 mg, or 125 mg, or 150 mg, or 175 mg, or 200 mg, or 225 mg, or 250 mg, or 275 mg, or 300 mg, or 325, or 350 mg, or 375 mg, or 400 mg, or 425 mg, or 450 mg, or 475 mg, or 500 mg, or 525 mg, or 550 mg, or 575 mg, or 600 mg, or 625 mg, or 650 mg, or 675 mg, or 700 mg, or 25 mg, or 750 mg, or 775 mg, or 800 mg, or 825 mg, or 850 mg, or 875 mg, or 900 mg, or 925 mg, or 950 mg, or 975 mg, or 1000 mg, or 1025 mg, or 1050, mg, or 1075 mg, or 1100 mg, or 1125 mg, or 1150 mg, or 1175 mg, or 1200 mg, or 1225 mg, or 1250 mg, or 1275 mg, or 1300 mg, or 1325 mg, or 1350 mg, or 1375 mg, or 1400 mg, or 1425 mg, or 1450 mg, or 1475 mg, or 1500 mg of the compound or a tautomer thereof, or a pharmaceutically acceptable salt, or ester of said compound or tautomer.
26. A medical device containing a compound according to any one of claims 1-6, or a tautomer thereof, or a pharmaceutically acceptable salt, or ester of said compound or tautomer. Melinta Therapeutics, Inc. By the patent attorneys for the applicant CULLENS
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161476138P | 2011-04-15 | 2011-04-15 | |
US61/476,138 | 2011-04-15 | ||
US201161535118P | 2011-09-15 | 2011-09-15 | |
US61/535,118 | 2011-09-15 | ||
US201261610363P | 2012-03-13 | 2012-03-13 | |
US61/610,363 | 2012-03-13 | ||
NZ61711612 | 2012-04-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ715818A NZ715818A (en) | 2017-09-29 |
NZ715818B2 true NZ715818B2 (en) | 2018-01-04 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9221827B2 (en) | Antimicrobial compounds and methods of making and using the same | |
US10947237B2 (en) | Antimicrobial compounds and methods of making and using the same | |
US10815238B2 (en) | Antimicrobial compounds and methods of making and using the same | |
MX2012004340A (en) | Antimicrobial compounds and methods of making and using the same. | |
US11999739B2 (en) | Antimicrobials methods of making and using the same | |
CA3023444A1 (en) | Antimicrobials and methods of making and using same | |
US10934295B2 (en) | Antimicrobials and methods of making and using same | |
NZ715818B2 (en) | Antimicrobial Compounds And Methods Of Making And Using The Same | |
NZ715818A (en) | Antimicrobial compounds and methods of making and using the same |